THE ROLE OF THE IL-17 RECEPTOR-A20 AXIS IN TUMOR GROWTH AND TUMOR MICROENVIRONMENT

by

Chi Yan

Submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy

at

Dalhousie University
Halifax, Nova Scotia
July 2017

© Copyright by Chi Yan, 2017
This thesis is dedicated to my lovely family
   For my wonderful wife, Qianni
   For my adorable daughter, Emma

巧笑倩兮缘堪爱，
福祉栾玥燕归来。
# Table of Contents

LIST OF TABLES
........................................................................................................... vii

LIST OF FIGURES
............................................................................................................ viii

ABSTRACT
.................................................................................................................. xi

LIST OF ABBREVIATIONS USED
................................................................................................. xii

ACKNOWLEDGEMENTS
........................................................................................................... xvi

CHAPTER 1 INTRODUCTION
.............................................................................................................. 1

1.1 Cancer biology, cancer stage and grade .................................................. 1

1.2 Hallmarks of cancer ..................................................................................... 4

1.3 The role of inflammation and the immune system in cancer ................... 7

1.3.1 Chronic inflammation in cancer .............................................................. 7

1.3.2 Inflammation in the context of immunosurveillance and immunoediting.. 8

1.3.3 Key constituents of the tumor microenvironment .................................... 9

1.3.3.1 Dendritic cells .................................................................................... 10

1.3.3.2 Monocytes and tumor-associated macrophages ................................ 11

1.3.3.3 Neutrophils ....................................................................................... 14

1.3.3.4 Myeloid-derived suppressor cells ...................................................... 15

1.3.3.5 NK and NKT cells ............................................................................ 15

1.3.3.6 T lymphocytes .................................................................................. 16

1.3.3.7 B lymphocytes ................................................................................ 18

1.3.3.8 Stromal cells .................................................................................... 19

1.3.3.9 Tumor cells ....................................................................................... 19

1.3.4 Mechanisms of immunosubversion ....................................................... 22

1.3.4.1 Immune suppression ....................................................................... 22

1.3.4.2 Immune exhaustion ........................................................................ 23

1.4 Key pro-inflammatory signaling pathways in cancer ............................ 24

1.4.1 Overview .............................................................................................. 24

1.4.2 NF-κB pathway .................................................................................... 24

1.4.3 MAPK pathway ................................................................................... 25

1.4.3.1 Overview ....................................................................................... 25

1.4.3.2 JNK pathway .................................................................................. 28
1.4.3.3 Biology and function of JNK isoforms ................................................................. 31

1.5 IL-17 and IL-17 receptor (IL-17R) family ................................................................. 32

1.5.1 Overview .................................................................................................................... 32
1.5.2 IL-17A, IL-17F and IL-17RA/RC axis .................................................................. 36
1.5.3 IL-17A functional paradox in cancer ..................................................................... 37
1.5.4 IL-17A signaling pathways .................................................................................... 40
1.5.4.1 Gene transcription ............................................................................................... 40
1.5.4.2 mRNA stability ................................................................................................. 42

1.6 Regulators of IL-17A signaling .................................................................................... 43

1.6.1 Positive regulators .................................................................................................. 43
1.6.2 Negative regulators ............................................................................................... 44
1.6.2.1 Biology of A20 .................................................................................................... 45
1.6.2.2 Molecular mechanisms of A20 ......................................................................... 46
1.6.2.3 The role of A20 in cancer .................................................................................. 46

1.7 Hypotheses and objectives .......................................................................................... 47

CHAPTER 2 MATERIALS AND METHODS ..................................................................... 48

2.1 Cells and Cell lines ....................................................................................................... 48
2.2 Mice .............................................................................................................................. 49
2.3 Construction and use of retroviral vectors and DNA plasmids ............................... 50

2.4 Gene expression analysis ........................................................................................... 51

2.4.1 RNA extraction, reverse transcription-PCR and quantitative real-time PCR (qPCR) ......................................................................................................................... 51
2.4.2 PCR microarray ...................................................................................................... 53
2.4.3 Droplet digital PCR (ddPCR) ................................................................................ 54

2.5 Cell proliferation assays .............................................................................................. 54

2.5.1 MTT assay ............................................................................................................... 54
2.5.2 Ki67 staining .......................................................................................................... 55
2.5.3 Growth curve assay ............................................................................................... 57
2.5.4 Cell cycle analysis .................................................................................................. 57

2.6 Cytokine ELISA .......................................................................................................... 57

2.7 Western blotting ......................................................................................................... 58

2.8 Electrophoretic mobility shift assay (EMSA) .............................................................. 59
2.9 Flow cytometry .......................................................................................................................... 61
  2.9.1 Extracellular staining ............................................................................................................. 61
  2.9.2 Intracellular staining ............................................................................................................. 61
  2.9.3 Apoptosis assay ..................................................................................................................... 62
2.10 In vivo models ............................................................................................................................ 64
  2.10.1 Isolation of immune cells from organs of tumor-bearing mice ........................................... 64
    2.10.1.1 Tumor ............................................................................................................................ 64
    2.10.1.2 Lymph node .................................................................................................................. 64
    2.10.1.3 Blood samples ............................................................................................................... 64
  2.10.2 Quantification of lung metastases by colony assay ............................................................. 65
2.11 Immunohistochemistry (IHC) staining and Image I densitometry ........................................... 65
2.12 Analysis of publicly available datasets .................................................................................... 66
2.13 Statistical analysis .................................................................................................................... 67
CHAPTER 3 RESULTS ........................................................................................................................ 68
  3.1 A novel role for IL-17R in repressing JNK1/JNK2 isoform-dependent tumor cell proliferation via the ubiquitin-editing enzyme A20 ............................................................. 68
    3.1.1 IL-17RC silencing in cancer cells directly alters tumor growth in a cell type dependent manner in vitro and in vivo ...................................................................................... 68
    3.1.2 IL-17RC silencing induces acquired-activation of distinct JNK isoforms in different tumor cells, which differentially regulates c-Jun-dependent homeostatic proliferation ................................................................. 76
    3.1.3 IL-17RC is required for maintaining basal A20 level that restrains homeostatic activation of JNK and NF-kB pathways ......................................................................................... 83
    3.1.4 The IL-17RC-A20 axis is required to selectively repress cytokine production downstream of NF-kB and JNK/c-Jun pathways ........................................................................ 84
    3.1.5 IL-17RA silencing in B16 melanoma and 4T1 mammary carcinoma cells enhances tumor cell growth in vitro and in vivo ......................................................................................... 88
    3.1.6 Baseline IL-17RA level restrains tumor cell proliferation by inhibiting homeostatic JNK/c-Jun activation .................................................................................................................. 95
    3.1.7 Baseline IL-17RA level is required for maintaining the basal production of A20 that controls aberrant activation of JNK and hyper-proliferation ........................................... 96
    3.1.8 Reconstitution of IL-17RA in RAKD clones restores parental proliferation, A20 expression and JNK activity .................................................................................................................. 106
  3.2 Loss of IL-17RA expression in cancer cells promotes an immunosuppressive TME ............... 109
3.2.1 IL-17RA silencing in B16 melanoma cells induces an immunosuppressive TME ................................................................. 109
3.2.2 Loss of baseline IL-17RA expression in B16 melanoma cells induces pro-inflammatory cytokine production in vitro and in vivo .......................................................... 113
3.2.3 The inflamed TME of B16-RAKD tumors converts host-derived CD45- cells into MHCII+PD-L1+ immunosuppressive cells ................................................................. 118
3.2.4 B16-RAKD tumors are enriched with PD-L1/PD-L2+ M2 macrophages...... 120
3.2.5 Loss of baseline IL-17RA expression in 4T1 breast carcinoma cells promotes Gr1+CD11b+ cells and immunosuppression in blood cells ......................... 123

3.3 Prognostic value of IL-17RA and A20 in cancer patients............................ 125
3.3.1 IL-17RA is co-expressed with A20 and bi-directionally altered in a subset of human cancers................................................................................................. 125
3.3.2 IL-17RA is significantly co-expressed with A20 and reduced in human CRC samples ................................................................................................................. 128
3.3.3 IL-17RA protein is significantly reduced in high grade CRC tumors, correlating with a poor clinical outcome................................................................. 135

CHAPTER 4 DISCUSSION................................................................................. 140

4.1 Summary of major findings...................................................................... 140
4.2 Implications and relevance of major findings........................................... 140
  4.2.1 Baseline verses induced IL-17/IL-17R/A20 signaling.............................. 140
  4.2.2 The role of JNK isoforms in the functional IL-17/IL-17R paradox in cancer 145
  4.2.3 IL-17R alteration and its prognostic value in human cancer management.... 146
4.3 Limitations of experimental system.......................................................... 161
  4.3.1 Apoptosis versus proliferation .......................................................... 161
  4.3.2 Lentiviral-shRNA/siRNA delivery system ........................................... 162
  4.3.3 Online database and human tissue array analyses.............................. 162
4.4 Proposed future directions.................................................................... 162
4.5 Concluding remarks.............................................................................. 168

BIBLIOGRAPHY ............................................................................................... 169

APPENDICES ................................................................................................. 194
LIST OF TABLES

Table 1. Colorectal cancer stage and grade................................................................. 6
Table 2. Selected receptor-mediated signaling pathways in tumor development......... 21
Table 3. Examples of IL-17/IL-17R signaling impacts on cellular turnover............... 39
Table 4. Primers used in this study. ............................................................................. 53
Table 5. Chemical inhibitors used in this study and their properties. ....................... 56
Table 6. List of antibodies used in western blotting and immunohistochemistry........ 60
Table 7. List of antibodies used in flow cytometry....................................................... 63
Table 8. Gene expression of Oncomine datasets used in this study......................... 106
Table 9. Gene expression of GEO-NCBI datasets used in this study ....................... 106
Table 10. A20 correlation analysis grouped by cancer types in NCI-60 cancer cell line panel (GDS4296) .......................................................... 119
Table 11. Correlation analysis of Cancer Cell Line Encyclopedia in cBioPortal........ 159
LIST OF FIGURES

Figure 1. The key cellular components of tumor microenvironment ........................................10
Figure 2. The four canonical MAPK signaling pathways ............................................................. 27
Figure 3. JNK signaling in the regulation of cellular apoptosis and proliferation ......................... 30
Figure 4. IL-17R family ligand-receptor structure .................................................................... 34
Figure 5. Schematic of IL-17/IL-17R signaling ........................................................................ 41
Figure 6. Specific knockdown of IL-17RC expression in B16 melanoma cells
attenuates tumor growth in vitro and in vivo ............................................................................ 69
Figure 7. Specific knockdown of IL-17RC expression in 4T1 cells promotes tumor
proliferation and tumor invasiveness in vitro and in vivo ......................................................... 72
Figure 8. IL-17RC silencing alters tumor cell apoptosis in vitro and in vivo in a
tumor-dependent manner ........................................................................................................... 74
Figure 9. IL-17RC silencing results in acquired-JNK activation but distinct c-Jun
activities in B16 and 4T1 cells ................................................................................................. 78
Figure 10. IL-17RC silencing induces acquired activation of different JNK isoforms
in different tumor cells, which differentially regulate c-Jun activities and homeostatic
cell proliferation ....................................................................................................................... 80
Figure 11. IL-17RC is required to maintain basal production of A20 and repress
homeostatic activities of JNK1 and JNK2 .............................................................................. 85
Figure 12. The IL-17RC-A20 axis selectively repress cytokine production
downstream of NF-κB and JNK/c-Jun pathways ....................................................................... 87
Figure 13. Knockdown of IL-17RA expression in B16 melanoma cells promotes
tumor growth in vitro .............................................................................................................. 89
Figure 14. Characterization of IL-17RA knockdown clones of 4T1 cells in vitro .............. 91
Figure 15. Flow cytometric analysis of PI-Annexin-V to quantify IL-17RA-associated
apoptosis in B16 and 4T1 cells ................................................................................................. 92
Figure 16. Knockdown of IL-17RA expression promotes tumor growth in vivo ............. 94
Figure 17. Baseline IL-17RA level restrains tumor cell proliferation via inhibiting
homeostatic JNK/c-Jun activation ............................................................................................. 97
Figure 18. IL-17RA/RC silencing leads to reduced A20 production and enhanced
activation of JNK and NF-κB pathways ................................................................................. 100
Figure 19. IL-17RA/RC silencing leads to reduced A20 production and enhanced activation of JNK in vivo. ................................................................. 103

Figure 20. BMDC and MEF with IL-17RA or IL-17RC deficiency show reduced basal expression of A20 and increased proliferation.............................. 104

Figure 21. Reconstitution of IL-17RA in RAKDs is able to restore the parental rate of proliferation and associated A20 expression and JNK/c-Jun activity. .......... 107

Figure 22. Reconstitution of A20 in RAKD clones is able to restore the normal rate of proliferation and associated JNK/c-Jun activity................................. 110

Figure 23. IL-17RA silencing in B16 melanoma cells promotes an immunosuppressive TME ............................................................................ 111

Figure 24. Loss of baseline IL-17RA in B16 melanoma cells selectively induces pro-inflammatory cytokine production in vitro and in vivo...................... 115

Figure 25. B16-RAKD tumors are enriched with host-derived CD45^MHCII^PD-L1^+ cells ........................................................................................................ 119

Figure 26. Enriched PD-L1/L2^+ M2 polarization in the TME of B16-RAKD tumors .. 121

Figure 27. IL-17RAKD 4T1 cells preferentially induce the expansion of granulocytic myeloid cells in peripheral blood..................................................... 124

Figure 28. Somatic copy numbers of IL-17RA and IL-17RC are bi-directionally altered in a fraction of human cancers in a cancer-type-specific manner .......... 126

Figure 29. IL-17RA is significantly co-expressed with A20 and reduced in CRC patients. .............................................................................................. 130

Figure 30. Altered IL-17R/A20 copy number level in CRC patients is associated with poor survival rate. ................................................................. 137

Figure 31. IL-17RA protein level is significantly reduced in high grade CRC tumors. 138

Figure 32. Proposed model for JNK1/JNK2 isoform-dependent tumor proliferation controlled by baseline IL-17/IL-17R level ......................................... 142

Figure 33. IL-17A triggers A20 and NF-kB induction and cell-type-dependent JNK activation......................................................................................... 147

Figure 34. IL-17RA/A20 axis restrains mitochondrial metabolism and protein synthesis while inducing inflammation in CRC ........................................ 150

Figure 35. Significant association between IL-17A-F/IL-17R axis with A20 alteration ...................................................................................... 154

Figure 36. A20 restrains IL-17A-induced proinflammatory cytokine production in human colon cell lines. ................................................................. 160
Figure 37. IL-17RC isoform expression pattern is associated with IL-17R/A20-dependent proliferation control.
Constitutive activation of NF-κB and JNK is frequently seen in malignancies; however, the underlying mechanisms remain incompletely understood. During my PhD study, I discovered a previously unrecognized role of interleukin 17 receptors (IL-17RA and IL-17RC) in repressing aberrant activation of NF-κB and JNK in cancer cells. Using a shRNA knockdown (KD) approach, I first demonstrated that IL-17RA or IL-17RC KD in murine B16 melanoma and 4T1 carcinoma cells caused aberrant expression and activation of NF-κB and different JNK isoforms along with markedly diminished levels of the ubiquitin-editing enzyme A20. We also demonstrated that differential up-regulation of JNK1 and JNK2 isoforms in the two tumor cell lines was responsible for the reciprocal regulation of c-Jun activity and tumor-specific proliferation. I further demonstrated that A20 reconstitution in IL-17RKD clones reversed aberrant JNK1/JNK2 activities and tumor-specific proliferation, confirming a sophisticated role for the IL-17R-A20 axis in controlling tumor proliferation. Notably, IL-17A stimulation resulted in selective up-regulation and down-regulation of different molecules in IL-17RKD clones compared to the parental control, highlighting parallel yin-yang activities associated with IL-17R-dependent signaling. Finally, immune profiling analysis revealed that the loss of IL-17R-A20 control in IL-17RAKD tumor cells favored the development of an immunosuppressive microenvironment in vivo. In order to validate these findings in human cancers, I conducted cross-cancer genome-wide analysis of somatic copy number alterations in IL-17R and A20 genes, and specifically examined its impact in colorectal cancer (CRC) development. Remarkably, CRC patients with concurrent copy number deletion in IL-17R and A20 had significantly reduced overall survival compared to their corresponding control patients. Accordingly, immunohistochemistry staining in CRC tissue arrays verified that high grade tumors had significantly reduced IL-17RA staining compared to low grade tumors. Collectively, my study reveals a critical role of IL-17R in maintaining baseline A20 production for controlling JNK isoform-dependent tumor-specific homeostatic proliferation and a novel role of the IL-17R-A20 axis in controlling tumor cell behavior. My work cautions the use of anti-IL-17R neutralization antibodies in cancer patients and sheds light onto the use of the IL-17R-A20 axis as prognostic and predictive markers in cancer patients, particularly in CRC patients.
### LIST OF ABBREVIATIONS USED

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>3’-UTR</td>
<td>3’-untranslated region</td>
</tr>
<tr>
<td>ACK</td>
<td>Ammonium-chloride-potassium</td>
</tr>
<tr>
<td>ADCC</td>
<td>Antibody-dependent cell-mediated cytotoxicity</td>
</tr>
<tr>
<td>ATCC</td>
<td>American type culture collection</td>
</tr>
<tr>
<td>Ag</td>
<td>Antigen</td>
</tr>
<tr>
<td>AJCC</td>
<td>American Joint Committee on Cancer</td>
</tr>
<tr>
<td>Akt/PKB</td>
<td>Protein kinase B</td>
</tr>
<tr>
<td>ALL</td>
<td>Acute lymphoblastic leukemia</td>
</tr>
<tr>
<td>AML</td>
<td>Acute myeloid leukemia</td>
</tr>
<tr>
<td>Amphotrop-X</td>
<td>Amphotropic Phoenix cells</td>
</tr>
<tr>
<td>AP-1</td>
<td>Activation protein-1</td>
</tr>
<tr>
<td>APC</td>
<td>Antigen presenting cell</td>
</tr>
<tr>
<td>ARE</td>
<td>AU-rich element</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>BAFF</td>
<td>B-cell activating factor</td>
</tr>
<tr>
<td>BCA</td>
<td>Bicinchoninic acid</td>
</tr>
<tr>
<td>BCG</td>
<td>Bacillus Calmette-Guerin</td>
</tr>
<tr>
<td>Bel-2</td>
<td>B-cell lymphoma 2</td>
</tr>
<tr>
<td>BM</td>
<td>Bone marrow</td>
</tr>
<tr>
<td>BMDC</td>
<td>Bone marrow derived dendritic cell</td>
</tr>
<tr>
<td>C/EBP</td>
<td>CCAAT/enhancer binding protein</td>
</tr>
<tr>
<td>CBAD</td>
<td>C/EBP-beta activation domain</td>
</tr>
<tr>
<td>CD</td>
<td>Cluster of differentiation</td>
</tr>
<tr>
<td>cDCs</td>
<td>Conventional dendritic cells</td>
</tr>
<tr>
<td>CDK</td>
<td>Cyclin-dependent kinase</td>
</tr>
<tr>
<td>CM</td>
<td>Complete medium</td>
</tr>
<tr>
<td>CNA</td>
<td>Copy number alteration</td>
</tr>
<tr>
<td>COX</td>
<td>Cyclooxygenase</td>
</tr>
<tr>
<td>CRC</td>
<td>Colorectal cancer</td>
</tr>
<tr>
<td>CRI</td>
<td>Cancer-related inflammation</td>
</tr>
<tr>
<td>CSF-1</td>
<td>Colony stimulating factor 1</td>
</tr>
<tr>
<td>CTL</td>
<td>Cytotoxic T lymphocytes</td>
</tr>
<tr>
<td>CTLA-4</td>
<td>Cytotoxic T-lymphocyte–associated antigen 4</td>
</tr>
<tr>
<td>DC</td>
<td>Dendritic cell</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>ddPCR</td>
<td>Droplet digital polymerase chain reaction</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco's modified Eagle's medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EMSA</td>
<td>Electrophoretic mobility shift assay</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen receptor</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence activated cell sorting</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal bovine serum</td>
</tr>
<tr>
<td>Flt3L</td>
<td>Fms-like tyrosine kinase 3 ligand</td>
</tr>
<tr>
<td>FN</td>
<td>Fibronectin</td>
</tr>
<tr>
<td>Foxp3</td>
<td>Forkhead box p3</td>
</tr>
<tr>
<td>FZD</td>
<td>Frizzled receptor</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde 3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GEO</td>
<td>Genome Expression Omnibus</td>
</tr>
<tr>
<td>GITR</td>
<td>Glucocorticoid-induced tumor necrosis factor receptor</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Granulocyte-macrophage colony stimulating factor</td>
</tr>
<tr>
<td>GPR81</td>
<td>G protein-coupled receptor 81</td>
</tr>
<tr>
<td>GSK3β</td>
<td>Glycogen synthase kinase 3 beta</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B virus</td>
</tr>
<tr>
<td>HCEC</td>
<td>Human colon epithelial cell</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HEPES</td>
<td>2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid</td>
</tr>
<tr>
<td>Her2</td>
<td>Human epidermal growth factor receptor 2</td>
</tr>
<tr>
<td>HIF</td>
<td>Hypoxia inducible factor</td>
</tr>
<tr>
<td>HMEC</td>
<td>Human mammary epithelial cell</td>
</tr>
<tr>
<td>HPV</td>
<td>Human papillomavirus</td>
</tr>
<tr>
<td>HuR</td>
<td>Human antigen R</td>
</tr>
<tr>
<td>IBD</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>ICOS-L</td>
<td>Inducible co-stimulatory molecule-ligand</td>
</tr>
<tr>
<td>ICO</td>
<td>Indoleamine 2,3-dioxygenase</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>Ig</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>IKK</td>
<td>Inhibitor of nuclear factor-kappa B kinase</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IL-17RA</td>
<td>IL-17 receptor A</td>
</tr>
<tr>
<td>IL-17RC</td>
<td>IL-17 receptor C</td>
</tr>
<tr>
<td>imDC</td>
<td>Immature dendritic cells</td>
</tr>
<tr>
<td>iNOS</td>
<td>Inducible nitric oxide synthase</td>
</tr>
<tr>
<td>IRF4</td>
<td>Interferon regulatory factor 4</td>
</tr>
<tr>
<td>IWK</td>
<td>Izaak Walton Killam</td>
</tr>
<tr>
<td>JAK</td>
<td>Janus kinase</td>
</tr>
<tr>
<td>JNK</td>
<td>c-Jun N-terminal kinase</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>Ly6</td>
<td>Lymphocyte antigen 6</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>MCP</td>
<td>Monocyte chemoattractant protein</td>
</tr>
<tr>
<td>MCPIP</td>
<td>Monocyte chemoattractant protein 1-induced protein</td>
</tr>
<tr>
<td>MDSC</td>
<td>Myeloid-derived suppressor cell</td>
</tr>
<tr>
<td>MEF</td>
<td>Mouse embryonic fibroblast</td>
</tr>
<tr>
<td>MHC</td>
<td>Major histocompatibility complex</td>
</tr>
<tr>
<td>MIP</td>
<td>Macrophage inflammatory protein</td>
</tr>
<tr>
<td>mM</td>
<td>Millimolar</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>MMP</td>
<td>Matrix metalloproteinase</td>
</tr>
<tr>
<td>NCBI</td>
<td>National Center for Biotechnology Information</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear factor-kappa B</td>
</tr>
<tr>
<td>NIK</td>
<td>Nuclear factor-kappa B-inducing kinase</td>
</tr>
<tr>
<td>NK</td>
<td>Natural killer</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>Nrf2</td>
<td>Nuclear factor (erythroid-derived 2)-like 2</td>
</tr>
<tr>
<td>NSAID</td>
<td>Nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>ORR</td>
<td>Objective response rate</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PBST</td>
<td>Phosphate buffered saline containing 0.01% Tween-20</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PD-1</td>
<td>Programmed cell death protein 1</td>
</tr>
<tr>
<td>pDCs</td>
<td>Plasmacytoid dendritic cell</td>
</tr>
<tr>
<td>PEI</td>
<td>Polyethyleneimine</td>
</tr>
<tr>
<td>PI</td>
<td>Propidium iodide</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphatidylinositol-3-kinase</td>
</tr>
<tr>
<td>PR</td>
<td>Progesterone receptor</td>
</tr>
<tr>
<td>PTEN</td>
<td>Phosphatase and tensin homolog</td>
</tr>
<tr>
<td>qPCR</td>
<td>Quantitative polymerase chain reaction</td>
</tr>
<tr>
<td>RB</td>
<td>Retinoblastoma</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>ROR</td>
<td>Retinoid orphan nuclear receptor</td>
</tr>
<tr>
<td>ROS/RNS</td>
<td>Reactive oxygen/nitrogen species</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>SAPK</td>
<td>Stress-activated protein kinase</td>
</tr>
<tr>
<td>SEFEX</td>
<td>Similar expression to fibroblast growth factor and IL-17R-extension</td>
</tr>
<tr>
<td>SEFIR</td>
<td>Similar expression to fibroblast growth factor and IL-17R</td>
</tr>
<tr>
<td>SF2</td>
<td>mRNA splicing regulatory factor 2</td>
</tr>
<tr>
<td>SHP2</td>
<td>Src homology 2 domain-containing tyrosine phosphatase 2</td>
</tr>
<tr>
<td>SNP</td>
<td>Single nucleotide polymorphism</td>
</tr>
<tr>
<td>STAT3</td>
<td>Signal transducer and activator of transcription 3</td>
</tr>
<tr>
<td>TAA</td>
<td>Tumor-associated antigen</td>
</tr>
<tr>
<td>TAB</td>
<td>Transforming growth factor beta-activated kinase 1-binding protein</td>
</tr>
<tr>
<td>TAK</td>
<td>Transforming growth factor beta-activated kinase</td>
</tr>
<tr>
<td>TAM</td>
<td>Tumor-associated macrophage</td>
</tr>
<tr>
<td>TCR</td>
<td>T cell receptor</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming growth factor beta</td>
</tr>
<tr>
<td>Th</td>
<td>T helper cell</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like receptor</td>
</tr>
<tr>
<td>TME</td>
<td>Tumor microenvironment</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>TNFAIP3</td>
<td>Tumor necrosis factor alpha-induced protein 3</td>
</tr>
<tr>
<td>TNM</td>
<td>Tumor, node, metastasis staging system</td>
</tr>
<tr>
<td>TPL</td>
<td>Tumor progression locus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>TRAIL</td>
<td>Tumor necrosis factor-related apoptosis-inducing ligand</td>
</tr>
<tr>
<td>TRAF6</td>
<td>Tumor necrosis factor receptor associated factor-6</td>
</tr>
<tr>
<td>Treg</td>
<td>Regulatory T cell</td>
</tr>
<tr>
<td>TSA</td>
<td>Tumor-specific antigen</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>α-GalCer</td>
<td>Alpha-galactosylceramide</td>
</tr>
<tr>
<td>μl</td>
<td>Microliter</td>
</tr>
<tr>
<td>μm</td>
<td>Micrometer</td>
</tr>
<tr>
<td>μg</td>
<td>Microgram</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

This thesis would not have materialized if it was not for the sincere guidance and support from numerous people to whom I would like to thank from the bottom of my heart.

I would like to thank my committee, Dr. Brent Johnston, Dr. Craig McCormick and Dr. David Hoskin, as well as my former co-supervisor Dr. Scott Halperin, for their valuable collaboration, scientific rigor and feedback, which have served as an invaluable source of guidance over the years. I would like to extend my gratitude to my external examiner, Dr. Ann Richmond, for taking the time out of her busy schedule to read my thesis and offer her insight into my research. Foremost is to thank my thesis advisor Dr. Jun Wang who allowed me to enter the world of cancer. Her constant encouragement, excellent acumen, immense knowledge and constructive criticism helped to build my own perception of what it takes to flourish in science.

Special thanks to the Department of Microbiology and Immunology at Dalhousie University for providing me an opportunity to learn and pursue an excellent career in molecular oncology and immunology. I am humbled to have been able to work in the CCFV lab alongside some of the most remarkable students, staffs and colleagues over the years. Sincere thanks for creating a friendly and collaborative working environment. Also, thank you to all the friends in the Tupper building for your time and resources throughout my program.

This acknowledgment would remain incomplete without expressing my gratitude towards my family. I wish to acknowledge the enduring support of my parents for their unceasing care, love and blessings. I sincerely thank my grandparents. Although you may not see the value of a PhD, you have always stood by me throughout graduate school, supporting me in every way possible. I am so grateful for the family that I have gained during this time, my wife Qianni and my baby daughter Emma who have helped me put into perspective what is most important to me. Thank you for always there cheering me up through the good and bad times.

Last, but not least, I wish to acknowledge the Cancer Research Training Program and the IWK Health Centre for funding my graduate research through the years.

持身立世，谨引自勉：为天地立心，为生民立命，为往圣继绝学，为万世开太平。
CHAPTER 1 INTRODUCTION

Cancer is a wide array of diseases characterized by abnormal growth of mutated cells, which can invade nearby and distant tissues. It is among the leading causes of death worldwide with a mortality rate of more than 50% (1). As a major cellular component in solid tumors, cancer cells not only alter the cellular turnover process to favor proliferation and survival, they are also able to subvert host defense mechanisms and establish a counter-regulatory immunosuppressive microenvironment to promote tumor development and progression. The molecular and cellular mechanisms by which cancer cells facilitate tumor development are complex and not fully understood. In particular, tumor cells are highly heterogeneous, which represents a major challenge in cancer management as it may directly imprint aggression of the disease and response to the anti-cancer treatment. There is an urgent need for improved understanding of the heterogeneity of tumor cells and development of novel prognostic biomarkers in cancer medicine (2).

1.1 Cancer biology, cancer stage and grade

Cancer develops through complex multistep processes that include initiation, promotion, progression and metastasis. Tumor initiation usually begins in normal cells that have the accumulation of genomic alterations in tumor suppressor genes, oncogenes and/or deoxyribonucleic acid (DNA) repair genes, creating the potential for malignant transformation (3). Tumor suppressor genes play a critical role in controlling cell proliferation, division and survival. Mutations in tumor suppressor genes lead to the production of abnormal proteins that enable cells to grow in an uncontrolled manner (4). The most frequently mutated gene is TP53, which is mutated/lost in approximately 50% of human cancers (5). The protein p53, encoded by TP53, is a transcription factor, which exerts a tumor-suppressive role through transcriptional regulation of downstream target genes (6). Several examples of p53 targeted genes are the cyclin-dependent kinase inhibitor p21 (CDKN1A) (7), proapoptotic B-cell lymphoma (BCL)-2 family members Bcl-2-associated X (BAX) (8), p53 upregulated modulator of apoptosis (PUMA) (9), ferredoxin reductase (FDXR, encoding a mitochondrial flavoprotein required for electron transport in metabolism) (10), damage-regulated autophagy modulator 1 (DRAM1, encoding a lysosomal membrane protein required for the induction of autophagy) (11), as well as Sestrins1 and Sestrins2 [encoding proteins required for repressing messenger
ribonucleic acid (mRNA) translation] (12). Notably, TP53 mutations are often detected in the inflamed, but non-dysplastic epithelium in patients with colitis, suggesting that chronic inflammation can directly cause genomic changes (13). Other examples of tumor suppressors include retinoblastoma protein (RB), phosphatase and tensin homolog (PTEN), cyclin-dependent kinase inhibitor CDKN2A (also known as p16) in melanoma, breast cancer proteins BRCA1 and BRCA2, as well as adenomatous polyposis coli in colorectal cancer (CRC) (14). In contrast to the tumor suppressor genes, oncogenes are generally mutated forms of normal cellular genes (proto-oncogenes) that are responsible for normal cellular proliferation, differentiation and apoptosis (15). They can be activated by structural alterations resulting from mutation or gene fusion, by juxtaposition to enhancer elements, or by amplification (16). The products of oncogenes can be classified into six broad groups: transcription factors, chromatin remodelers, growth factors, growth factor receptors, signal transducers, and apoptosis regulators (16). In melanoma, the most common oncogenic mutations are neuroblastoma RAS viral oncogene homolog (NRas) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (60-70%) (17), whereas avian myelocytomatisis viral oncogene homolog (Myc) and epidermal growth factor receptor (EGFR)2 are present in ~20% of breast cancer patients and HRas and KRas are found in 20-30% of CRC patients (16). Furthermore, oncogenic proteins can also be induced by viral infections, which contribute in approximately 15-20% of cancer cases worldwide (18, 19). Lastly, DNA damage occurs as a result of both endogenous (e.g., hydrolysis, oxidation and replication errors), as well as exogenous mechanisms (e.g., radiation and chemical agents in the environment) during the process of tumor development. Since DNA repair genes are involved in the process of fixing damaged DNA (20), alterations in these genes lead to the development of additional genetic mutations and epigenetic modifications in other genes, which may cause the cells to become cancerous.

While genetic mutations result in altered cellular proliferation that may initiate carcinogenesis, they also result in the generation of tumor-specific antigens (TSAs, or neoantigens) and tumor-associated antigens (TAAs), critical components for induction of anti-tumor immune responses known as immunosurveillance (21-23). Specifically, TSAs are derived from proteins that are specific to the tumor, such as mutated self-proteins or proteins from oncogenic pathogens (24). Thus, the immune responses against TSAs are
specific and potent, but usually restricted to a certain tumor (25). By contrast, TAAs are normal self-proteins that exhibit abnormal quantities or locations within the tumor cells (24). As a result, TAAs are less immunogenic than TSAs in general; however, these responses tend to have a broad spectrum activity to a variety of tumors (24). Finally, genetic mutations may trigger inflammatory responses that are required for inducing anti-tumor immune responses, but often times, are involved in mediating aberrant cancer-associated inflammation to promote tumor development. For instance, the \textit{K}Ras gene encodes a GTPase transductor protein, which is mutated in \(~20\)% of all cancers (26), with the highest mutation rate \(>90\)% in pancreatic cancer (27). Of importance, \textit{Kras} mutation alone in mice is insufficient to trigger the initiation of pancreatic neoplasia; however, chronic pancreatitis can provide an inflammatory environment that exhibits aberrant nuclear factor-kappa B (NF-\(\kappa\)B) activation with enriched inflammatory infiltrates, necessary for Kras-induced pancreatic tumorigenesis (28). In recent years, somatic copy number alterations (CNA) have been recognized as one type of genetic alteration that has a critical role in tumorigenesis (29). Indeed, CNA are extremely common in lineage-specific and pan-cancer types (30, 31).

Tumor promotion involves the proliferation of genetically altered cells and progression involves an increase in the size of the tumor, the spreading of the tumor and the acquisition of additional genetic changes. While the promotion phase is usually asymptomatic, and tumor growth can be counter-balanced by immunosurveillance for a prolonged period of time, tumor progression exhibits increased tumor growth and invasiveness due to the outgrowth of less immunogenic tumor cells and/or induction of an immunosuppressive tumour microenvironment (TME) (32). Cancer metastasis and the associated cancer relapse are involved in over 90\% of cancer deaths and are associated with the worst prognosis (1). Metastasis requires complex biological processes to enable primary tumor cells to migrate through the blood stream, or the lymphatic system, to where they can colonize and develop to form secondary metastatic loci (33).

Of note, the host immune system is a very active component participating in different stages of cancer by driving a process called immunoediting (see section 1.3.2), which dictates tumor fate through the avoidance of innate and adaptive immune mechanisms. It
is increasingly recognized that the immune system not only protects against cancer development, but also shapes the character of emerging tumors.

Clinically, pathological stages of cancers are defined via the TNM (tumor, node, metastasis) system according to the American Joint Committee on Cancer (AJCC) (e.g., CRC staging as shown in Table 1) (34). T represents the initial size of the primary tumor and whether it has invaded nearby tissue, whereas N shows the presence and extent of the tumor involvement in the draining lymph nodes, and M indicates the presence of distant metastatic tumors. The size and the spread status of cancers provide a general indication for prognosis and treatment (35). To further evaluate how abnormal or malignant a tumor is, histological grading has been applied (e.g., CRC grade as shown in Table 1). The grade of cancers is also a useful indicator in prognosis; however, it has been shown to be a stage-independent prognostic factor (36). In general, low-grade tumors have a better prognosis since they exhibit a lower growth rate and are less likely to spread compared to high-grade tumors (34, 37).

1.2 Hallmarks of cancer


Tumor-associated inflammation contributes to multiple hallmarks of cancer by providing bioactive molecules and cellular components to the TME. In colitis-associated CRC (13), inflammatory conditions may be present before a malignant change occurs. Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of the tumor. Regardless of its origin,
“smoldering” chronic inflammation in the TME has many tumor-promoting effects. It aids in the genetic instability, proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents (40-42).

The molecular pathways associated with tumor-associated inflammation are now being unraveled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment. In this regard, my PhD thesis characterizes a novel molecular mechanism controlled by the pro-inflammatory cytokine interleukin 17 receptors (IL-17RA and IL-17RC) on tumor cells in both directly regulating tumor growth and survival and indirectly shaping immune responses in the TME.
Table 1. Colorectal cancer stage and grade.

<table>
<thead>
<tr>
<th>TNM stage groupings</th>
<th>T: tumour, N: node, M: metastasis.</th>
<th>Tis: carcinoma in situ: intraepithelial or invasion of lamina propria.</th>
<th>T1: tumour invades submucosa.</th>
<th>T2: tumour invades muscularis propria.</th>
<th>T3: tumour invades through the muscularis propria into the subserosa or into non-peritonealised perirectal tissues.</th>
<th>T4: tumour invades directly into other organs or structures and/or perforates visceral peritoneum.</th>
<th>N1: metastasis in 1-3 regional (peri-rectal) lymph nodes.</th>
<th>N2: metastasis in 4 or more regional lymph nodes.</th>
<th>M1: distant metastasis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>T1~T2</td>
<td>N0</td>
<td>M0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>T3~T4</td>
<td>N0</td>
<td>M0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>Any T</td>
<td>N1~N2</td>
<td>M0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Histological grade**

| Grade 1            | Well-differentiated               | Low Grade              |                                |                                |                                |                                |                                |                                |                  |
|-------------------|----------------------------------|------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|                  |
| Grade 2           | Moderately differentiated         |                        |                                |                                |                                |                                |                                |                                |                  |
| Grade 3           | Poorly differentiated             |                        |                                |                                |                                |                                |                                |                                |                  |
| Grade 4           | Undifferentiated                  |                        |                                |                                |                                |                                |                                |                                |                  |

Adapted from (34, 36).
1.3 The role of inflammation and the immune system in cancer

The term inflammation was first introduced by Aulus Cornelius Celus, referring to a local response characterized by redness, swelling, warmth, pain due to increased blood flow, capillary dilation, edema and leukocyte infiltration (43). Inflammation can be triggered by bacterial or viral infections, exposure to irritants (such as toxins) or trauma and is generally divided into acute and chronic inflammation based on the kinetics of the response. In 1863, Rudolf Virchow observed leukocyte infiltration into tumor sites, providing the first evidence to support the notion that cancer lesions are inflamed tissues (44). In general, acute inflammation in a cancer lesion is viewed as a good response, or at least benign, given that it stimulates immunosurveillance against cancers. By contrast, it is becoming increasingly recognized that chronic inflammatory conditions have pathological effects during cancer development (45) and it is widely accepted as the 10th hallmark of cancer (39, 40).

1.3.1 Chronic inflammation in cancer

Existing evidence indicates that around 25% of human cancer cases are related to chronic and unresolved inflammation caused by infection or physicochemical agents (46, 47). Chronic infection caused by various infectious agents, including viruses, bacteria and parasites, is an established risk factor of various cancers. For instance, Helicobacter pylori infection in humans induces chronic gastritis, which is associated with a more than 2-fold increase in the risk of stomach cancer (48, 49). While human papillomavirus (HPV) is a major cause of cervical cancer in women (50), chronic hepatitis triggered by hepatitis B virus (HBV) or hepatitis C virus (HCV) infection can lead to hepatocellular carcinoma (51). In addition, chronic parasitic infections with different strains of parasites infecting specific organs leads to various cancers, such as schistosomiasis induced cystitis and fibrosis, which are known to increase the risk of carcinoma of the bladder, liver, and rectum, as well as follicular lymphoma of the spleen (52). Furthermore, chronic inflammation caused by various environmental stimuli is also associated with an increased risk of cancer. For instance, there is a strong link between gastric acid-induced chronic reflux oesophagitis and the development of esophageal carcinomas (53). Lastly, chronic inflammatory diseases are also associated with increased risk of cancer. While
inflammatory bowel diseases may promote the development of CRC, obesity-associated inflammation is linked to postmenopausal breast, colon, and endometrial cancers (54, 55).

The concept of chronic inflammation in the promotion of cancer is also supported by the observation that nonsteroidal anti-inflammatory drugs (NSAIDs) are able to reduce the incidence and mortality of several cancers (56, 57). Multiple clinical trials have demonstrated a clear link between long-term aspirin (an inhibitor of cyclooxygenase [COX]1 and COX2) use and a reduction in the incidence and mortality for several cancer types, especially esophageal adenocarcinoma, CRC and stomach cancers, with an overall effect of 20% to 25% (58). Two large Danish cohort studies also showed a reduced risk for colorectal, stomach and ovarian cancer in non-aspirin NSAIDs users, but no clear differences in the risk estimates with breast cancer (59, 60). In addition, the long-term (>5 years), high-intensity use of COX2-specific non-aspirin NSAIDs was associated with a 30% to 45% reduction in CRC risk (61). However, not all chronic inflammatory conditions increase cancer risk and some of them, such as autoimmune disease-associated inflammation (e.g., rheumatoid arthritis or psoriasis), may even antagonize tumorigenesis (41, 62).

1.3.2 Inflammation in the context of immnosurveillance and immunoediting

The theory of cancer immnosurveillance explains the involvement of the immune system and beneficial inflammatory responses in cancer management; however, the fact that tumors develop in patients with a fully functional immune system suggests that it is only part of the story (32). In the last 2 decades, the concept of immunoediting has emerged, which has redefined the role of the immune system in cancer and more accurately describes the many facets of immune system–tumor interactions. The immunoediting process is very dynamic, which has three defined phases, namely, elimination, equilibrium and escape. Notably, inflammatory responses are an integral part of the immunoediting process.

The first elimination period involves the protective role of immnosurveillance wherein the immune system is able to find and eliminate most or all of the tumor cells before they grow to a clinically noticeable size. Inflammatory responses are indeed required for the generation of strong anti-tumor immunity. However, some tumor cells may manage to survive initial immune destruction and enter an equilibrium phase, in which the host immune system actively interacts with tumor cells and holds the tumor in a state of
functional dormancy (63, 64). Due to constant pressure from the immune system, some tumor cells undergo genetic and epigenetic changes, leading to generation of tumor variants that have a reduction or lack of expression of recognizable TSAs. These newly evolved tumor subclones possess poor immunogenicity due to antigen loss and are highly resistant to immune recognition and immune attack. While tumor cells continuously divide and grow, inflammatory cytokines and chemokines are produced and various cellular components of the innate and adaptive immune system are recruited into the TME in order to counteract tumor growth. However, tumor cells can evade anti-tumor immunity by facilitating immunosubversion mechanisms (see section 1.3.4) to avoid recognition and elimination. Tumor cells may evade immune recognition and killing through multiple mechanisms, such as loss of TSA, down-regulation of major histocompatibility complex (MHC) and/or co-stimulatory molecules, expression of molecules that allow resistance to host immunity, and/or induction of an immunosuppressive TME (64). The battle between the tumor and the immune system is a constant and dynamic process, which can last for months to decades. Although the molecular and cellular mechanisms underlying the immune-mediated tumor dormancy remain incompletely understood, the equilibrium phase is believed to reach a balance between immune stimulatory and immune inhibitory mechanisms, such as anti-tumor cytokines (e.g., IFN-γ) and pro-tumor cytokines (e.g., IL-10) (63). During the escape phase of cancer immunoediting, the immune system fails to control tumor growth and the tumor subclones progress causing clinically apparent disease. Notably, the entire cancer immunoediting process occurs in the TME, dynamically shaping the TME and being shaped in return by constituents of the TME.

1.3.3 Key constituents of the tumor microenvironment

An inflammatory tumor microenvironment has a complex tissue structure composed of noncellular and cellular elements. The noncellular components include soluble factors, signaling molecules, extracellular matrix, and mechanical (e.g., tumor vasculature and interstitial fluid pressure), as well as environmental (e.g., hypoxia and low pH) cues (65). The cellular component consists of tumor cells, stromal cells and tumor-infiltrating immune cells. Stromal cells are the cells that make up tumor-associated blood vessels (endothelial cells and pericytes) and the cells that contribute to structural integrity (fibroblasts). Based on the functional role of immune cells, tumor-infiltrating immune cells
can be divided into two distinct functional subtypes (Figure 1). While immune stimulatory cells are desirable for establishing immunosurveillance, immune suppressive cells are responsible for conducting immune subversion. Key examples of immunosurveillance cells include cytotoxic T lymphocytes (CTLs), type 1 tumor-associated macrophages (TAM1), natural killer cells (NK), immune stimulatory dendritic cells (DCs) and type 1 T helper cells (Th1). Examples of immunosuppressive cell subsets include T regulatory cells (Tregs), immature dendritic cells (imDC), myeloid-derived suppressor cells (MDSC), and type 2 macrophages (M2). In the following sections, I will discuss the role of several major cellular components and their associated molecules in inflammation, immune responses and cancer.

1.3.3.1 Dendritic cells

DCs are the most potent professional antigen presenting cells (APCs) that bridge innate and adaptive immunity via priming T cells for activation and expansion. Fms-like tyrosine kinase 3 ligand (Flt3L) and granulocyte-macrophage colony stimulating factor (GM-CSF) are major factors required for DC differentiation in the bone marrow (BM). Currently, conventional DCs (cDCs) and plasmacytoid DCs (pDCs) are the two major subsets of DC which are defined according to their phenotype, tissue distribution, specific transcriptional factors for DC fate development and functional properties (66). Of note, cDCs are the predominant population of DCs and exhibit strong phagocytosis and Ag presentation capacities. cDCs activate adaptive immune responses; however, they also can induce immune tolerance under specific conditions (66, 67). While pDCs represent a small population of DCs, they specialize in the generation and secretion of type I interferons and subsequently induce activation of CTLs and NK cells, which antagonize tumor development (66, 68-70). However, in certain TMEs, such as ovarian, head and neck, breast tumors and melanoma, pDCs also tend to be tolerogenic, which favor tumor progression and are often associated with poor prognosis (66, 70). Tolerogenic DCs, such as iDCs, can be induced by immunosuppressive IL-10 in the TME, stimulating autocrine IL-10 and the generation of Tregs (67). While mature DCs provide co-stimulatory molecules to promote division and survival in T cells, such as B7.1/B7.2 (CD80/CD86), inducible co-stimulatory molecule ligand (ICOS-L), tumor necrosis factor (TNF)-super family ligands, including CD40, 4-1BB (CD137), glucocorticoid-induced TNFR-related
protein (GITR), OX40 (CD134) and death receptor 3 (DR3), the tolerogenic DCs are characterised by a low expression of costimulatory and MHC molecules, low expression of IL-12 and high production of IL-10 and indolamine-2,3-dioxygenase (IDO) (67, 71, 72). Therefore, the function of DCs in cancer is context-dependent. The immunosuppressive TME can cause dysfunction of DCs, which is a main factor influencing the efficacy of DC-based therapies (66).

1.3.3.2 Monocytes and tumor-associated macrophages

Monocytes (~8% of circulating leukocytes) are derived from hematopoietic stem cells in the bone marrow and are an important cellular component of the innate immune system. The two best-characterized monocyte subsets in mice are circulating Ly6C°highCCR2° inflammatory monocytes and Ly6C°lowCCR2° resident monocytes (73, 74). The human counterparts are also identified and phenotypically characterized by CD14°highCD16° and CD14°lowCD16°, respectively. In addition to circulating in the peripheral blood, monocytes may seed into tissue sites and differentiate into tissue macrophages (75). While some macrophages are seeded into developing tissues during the embryonic stage, others are recruited into the tissue sites in response to inflammatory stimuli and undergo in situ proliferation or de novo differentiation (76). It is well known that macrophages have evolutionarily conserved functions in tissue maintenance and host defense and are capable of immune modulation, phagocytosis and Ag-presentation, despite being weaker APC compared to DCs due to reduced co-stimulatory molecule levels (77). Notably, macrophages are heterogeneous and plastic and therefore may exhibit a wide spectrum of activation profiles, ranging from classically activated (M1 macrophages) to the alternatively activated (M2 macrophages) (74, 78).
Tumor cells have long been recognized to be able to create a special microenvironment to subvert immunity and promote their own growth. The immunosurveillance immune effector cells, such as cytotoxic T lymphocyte (CTLs), tumor-associated macrophage M1 (TAM1) and natural killer cells (NK), with the help of dendritic cells (DCs) and type 1 T helper cells (Th1) are able to recognize and eliminate tumor cells. However, tumor cells can secrete cytokines that recruit suppressive cells, such as T regulatory cells (Tregs), immature myeloid cells, including immature dendritic cells (imDC) and myeloid-derived suppressor cells (MDSC), and M2 macrophages. The imDC can cause T-cell anergy due to a lack of co-stimulatory molecules. M2 macrophages and MDSCs inhibit T-cell responses through a variety of mechanisms, including nutrient sequestration via arginase, reactive oxygen/nitrogen species (ROS/RNS) generation, as well as interference with trafficking into the tumor site. Immunosuppressive cytokines and the up-regulation of immunosuppressive enzymes, like indolamine-2,3-dioxygenase (IDO) and arginase, which catabolize essential nutrients are required for effector cell activation and produce immunosuppressive catabolites. Furthermore, tumor cells promote the production of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) to favor angiogenesis, and up-regulate inhibitory molecules, such as PD-L1. As such, tumor-promoting immunosuppression dampens immunosurveillance, which otherwise inhibits tumor growth. Chronic inflammation plays a detrimental role and regulates all aspects of the TME. Nevertheless, the role of proinflammatory IL-17 in the TME is controversial.

Figure 1. The key cellular components of tumor microenvironment (63, 79).
TAMs are a major component of tumor infiltrating immune cells in solid tumors, which could represent up to 50% of the tumor mass (80). The increased number of TAMs at tumor sites is attributed to local expansion of tissue resident macrophages (embryonic or monocytic-derived) and/or the recruitment of circulating inflammatory monocytes (80, 81). One major population of TAMs is derived from circulating inflammatory monocytes, which are recruited and further expanded within tumor sites. CCL2 (or monocyte chemotactic protein-1, MCP-1) and colony stimulating factor 1 (CSF-1) signaling are shown to be critical for this process, which may function in an autocrine manner (81). Depending on the specific TME stimuli, including the profile of cytokines, chemokines and growth factors, TAMs are polarized into M1 or M2 phenotypes, which may positively or negatively regulate anti-tumor immune responses and the fate of tumor development and progression (76, 82, 83). The M1 subset is characterized as CCR2\(^{\text{high}}\)CD14\(^{\text{high}}\)CX3CR1\(^{\text{CD16}^{-}}\) in humans and CCR2\(^{\text{high}}\)CX3CR1\(^{-}\) and Ly6C\(^{\text{high}}\) in mice, which have an anti-tumor or “killing” phenotype (78). The M1 TAMs are produced upon IFN-\(\gamma\) exposure, which stimulates inducible nitric oxide synthase (iNOS) and the production of nitric oxide (NO). The high level of NO may cooperate synergistically with proinflammatory and cytotoxic IFN-\(\gamma\) to kill the tumor cell.

By contrast, the M2 subset is defined as CD14\(^{\text{low}}\)CD16\(^{\text{mid-high}}\)CCR2\(^{-}\)CX3CR1\(^{\text{high}}\) in humans and Ly6C\(^{\text{low}}\)CCR2\(^{-}\)CX3CR1\(^{\text{high}}\) in mice (84-87). While the M2 TAMs are induced primarily by IL-4 and IL-13, a tumor milieu enriched with IL-10, transforming growth factor (TGF)-\(\beta\), endothelin-2 and VEGF also favors the differentiation of the M2 TAMs (88). In general, M2 macrophages produce a series of growth factors, cytokines, and extracellular matrix-modeling molecules and increase expression of arginase, which induce tumor cell proliferation, angiogenesis, and the tissue remodeling process (“healing” phenotype) (89). It has been shown that M2 macrophages are enriched in necrotic and hypoxic areas, which favor the production of hypoxia-inducible factor (HIF)-1\(\alpha\)-dependent molecules (e.g., VEGF, CXCL12, and CXCR4) (90). The aberrant level of CXCL12 and its receptor CXCR4 in the TME promotes proliferation, migration and invasion of cancer cells (91). M2 macrophages produce a series of proangiogenic factors that sustain and promote tumor growth, such as VEGF, platelet-derived growth factor (PDGF), TGF-\(\beta\), and members of the fibroblast growth factor family. Furthermore, M2 TAMs produce matrix
metalloproteinases MMP-7, MMP-2, MMP-9, MMP-1, which may promote tumor metastasis (82, 92). In addition, M2 TAMs can suppress T-cell-mediated anti-tumor immunity via promoting immunosubversion mechanisms (see section 1.3.4).

1.3.3.3 Neutrophils

Neutrophils are short-lived granulocytes, representing the most abundant subpopulation of leukocytes in the human blood. The production and turnover process of neutrophils is controlled by pro-inflammatory cytokine IL-17A-induced G-CSF production (93, 94). While neutrophils are mainly involved in the innate immune response against microbial infections (95-97), increased levels of neutrophils have been observed in several cancer types, such as melanoma, breast and colon cancer (90). Neutrophil recruitment is initiated by the induction of selectins and intercellular adhesion molecules (ICAM) on the surface of the endothelium that result from stimulation by inflammatory mediators, including histamine, cysteinyi leukotrienes, cytokines and chemokines (98, 99). In human tumors, neutrophil recruitment occurs mainly in response to IL-8 (or CXCL8), which is strongly induced by hypoxia (100, 101). After being recruited into the tissues, neutrophils are activated and able to generate reactive oxygen species (ROS) and release various pro-inflammatory proteins from intracellular granules, which include myeloperoxidase, lactoferrin, defensin, lysozyme, and proteases (e.g., elastase and gelatinase). These factors can cause tissue damage and cell lysis, as well as potential DNA damage (95). Like all other immune cells, neutrophils contribute to tumor outcome in a complex way. Similar to macrophages, neutrophils can also be polarized and display different phenotypes spreading from an antitumor (N1-like) to a pro-tumor (N2-like) phenotype (97, 102). Recent studies in experimental models have provided extensive support for the existence of pro-angiogenic (N2) or anti-tumor (N1) neutrophil phenotypes (102). The major player in the switch between the two phenotypes appears to be TGF-β, as increased levels of TGF-β stimulated polarization toward N2 neutrophils (102, 103). Neutrophils can produce a plethora of cytokines (including TNF-α, IL-1β, IL-12, IL-1Rα, and VEGF), chemokines (CXCL1, CXCL8, CXCL9, CCL3, and CCL4) and proteases (such as MMP9) (82). In addition, neutrophils can directly induce VEGF-dependent angiogenesis via CXCR2 binding chemokines (104, 105). More recently, neutrophils have also been reported to capture circulating cancer cells through the release of neutrophil-derived extracellular
traps, which favors the entry of metastatic cancer cells into tissues (106).

1.3.3.4 Myeloid-derived suppressor cells

MDSCs are a heterogeneous population of immature myeloid cells that share several common markers of monocytes, macrophages and neutrophils (107). As such, it may be difficult to distinguish among MDSCs, TAMs and tumor-infiltrating N2 neutrophils, since they possess similar immunosuppressive activities. Nevertheless, MDSCs often accumulate in cancer patients and produce arginase and IDO to suppress the immunosurveillance of several immune cell types, including M1 macrophages, NK cells, DCs and T cells (108, 109). Moreover, MDSCs can also induce the development and differentiation of suppressive immune cells, such as M2 macrophages and Tregs (110, 111). In mice, MDSCs are broadly characterized as Gr1^+CD11b^+. In particular, Gr1 is a myeloid differentiation marker, which contains two lymphocyte antigen 6 complexes (Ly6C and Ly6G), that are commonly used for the classification of two MDSC subsets in tumor-bearing mice: CD11b^+Ly6C^lowLy6G^+ granulocytic MDSCs (G-MDSCs), as well as CD11b^+Ly6C^highLy6G^- monocytic phenotype MDSCs (M-MDSCs) (112, 113).

1.3.3.5 NK and NKT cells

Natural killer (NK) cells are innate lymphocytes that recognize and kill virus infected cells and tumor cells through the expression of various activating and inhibitory receptors on the cell surface (114, 115). As an important component in immunosurveillance, NK cells exert direct cellular cytotoxicity without prior sensitization and secrete immunostimulatory cytokines, such as IFN-γ, for cancer elimination. According to the “missing-self” hypothesis, NK cells bearing killer-cell immunoglobulin-like receptors (KIRs) (or Ly49 receptors in mouse) preferentially target cells that have a reduction or lack of MHC-I expression, which is a common phenomenon in cancer cells (116). Furthermore, NK cells can make use of the fragment crystallizable (Fc) receptor to exert antibody-dependent cell-mediated cytotoxicity (ADCC) against antibody-coated tumor cells (116). Upon activation, NK cells exhibit elevated Fas-FasL interaction with target cells, along with the release of cytotoxic granules (perforin and various granzymes), leading to the apoptosis of target cells (117).

Natural killer T (NKT) cells are unique lymphocytes that have characteristics of both
NK cells and T lymphocytes. The differences in T cell receptor (TCR) rearrangements have allowed NKT cells to be separated into two categories, type I and type II (118). Type I NKT cells, or invariant or iNKT cells, are characterized by the expression of restricted invariant TCR encoded by Vα14Jα18 in mice and Vα24Jα18 in humans. These cells recognize the glycolipid Ag α-galactosylceramide (α-GalCer) in association with non-polymorphic CD1d molecules. Type I NKT cells are the predominant population of NKT cells and are usually associated with anti-tumor immunity (118, 119). In sharp contrast, CD1d-restricted type II NKT cells express a wide range of TCRs that recognize CD1d but do not recognize α-GalCer, which have the capacity to suppress the immunosurveillance response. Currently, much less is known about type II than type I NKT cells. However, in tumor immunity, the two NKT subsets (type I and type II) are reported to cross-regulate one another (120, 121).

1.3.3.6 T lymphocytes

T lymphocytes of the adaptive immune system have multi-faceted roles in cancer. In the three-signal model of Ag-specific T cell activation and expansion, binding of the TCR to Ag-loaded MHC (signal 1) on APCs is required for the activation of naive T cells. In order to generate and maintain an adaptive T cell response, full activation of a specific T cell lineage also requires simultaneous engagement of a co-stimulatory signal (signal 2), which is generated by the binding of CD28 on T cells to B7.1/B7.2 (CD80/CD86) on APCs, and an appropriate cytokine environment (signal 3) (122). However, T cell activation is also modulated by coinhibitory molecules, including molecules like cytotoxic T-lymphocyte–associated antigen (CTLA)4 and programmed cell death protein (PD)-1 (123).

CD4+ T helper cells (also known as Th cells) play critical roles during adaptive immune responses (124). Following activation, CD4+ T cells can be differentiated into various Th subsets. Four CD4+ Th cell lineages are generally recognized, namely, Th1, Th2, Th17 and Treg cells, although other Th lineages exist (125). The cytokine environment controls specific transcription factors that are required for Th cell differentiation. Th1 cells express the signature transcription factor T-bet and mainly produce IFN-γ, which is important for the activation of NK cells, M1 macrophage and CTLs in the clearance of intracellular pathogens and tumor cells. In comparison, Th2 cells produce IL-4, IL-5, IL-10 and IL-13, which cross-regulate Th1 responses and favor tissue
remodeling, angiogenesis and tumor promotion (126, 127). Th17 cell differentiation requires a combined stimulation of TGF-β, IL-6, IL-23, as well as IL-21 in mice (128) or IL-1β in humans (129). These cells express the IL-23 receptor (IL-23R) and are characterized by the secretion of high levels of the pro-inflammatory cytokines IL-17 (or IL-17A), IL-17F, as well as IL-21, IL-22 and the (130-132). In addition, Th17 cells also have unique expression of the transcription factor retinoid orphan nuclear receptor (RORγt in mouse, RORC in human), which is regulated by signal transducer and activator of transcription (STAT)3 and IFN regulatory factor 4 (IRF4) (133, 134). Overexpression of RORγt in CD4 T cells promotes Th17 differentiation and inhibits Th1 and Th2 lineage differentiation (133). Th17 cells play critical roles in autoimmunity and during immune responses against extracellular bacteria and fungi (135). However, the role of Th17 cells and their signature cytokine IL-17 in cancer is highly controversial (136) (see section 1.5.3). Furthermore, Tregs are another distinct T cell lineage endowed with regulatory properties that suppress a variety of innate and adaptive immune cells (137, 138). Tregs block antitumor immune responses via a number of contact-dependent and independent mechanisms (139).

CD8+ CTLs play a critical role in immunity against intracellular infections and cancer (140). The cytolytic activity of CTLs is triggered by the recognition of Ag-bearing MHC-I on target cells. The direct interaction of CTLs with target cells is followed by efficient delivery and release of lytic granules or the engagement of Fas/FasL, resulting in the induction of apoptosis and shrinkage of the tumor lesion (141, 142). In addition to cytolytic function, CTLs also produce IFN-γ to indirectly inhibit tumor-induced angiogenesis (143). However, in the context of chronic Ag exposure in chronic inflammation-associated cancer, CTLs may become exhausted and exhibit reduced or defective proliferation, cytokine production and lytic functions (144). Gene profiling and phenotypical studies in mice and humans with chronic viral infections and cancer have shown that exhausted T cells upregulate co-inhibitory molecules, including PD-1, CTLA-4, T cell immunoglobulin, mucin-3 (Tim-3), lymphocyte activation gene 3 (LAG-3), and T cell immunoreceptor with Ig tyrosine-based inhibition motif domain (TIGIT) (71, 144). Notably, expression of multiple co-inhibitory molecules appears to correlate with more severe dysfunction of CTLs in cancer. For instance, it has been shown that the PD-1+TIM3+ CTLs produce less
IFN-γ, TNF, and IL-2, compared to PD-1+TIM3- CTLs in patients with advanced melanoma (145).

1.3.3.7 B lymphocytes

Besides T lymphocytes, B cells are another subset of adaptive immune cells and are responsible for humoral immunity. Naive B cells express both surface immunoglobulins (Ig) M and IgD. Once a B cell encounters a specific Ag that engages its membrane-bound antibody, it serves as an APC to present the Ag on its surface to a unique Th population called follicular T helper cells (Tfh) (146). The interaction with Tfh cells induces the activation of B cells, which undergo clonal expansion and develop into effector plasma cells and memory B cells (146). Plasma cells produce large amounts of Ag-specific antibodies and can undergo somatic hypermutation and class switching to IgA, IgG, or IgE subtypes (146, 147).

The current understanding of B cells in the TME and tumorigenesis is quite limited and highly controversial. B cells do infiltrate into the TME (148, 149); however, they have been reported to induce both pro- and anti-tumor responses (150). In particular, B cells can exert antitumor effects via serving as potent APCs to enhance the activity of Th cells and CTLs. Secondly, the production of tumor-specific antibodies is important in mediating ADCC (151). Finally, B cells are reported to have a direct tumor killing effect via the secretion of granzyme B (152). However, B cells may skew macrophage differentiation into an M2-like, pro-angiogenic phenotype that favors tumor progression (153). Furthermore, B cells may stimulate Th2 cells and immunosuppressive Treg differentiation (154, 155). Furthermore, some regulatory B cells may produce the immunosuppressive cytokines TGF-β and IL-10 (156). Therefore, the balance of functionally distinct B cell subsets may determine whether B cells have pro- or anti-tumor functions.

In summary, both innate and adaptive components of the immune system contribute to an inflammatory TME (Figure 1). Specifically, the key features of tumor-associated inflammation include the infiltration and polarization of immune cells, predominantly immunosuppressive tumor-infiltrated M2 macrophages, MDSCs, Tregs and type 2 neutrophils; the presence of inflammatory cytokines and chemokines, such as TNF, IL-1, IL-6, as well as CCL2 and CXCL8; and lastly, the occurrence of tissue remodeling, metabolic alteration and angiogenesis under hypoxic conditions (157, 158). NK cells and
CTLs are critical immune cells engaged in tumor killing (via perforin, granzyme B and death ligand dependent mechanisms). Th1 cells confer anti-tumor immunity via IFN-γ production and provide important help to CTLs via activating DCs, a process called DC licensing (66). On the other hand, Th2 and Tregs suppress anti-tumor immune responses and are therefore pro-tumorigenic. In addition, different subsets of NKT cells and B cells are involved in both immunosurveillance and immunosuppression, which may positively or negatively regulate tumor development.

1.3.3.8 Stromal cells

The importance of stromal cells in tumorigenesis has been implicated in several animal xenograft models (159, 160). Emerging evidence suggests that stromal cells may respond to tumor cells and/or immune cells within the TME and promote tumorigenesis through the release of soluble mediators, including cytokines (e.g., IL-6 and TGF-β), chemokines (e.g., CXCL12), and growth factors (e.g., hepatocyte growth factor and fibroblast growth factor). For example, it has been shown that CXCL12 secreted by the tumor stromal cells attracts endothelial cell precursors to promote angiogenesis. Furthermore, stromal cell-derived extracellular matrix glycoprotein, tenascin C, promotes the stemness of cancer cells and the enhancement of the degrading capacity of the three-dimensional extracellular matrix, which support tumor cell metastasis (161-163). Therefore, existing evidence suggests that stromal cells play a critical role in shaping the specific TME and regulating tumor cell behavior (161, 162). However, it is relatively less understood how tumor cells may influence the property of stromal cells.

1.3.3.9 Tumor cells

While functionally distinct immune cells are recruited by inflammatory responses in TME, chronic inflammation may promote tumorigenesis by reeducating the TME through suppressing tumor extracellular matrix remodeling, innate and adaptive anti-tumor immunity; and/or by reinforcing angiogenesis and lymphangiogenesis; and/or by enhancing DNA damage and pro-proliferative and survival effects of the tumor cells (164-168). While immune cells and stromal cells are important cellular components in mediating chronic inflammation, malignant cells play a unique role in tumor-associated inflammation. Tumor cells are not only capable of producing different soluble mediators
to amplify inflammation, but also respond to various stimuli to modulate the immune responses, which can directly and/or indirectly influence the course of tumorigenesis (41). A variety of receptor-mediated signaling pathways may be utilized by cancer cells for self-evolving and adapting the TME, thereby modulating the process of tumor development. These signaling pathways may be involved in cell adhesion, inflammatory responses, hormone responses, growth and survival pathways, or they may be required for metabolic and stemness regulation (listed in Table 2). In particular, overexpression of IL-6 is found in many types of tumors and nearly all hallmarks of cancer are influenced by IL-6 during tumour development. The IL-6-triggered activation of primarily JAK/STAT3, but also Ras/Raf/MEK/MAPK and PI3K/AKT signalling pathways, stimulate tumor cell proliferation, survival, promote angiogenesis, invasiveness and metastasis and is also known to regulate cancer cell metabolism, as well as induce therapeutic resistance in cancer (41, 169).
Table 2. Selected receptor-mediated signaling pathways in tumor development

<table>
<thead>
<tr>
<th>Gene altered</th>
<th>Biological function in cancer</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR</td>
<td>Activation of the CDK4/6-Cyclin D for cell cycle progression via RAS-RAF-MEK-ERK-AP1 and PI3K-AKT-mTOR signaling</td>
<td>(170)</td>
</tr>
<tr>
<td>Cadherin</td>
<td>Transmembrane Ca^{2+}-dependent adhesion receptors, suppress tumor growth and invasiveness</td>
<td>(171)</td>
</tr>
<tr>
<td>IL-6R</td>
<td>Promotes STAT3-dependent tumor cell proliferation, stemness, invasiveness and inflammation</td>
<td>(172)</td>
</tr>
<tr>
<td>TLR4</td>
<td>Promotes tumor growth, cell migration and invasion, as well as inducing tumor apoptosis and inflammation</td>
<td>(173)</td>
</tr>
<tr>
<td>TNFR1</td>
<td>Cytotoxicity, promotes cancer cell proliferation and metabolism, induces cancer-related inflammation</td>
<td>(174)</td>
</tr>
<tr>
<td>IL-1R1</td>
<td>Initiates and propagates inflammation, promotes cancer growth</td>
<td>(175)</td>
</tr>
<tr>
<td>ER/PR/Her2</td>
<td>Hormone and growth factor receptors, mediates tumorigenesis, cell growth, apoptosis and resistance to chemotherapy (176-178)</td>
<td></td>
</tr>
<tr>
<td>GPR81</td>
<td>Lactate-specific cell-surface G-protein-coupled receptor, promotes lactate metabolism, cancer growth, survival and angiogenesis (179)</td>
<td></td>
</tr>
<tr>
<td>Notch</td>
<td>Promotes self-renewal, differentiation and proliferation of stem-like population of cancer cells</td>
<td>(180)</td>
</tr>
<tr>
<td>FZDs</td>
<td>Wnt receptors, promote tumor cell growth, invasion, motility, stemness and metastasis</td>
<td>(181)</td>
</tr>
</tbody>
</table>

1.3.4 Mechanisms of immunosubversion

1.3.4.1 Immune suppression

It has become clear over the last few decades that an immunosuppressive TME supports tumor cell proliferation, survival, metabolic reprogramming, angiogenesis and metastasis (Figure 1) (65). Immunosuppressive cells (e.g., Tregs and MDSCs) inhibit effector functions of tumor-infiltrating lymphocytes, such as T cells and NK cells, through either cell-cell interactions (182) or the release of soluble factors, such as IL-10, TGF-β and VEGF, that suppress the local immune responses in a paracrine fashion (183). The immunosuppressive cytokines may inhibit effector T cells indirectly through dendritic cells to attenuate the infiltration of T cells into the tumor bed (184) and/or directly by repressing the Ag presentation process for the activation of T cells (185).

A variety of immune cell-mediated suppressive mechanisms are described in the literature, many of which are known to be shaped by the soluble mediators and/or surface molecules expressed by tumor cells and/or stromal cells (62, 79, 183). For instance, granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF, respectively), induced by proinflammatory cytokines (e.g., IL-1, IL-6 and IL-17) in the TME, promote the accumulation, expansion, and activation of MDSCs (107, 186, 187). In addition, tumor cells secrete high levels of tryptophan and L-arginine metabolizing enzymes, such as IDO and arginase, into the TME which lead to the depletion of these building blocks that are essential for T cell proliferation (188). The metabolic disturbance, along with hypoxia and pH imbalance, in the TME result in further generation of ROS/RNS, which fuels chronic inflammation and the imbalance of immunosurveillance and immunosuppression.

Tumors also evade cell surface death receptor signals, such as Fas (189) and TNF-related apoptosis-inducing ligand (TRAIL) receptor (190), via down-regulation, mutation, or loss of expression. Furthermore, tumor cells can directly escape TCR recognition by HLA-loss and generating MHC class I processing-defective variants (191), the loss or down-regulation of HLA class I antigens (192), or by disabling other co-stimulatory signals of the antigen processing machinery (193). In addition, tumor cells may upregulate cell surface co-inhibitory ligands, such as PD-L1 (194), which mediate T-cell anergy (or immune exhaustion).
1.3.4.2 Immune exhaustion

The concept of immune exhaustion was first introduced to describe the stepwise and progressive loss of T-cell functions during chronic viral infections (195). Exhausted T cells express arrays of inhibitory molecules and distinctive patterns of cytokine receptors, transcription factors and effector molecules, which distinguish these cells from conventional effector, memory and anergic T cells (71, 144). PD-1, along with Tim-3 and Lag-3, are the most prominent coinhibitory receptors expressed by exhausted T cells. PD-1 is expressed by a variety of immune cells, including CD4+ and CD8+ T cells, B cells, monocytes, DCs and macrophages (196-199). PD-1 binds to two ligands: programmed cell death 1 ligand 1 (PD-L1, B7-H1, or CD274) and PD-L2 (B7-DC, or CD273). PD-L1 is broadly expressed on hematopoietic and non-hematopoietic tissues, whereas PD-L2 is only expressed on hematopoietic cells, such as DCs, macrophages, mast cells and B cells (200-203). The overexpression of (PD-L1 in mouse and human cancers supported a role for exhausted T cells in cancer (204, 205), which was later shown to render tumor cells less susceptible to the specific TCR-mediated lysis by cytotoxic T cells (194, 206).

T cell exhaustion is mediated by PD-1 forming negative costimulatory microclusters, which recruit the phosphatase SHP2 (Src homology 2 domain-containing tyrosine phosphatase 2) and TCRs, leading to the dephosphorylation of CD28 (207) and other TCR signaling molecules (205, 208). The exhausted T cells are incapable of further activation or division even when exposed to the antigen in pro-stimulatory conditions, which in turn induces anergy or apoptosis of these tumor-specific T cells (196). The expression of PD-1 by tumor-infiltrating lymphocytes (209), along with the constitutive or inducible expression of PD-L1/L2 in numerous tumor types (210, 211), have been correlated with invasiveness, metastasis and poor prognosis in cancer.

T-cell exhaustion is largely induced in the specific TME in cancer patients. Tumor cells, stromal cells and tumor-infiltrating immune cells (tumor-associated DC, Treg, TAM and MDSC) are major cellular components that regulate exhaustion by secreting soluble mediators and expressing specific ligands of inhibitory receptors. The induction of PD-L1 on cancer cells is mediated through multiple mechanisms, including cytokines and growth factors (primarily IFN-γ, but also type I IFNs, IL-4, IL-10 and VEGF) (196, 206, 212), the activation of oncogene pathways (e.g., EGFR) (213), the loss of tumor suppressor signals
(e.g., PTEN) (214) and other environmental cues (e.g., hypoxia) (215). Being a ligand to PD-1, PD-L2 also dampens the functional activity of effector T cells (216). However, the transcriptional regulation of PD-L2 is less well defined (206). Compared to PD-L1, PD-L2 can also be induced by some inflammatory cytokines, especially IL-4, along with other mediators (e.g., GM-CSF, IFN-γ and IFN-β) (200, 217, 218).

1.4 Key pro-inflammatory signaling pathways in cancer

1.4.1 Overview

During chronic inflammation, a wide array of intracellular signaling pathways, comprising cell surface receptors, kinases, and transcription factors, are often dysregulated, leading to malignant transformation, tumor development and metastasis (45, 219, 220). Inflammation activates a variety of protein kinases, including members of the Janus kinase (JAK), phosphatidyl-inositol-3-kinase (PI3K), and mitogen-activated protein kinase (MAPK) families to alter cellular proliferation. Besides protein kinases, inflammation also induces aberrant activation of transcription factors, such as STAT family members, hypoxia inducible factor-1α (HIF-1α), NF-κB and activation protein-1 (AP-1) downstream of the MAPK pathway, which have been implicated in tumor growth, angiogenesis, and metastasis (41, 219, 220). In the following sections, I will specifically discuss the signalling pathways that are highly relevant to my thesis.

1.4.2 NF-κB pathway

NF-κB consists of hetero- and homo-dimers of five different proteins (p50, p52, p65 or RelA, RelB, and c-Rel) sharing a conserved N-terminal region that can bind DNA (221). In most cases, NF-κB is trapped as an inactive form in the cytoplasm due to direct binding to inhibitor proteins of the IκB family, such as IκB-α. Upon activation by pro-inflammatory cytokines or stress stimuli [e.g., hypoxia, ROS and ultraviolet (UV)], activated NF-κB is liberated and translocated to the nucleus where it binds to the κB elements located in the proximal promoter region of genes of proinflammatory mediators, such as cytokines (222), iNOS (223), and COX2 (224). Specifically, the canonical (or classical) NF-κB pathway is triggered by IKKαβγ-induced IκBα degradation, leading to p50/RelA heterodimer nuclear localization and the gene expression of proinflammatory cytokines, chemokines, growth factors and MMPs. By contrast, the non-canonical (or alternative) pathway is largely
caused by activation of NF-κB-inducing kinase (NIK) mediated IkBα degradation, leading to p52/RelB heterodimer nuclear localization. This pathway differs from the canonical pathway in that only certain receptor signals (e.g., B-cell activating factor [BAFF], CD40) activate this pathway for adaptive immune responses and secondary lymphoid organ development (225). In the third pathway, IKK activation is not required. DNA damage (UV irradiation), certain chemotherapeutic drugs, or alternative reading frame (ARF) tumor suppressor inactivation results in the activation of this pathway and leads to p50 (or p52) homodimers entering the nucleus. The complex induces pro-apoptotic gene transcription and functions as a tumor suppressor (226). How this atypical pathway is regulated is largely unknown.

The canonical NF-κB is constitutively activated in many tumors (227, 228) and in chronic inflammatory conditions such as inflammatory bowel disease (IBD) and gastritis (229, 230). As a cancer-promoting factor, the classical NF-κB pathway represses apoptosis (231) and promotes angiogenesis (232), tumor metastasis (233), and cell cycle progression (234). To date, the molecular mechanisms underlying constitutive NF-κB activation in cancer are incompletely understood, although the stress conditions in TME (41, 230, 235), such as hypoxia, production of ROS/RNS and pro-inflammatory stimuli, are believed to play important roles in the process.

1.4.3 MAPK pathway
1.4.3.1 Overview

MAPKs are ubiquitously expressed and play an essential role in intracellular transduction of signals activated by a wide variety of extracellular stimuli, such as growth factors and stress (Figure 2) (236). Activation of the MAPK cascade consists of 3~5 tiers of protein kinases that are activated in a sequential, tight and specific fashion, in which one or more of each tier goes on to phosphorylate and activate components of the next tier. For instance, a MAP3K phosphorylates and activates a downstream dual-specificity MAP2K, which in turn stimulates MAPK activity through dual phosphorylation on threonine and tyrosine residues within a conserved tripeptide motif (Thr-X-Tyr) (237). The MAPK family proteins activate distinct cascades: extracellular signal-regulated kinase (ERK)1/2 pathway, p38-MAPK pathway, c-Jun N-terminal kinases (JNK)1/2/3 pathway, and ERK5 (also known as Big MAP kinase, or BMK1) pathway, according to their most downstream
kinase tier (238). The MAPK signaling cascades are highly conserved and mediate a plethora of critical cellular functions, including proliferation, differentiation, migration, apoptosis and inflammation (238, 239).

In 2002, the Cancer Genome Project conducted by the Sanger Institute identified hyper-activation of the MAPK pathway in over 90% of melanoma patients, which drew the world’s attention to this pathway for potential targeted cancer therapies (240). Notably, the most frequently affected genes lay in the RAS-RAF-MEK (MAPK/ERK kinase)1/2-ERK1/2 cascade, with alterations on BRAF (40%–50%) and NRAS (15%–20%), which usually present as oncogenic gain-of-function mutations (240). In other solid and hematopoietic malignancies, KRAS or NRAS mutations have been found in about 55% of metastatic CRC [10-14]. While BRAF is mutated in about 20% of all cancers, lower rates of BRAF mutations have been observed in lung cancer (2-4%), whereas KRAS mutations remain the most frequent alteration (20-30%) in lung cancer (241). Furthermore, KRAS or NRAS mutations also occur in a significant number of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (20%-30%) (242-244). Of note, KRAS mutation in epithelial neoplastic cells directly induces the expression of proinflammatory cytokines and cytokine receptors, such as IL-17A and IL-17RA, highlighting the importance of inflammation in tumor development (245, 246).

The aberrant activation of JNK proteins has been reported in multiple cancer cell lines and tissue samples (247-250). In a mouse model of intestinal cancer, Apc^{Min} (Min, multiple intestinal neoplasia) mice bearing non-phosphorylatable mutant form of c-Jun developed smaller and fewer polyps, confirming the oncogenic function of c-Jun in tumorigenesis (251).
Figure 2. The four canonical MAPK signaling pathways. Modified from (237-239).
1.4.3.2 JNK pathway

The JNK branch of the MAPK pathway, also known as stress-activated protein kinases (SAPKs), are activated by a wide range of stimuli, including pro-inflammatory cytokines and stress signals, such as UV-irradiation and starvation, as well as some mitogenic signals such as lipopolysaccharide (LPS) (252, 253). These stimuli may recruit and phosphorylate the GTPase Ras-related C3 botulinum toxin substrate 1 (RAC1), which sequentially activates the p21-protein activated kinase family to phosphorylate and activate members of the MAP3K kinase tier. The MAP3K tier dual-phosphorylates MAP2K4 (MKK4) at Ser257 and Thr265, or MAP2K7 (MKK7) at Ser271 and Thr275, which in turn, activate the three members in the JNK family, including MAPK8 (JNK1), MAPK9 (JNK2), and MAPK10 (JNK3). While, MKK4 and MKK7 preferentially phosphorylate JNKs on tyrosine and threonine residues, respectively, mice with targeted deletions in either MKK4 or MKK7 genes exhibited early embryonic death, supporting an essential role for the JNK-MAPK signaling pathway in the regulation of developmental processes (254). MKK4 is also required for maintaining peripheral lymphoid homeostasis and therefore acts as a tumor suppressor (255). Dysregulation of the JNK cascade has been reported in cancer. For example, activating oncogenic RAC1 mutations have been found at a high frequency in melanoma (256). Furthermore, deletion and/or epigenetic silencing of MKK4 have been reported in breast, biliary, pancreatic, and prostate cancers (257, 258).

Upon stimulation, JNKs phosphorylate and activate a number of nuclear and non-nuclear proteins, including AP-1, p53, ATF2, STAT3 and nuclear factor of activated T-cells (NFAT), for signal transduction. In particular, AP-1 is a transcription factor that is formed by the dimerization of Jun proteins (c-Jun, JunB, JunD) with Fos proteins (c-Fos, FosB, Fra-1, Fra-2), to control cell proliferation, differentiation, cell death, inflammation and cell metabolism (252, 253). Oncogenic Ras-mediated cellular transformation has been shown to involve the induction of AP-1 activity and the accumulation of Cyclin D1, a signature protein downstream of c-Jun (259). Another important target is the tumor suppressor p53 whose expression as well as transcriptional function are regulated by AP-1 proteins (260). As such, the dysregulated expression of AP-1 is involved in tumorigenesis (261). Notably, the composition of AP-1 dimers and the relative abundance of individual AP-1 subunits, as well as the cell type and the cellular environment, are important factors.
for determining cell fate (260, 262, 263). Specifically, the biological activity of c-Jun is controlled by post-translational phosphorylation of serine-63 and/or serine-73 residues, as well as the turnover level of c-Jun expression (264). While c-Jun is activated by JNK-mediated N-terminal phosphorylation, the phosphorylation of c-Jun at threonine-239 and serine-243 by glycogen synthase kinase 3 (GSK3) creates a high-affinity binding site for polyubiquitination and proteasomal degradation (265). Similar to the MKK4/7 deficient mice, embryonic lethality has also been reported at mid-gestation in c-Jun knockout (c-Jun−/−) mice due to impaired hepatogenesis (266, 267). Furthermore, c-Jun−/− fibroblasts exhibit a severe defect in cell cycle progression, suggesting that the JNK/c-Jun pathway is a key mediator of cellular proliferation (Figure 3) (267).

The JNK pathway is also involved in apoptotic pathways, which include death receptor-initiated extrinsic pathways and intrinsic pathways involving mitochondria (Figure 3) (268). JNK is able to phosphorylate and inactivate the proapoptotic Bcl-2 family protein Bad, thereby suppressing IL-3 withdrawal-induced apoptosis in B cell lymphoma/leukemia (269). JNK activation is also involved in pro-apoptotic pathways. An important activator of the JNK apoptotic pathway is TNF-α, a pro-inflammatory cytokine that governs cell survival via promoting either cell proliferation or apoptosis (270). However, JNK activation alone can only potentiate apoptosis and is not sufficient to induce apoptosis. Furthermore, the activation of the NF-κB pathway inhibits TNF-α-induced JNK-dependent apoptosis (271). Nevertheless, this pro-survival role of NF-κB is not observed in JNK-dependent apoptosis triggered by IL-1 or UV. Therefore, JNK may mediate apoptosis in a stimulus- and cell type-dependent manner (272). In addition, JNK-induced apoptosis has been proposed to drive the surviving neighboring cells to proliferate in NF-κB-deficient Drosophila and animal models through a process named “Compensatory Growth” (Figure 3) (273-275), which adds even more complexity to the role of JNK in mediating cellular turnover.
Figure 3. JNK signaling in the regulation of cellular apoptosis and proliferation (253, 268, 275).
1.4.3.3 Biology and function of JNK isoforms

The generation of mice deficient in one or more of the JNK isoforms, as well as shRNA targeted JNK isoform-specific knockdown on cell lines, have facilitated the functional analysis of the role of individual JNKs. While JNK1 and JNK2 are expressed broadly, JNK3 is expressed predominantly in the brain, testis, and heart (276). Consistently, in the adult mouse brain, JNK3, but not JNK1 or JNK2, was required for the kainic acid (kainate)-induced apoptosis of hippocampal neurons (277) and the loss of neurons following ischemic injury (278), clearly demonstrating that JNK3 plays a vital role in mediating stress-induced apoptotic responses of neurons.

While the two ubiquitously expressed JNK proteins—JNK1 and JNK2 are shown to have overlapping roles in various biological functions, such as promoting cytokine production, they are reported to have distinct roles in controlling c-Jun-dependent cellular proliferation (Figure 3) (253, 279, 280). Under homeostatic conditions, JNK2 mainly targets c-Jun for degradation, whereas following stimulation, JNK1 becomes dominant, phosphorylating and stabilizing c-Jun, leading to transcriptional activation (281). Consequently, JNK1 and JNK2 are shown to oppositely regulate the stability and activation of c-Jun-dependent proliferation in fibroblasts. Specifically, JNK1 promotes and JNK2 inhibits cell cycle progression, a phenotype that is directly correlated with c-Jun phosphorylation and AP-1 activity (279). The increased proliferation of JNK2−/− fibroblasts is primarily due to compensatory increases in JNK1/c-Jun expression and function (282). The opposing roles of JNK1 versus JNK2 in proliferation have also been reported in erythrocytes and keratinocytes (279). Furthermore, the epidermis isolated from JNK2−/− and JNK1−/− mice is hyperplastic and hypoplastic, respectively (280).

In addition to controlling cell proliferation, JNK1, but not JNK2, has been shown to promote UV- or TNF-α-induced apoptosis in skin cancer cells (283, 284). Conversely, JNK2 is shown to constitutively suppress JNK1-mediated apoptosis in multiple myeloma cells and promote cell survival (249). Notably, the loss of both JNK1 and JNK2 in murine embryonic fibroblasts protects them from apoptosis due to defective death signaling (285). Taken together, both JNK1 and JNK2 are involved in apoptosis in an antagonistic manner, it is likely that JNK1 exhibits a dominant role over JNK2 to promote apoptosis.

Furthermore, whether JNK1 and JNK2 act as oncogenes or tumor suppressor genes
has been examined using KO mice. In carcinogen-induced hepatocellular carcinoma and skin cancer models, increased and reduced tumor incidence were exhibited in JNK1\(^{−/−}\) and JNK2\(^{−/−}\) mice, respectively (247, 286, 287). Importantly JNK1\(^{−/−}\) mice also develop spontaneous intestinal tumors, which further confirmed the tumor suppressor role of JNK in the cancer initiation process (288). However, how cancer cells utilize JNK isoform-dependent control in cancer development is largely unknown.

In current clinical applications, patients respond transiently to MAPK pathway inhibitors, such as BRAF and MEK inhibitors used in melanoma patients. These drugs have toxic effects on non-cancer cells and generate drug-resistance leading to cancer relapse in more than 70% of patients (289). Thus, biomarker studies are needed to identify those tumors that are susceptible to MAPK inhibition and to provide support for potential combinational treatments. Given that current JNK inhibitors that have been developed for cancer therapy have several limitations, such as a lack of specificity and cellular toxicity (253), conditional genetic experiments of specific JNK isoforms in different cancer types are necessary to better define the molecular mechanisms of JNK function.

1.5 IL-17 and IL-17 receptor (IL-17R) family

1.5.1 Overview

IL-17A (IL-17) is recognized as one of the most potent cytokine stimuli in chronic inflammation (290, 291). IL-17A and IL-17 receptor A (IL-17RA) are the founding members of the IL-17/IL-17R family which consists of six structurally related ligands (IL-17A to IL-17F) and five receptors (IL-17RA to IL-17RE) (Figure 4) (129, 291-293). While the ligands are identified based on the rate of amino acid homology with IL-17A, members of the IL-17Rs are defined by the conservation of a SEFIR (similar expression to fibroblast growth factor and IL-17R) domain in the cytoplasmic tail (294). The extracellular domains of IL-17Rs contain two fibronectin (FN) III-like motifs, which mediate protein-protein interactions, such as pre-assembly of the IL-17R complex for dimerization and ligand binding (294-296). Notably, both IL-17RA and IL-17RC possess an extra ~100 residues beyond the conventional SEFIR domain. This non-conserved region is termed as the SEFIR-extension (SEFEX) domain and is required for IL-17RA and IL-17RC signaling functionality (297-299). Unique to IL-17RA, following the SEFIR/SEFEX domain in the cytoplasmic tail, there is an additional motif named CCAAT/enhancer binding protein
(C/EBP)-β activation domain (CBAD), whose function is associated with negative regulation of IL-17RA signaling (see section 1.6.2) (297, 300). Consistent with the unique structure of IL-17RA, it is located on chromosome 22, while all other family receptor subunits are encoded by a cluster on chromosome 3 (301, 302).

The IL-17 family ligands signal through multimeric receptor complexes, which are formed by the association of receptor subunits with one another (Figure 4) (291). IL-17RA is a common receptor subunit shared by the ligands IL-17A, IL-17F, IL-17C and IL-17E (IL-25). IL-17RC is an obligate co-receptor for IL-17RA and forms multimeric RA/RC complexes for IL-17A, IL-17F and IL-17A/F signaling (292). IL-17B signals through homodimeric IL-17RB, whereas IL-17C and IL-17E utilize receptor complexes of IL-17RA-RE and IL-17RA-RB, respectively (303). Currently, the receptors for IL-17D and IL-17RD remain unknown (291).

IL-17 receptor subunits are expressed in multiple tissues: IL-17RA is expressed ubiquitously, with a relatively higher level in hematopoietic immune cells (304, 305). By contrast, IL-17RC expression in hematopoietic cells is low, but high in non-hematopoietic structure cells of the prostate, liver, kidney, thyroid and joints (306, 307). IL-17RB is expressed in a variety of endocrine tissues, the kidney, pancreas, liver, intestine and on Th2 cells (308). IL-17RD is mainly expressed in the epithelial cells of breast, thyroid gland and prostate (309), as well as endothelial cells (310), whereas IL-17RE is found in the pancreas, brain and prostate (292). It is likely that different distributions of IL-17Rs are correlated with distinct biological functions of the IL-17 cytokine family members in various tissue compartments.
Figure 4. IL-17R family ligand-receptor structure (291, 303).

Some of the ligands or receptors are shown as unknown ligands and receptors. There are no known ligands for IL-17RD homodimers and IL-17RD/IL-17RA heterodimers. There is no known receptor for IL-17D. FN, fibronectin. SEFIR, similar expression to fibroblast growth factor and IL-17R. SEFEX, similar expression to fibroblast growth factor and IL-17R-extension. TILL, Toll/IL-1 receptor-like loop. CBAD, C/EBP-beta activation domain.
Among the IL-17 family ligands, pro-inflammatory IL-17A and IL-17F are the closest, share ~55% homology, and best understood family members (129). They are secreted as IL-17A and IL-17F homodimers, as well as IL-17A/F heterodimers. Both IL-17A and IL-17F induce activation of NF-κB and MAPK pathways in targeted cells, leading to the production of other pro-inflammatory cytokines, chemokines, and other molecules including growth factors and MMPs (291). While the homodimer of IL-17A is 10-30 fold more potent than IL-17F in activating proinflammatory responses, the heterodimer has an intermediate efficacy (301, 311). Notably, in the context of cytokine-driven inflammation, which is enriched for proinflammatory mediators, such as TNF, there is a clear synergy between IL-17F and TNF, reaching a comparable potency to the effect that is induced by the combination of TNF and IL-17A (312, 313). IL-17A and IL-17F fuel inflammation through the production of a variety of inflammatory cytokines (e.g., IL-6), chemokines (e.g., IL-8 and CXCL1), and growth factors (e.g., GM-CSF and G-CSF), which facilitate leukocyte differentiation and recruitment, particularly neutrophils and monocytes, into the inflammatory sites (291-293, 314). IL-17A also stimulates IL-12 production by DCs thereby, bridging innate and adaptive immunity (315). In addition, IL-17A-induced CCL20 favors the migration of Th17 cells and immature dendritic cells which interact with local mesenchymal cells, leading to a massive secretion of IL-17A at the site in an autocrine fashion (294, 295). Besides the potent proinflammatory role of IL-17A in neutrophil differentiation, migration and activation, it also contributes to the induction of angiogenesis by promoting VEGF production (316), plays roles in maintaining gut barrier function and host defense against extracellular pathogens (317-319). IL-17A also plays important roles in the pathogenesis of auto-immune and inflammatory diseases, with increased concentrations documented in psoriasis, rheumatoid arthritis, inflammatory bowel disease, allergic asthma and cancers (136, 298, 320-322). After its first description in 1993-1995, IL-17A/IL-17RA signaling has been recognized as a target in chronic inflammation due to its role in the pathogenesis of numerous autoimmune and inflammatory diseases, as well as cancers (316, 323-325). However, while promising outcomes were observed in certain diseases such as psoriasis and psoriatic arthritis, clinical trials of secukinumab (anti-IL-17A) and brodalumab (anti-IL-17RA) in Crohn’s disease were terminated early due to worsening of disease in the treatment group (326, 327), highlighting the need to further
investigate this axis in a tissue microenvironment specific manner.

Compared to IL-17A and IL-17F, the functions of IL-17B, IL-17C, IL-17D and IL-17E in cellular turnover and immune responses are less well defined. IL-17B promotes tumorigenesis via the induction of NF-κB dependent anti-apoptotic protein Bcl-2 (B-cell lymphoma 2) expression and heightens inflammation through augmented neutrophil accumulation and granulopoiesis (308). As such, elevated IL-17B expression often correlates to poor prognosis in breast cancer patients (303). Similarly, IL-17C exhibits an autocrine ability to induce Bcl-2 and Bcl-xL expression in epithelial cells, which in turn, promotes cell survival and tumorigenesis (328). Furthermore, as an IL-17RA ligand, IL-17C also induces the production of proinflammatory cytokines, chemokines and antimicrobial peptides (329, 330). IL-17D was reported to promote pro-inflammatory gene expression in endothelial cells and exhibits a mild inhibitory effect on myeloid progenitor cell proliferation in vitro (331). More recently, the expression of IL-17D has been reported to be triggered by oxidative stress through the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), which offers protection to the host by recruiting NK cells to suppress tumor growth (310) and viral infection (332). IL-17E is the most distant homolog with IL-17A of 17% homology. IL-17E is produced by epithelial cells, eosinophils, basophils, mast cells, monocytes, macrophages and T cells (292, 293). In sharp contrast to other IL-17 family ligands, IL-17E presents distinct functional behavior, stimulating lymphocytes to produce Th2-related cytokines, such as IL-4 and IL-13. To this end, IL-17E inhibits Th1-mediated anti-tumor responses and plays roles in allergic inflammation and host defense against parasites (333-335). Recently, a pro-apoptotic role of IL-17E has also been identified in breast cancer cells (336), suggesting the role of IL-17E in cancer may be context-dependent.

1.5.2 IL-17A, IL-17F and IL-17RA/RC axis

A wide range of cell types, including type 17 CD4+ T helper cells (Th17), γδ T cells, and innate lymphoid cells (337-339), as well as tissue structure cells like Paneth cells of the intestinal epithelium (340), are capable of producing IL-17A. The expression, signaling and biological function of IL-17F often overlap with IL-17A, however, minor differences lay in their relative distributions in various organs and cell types, as well as their receptor binding affinities (291, 293).
In humans, IL-17RA has an extremely low affinity to IL-17F, but can bind to IL-17A with a higher affinity than IL-17RC; whereas IL-17RC binds with higher affinity to IL-17F than to IL-17A (307). Therefore, cells with high IL-17RC expression could be highly responsive to IL-17F, whereas cells with low IL-17RC expression but high IL-17RA expression might respond better to IL-17A. The situation is somewhat different in mice, in which IL-17RA binds both IL-17A and IL-17F equally, whereas IL-17RC binds strongly only to IL-17F (292). Although human IL-17A and IL-17F homodimers can bind independently to IL-17RA and IL-17RC, both chains are reported to be required for IL-17A and IL-17F biological functions such as ligand-induced chemokine production (292, 341).

Notably, more than 20 spliced variants of human IL-17RA have been reported in NCBI databases (AceView) and at least 90 splice isoforms of IL-17RC are identified in human prostate cancer lines (292, 301). Similarly, mouse IL-17RA and IL-17RC are found to have at least 3 and 6 splice variants according to NCBI databases, respectively (292, 301). While full-length IL-17RA and RC are required for intracellular signal transduction leading to chemokine production (292, 341), the biological role of truncated splicing variants of IL-17RA and IL-17RC is unknown.

1.5.3 IL-17A functional paradox in cancer

IL-17A is a pleiotrophic inflammatory cytokine that has multi-faceted roles in cancer (136, 316). Clinical studies have detected IL-17A-producing cells in a variety of human cancer samples with elevated frequencies of tumor-infiltrating Th17 cells in ovarian, melanoma, breast and colon cancers (136, 342). Consistently, there is an increased IL-17A level in blood from patients with gastric (343) or lung cancers (344). Notably, phenotypic analyses suggested that tumor-infiltrating Th17 cells do not express CCR2, CCR5 or CCR7, which limit their capacity to home to the draining lymph nodes (345). This feature may explain the accumulation of Th17 cells in the TME, where CCL20 and CXCL12 are expressed at high levels (346). Furthermore, Th17 can secret CCL20 in an autocrine manner (347), which could enhance their recruitment to the tumor site.

An increased level of IL-17A in cancer patients is associated with poor prognosis in some studies, but improved prognosis in other reports (136, 316). To deal with this controversy, the role of IL-17A in tumorigenesis has been postulated to depend on multiple
factors including the specific tumor type and the cellular sources of IL-17A (136, 291, 316, 345). Various molecular and cellular mechanisms are reported to mediate the pro-tumor and/or anti-tumor functions of IL-17A. IL-17A can control cancer development via promoting inflammatory responses (324, 348), or inducing the production of VEGF and MMPs to favor angiogenesis, tumor invasion, and establishment of metastatic foci at secondary sites (349-352), or by facilitating tumor growth via enhancement of the IL-6-STAT3 signaling pathway (353). IL-17 may also promote an immune-suppressive TME by inducing the production and recruitment of MDSCs and Tregs (345, 354). In sharp contrast, the anti-tumor effect of IL-17 is attributed to increased immune responses by effector T cells and NK cells (355, 356). Finally, IL-17A may directly influence tumor growth, survival and neoplastic transformation in a cell type-dependent manner (Table 3). Notably, while IL-17A is reported to induce neoplastic transformation and proliferation with suppression of apoptosis in some tumor cell lines in vitro, it fails to do so in many other tumor cell lines (355, 357), and some primary cell types (358-360). This phenomenon suggests that the role of IL-17A signaling in tumor cell proliferation and survival is tightly regulated. However, the molecular mechanisms underlying the tumor-specific control of cellular turnover are largely understudied.
Table 3. Examples of IL-17/IL-17R signaling impacts on cellular turnover.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Model</th>
<th>Biological function</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-17</td>
<td>Human cervical cancer cell lines</td>
<td>No direct effect on <em>in vitro</em> cellular proliferation</td>
<td>(357)</td>
</tr>
<tr>
<td>IL-17</td>
<td>P815 &amp; J558L cells</td>
<td>No direct effect on <em>in vitro</em> cellular proliferation</td>
<td>(355)</td>
</tr>
<tr>
<td>IL-17</td>
<td>HIEC</td>
<td>Inhibits p38-MAPK-dependent proliferation without altering survival</td>
<td>(358)</td>
</tr>
<tr>
<td>IL-17RC</td>
<td>KO mouse</td>
<td>Promotes the formation and growth of prostate adenocarcinoma</td>
<td>(361, 362)</td>
</tr>
<tr>
<td>IL-17RC</td>
<td>Human prostate cancer cell lines</td>
<td>Anti-apoptotic in androgen-independent prostate cancer cell lines</td>
<td>(363)</td>
</tr>
<tr>
<td>IL-17RA</td>
<td>KD in 4T1 cells</td>
<td>Promotes tumor proliferation with inhibition of apoptosis in pooled shRNA-transfected clones</td>
<td>(364)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Human ASMC</td>
<td>Promotes ERK1/2-MAPK-dependent proliferation</td>
<td>(365)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Human &amp; mouse prostatic cell lines</td>
<td>No direct effect on <em>in vitro</em> cellular proliferation</td>
<td>(359)</td>
</tr>
<tr>
<td>IL-17</td>
<td>JB6 Cl41 &amp; MCF7 cells</td>
<td>Induces TPL2-dependent neoplastic transformation</td>
<td>(366)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Human FLS</td>
<td>Promotes the STAT3-dependent survival and proliferation</td>
<td>(367)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Mouse NSC</td>
<td>Inhibits proliferation and differentiation without inducing cytotoxicity or apoptosis</td>
<td>(360)</td>
</tr>
<tr>
<td>IL-17</td>
<td>AGS &amp; SGC790I cells</td>
<td>Promotes cell proliferation and monolayer wound healing with inhibition of apoptosis</td>
<td>(368)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Human MM cells</td>
<td>Induces cell proliferation and migration with inhibition of cellular apoptosis and adhesion</td>
<td>(369)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Mouse keratinocytes</td>
<td>Promotes TRAF4-ERK5-dependent keratinocyte proliferation and tumor formation</td>
<td>(370)</td>
</tr>
<tr>
<td>IL-17</td>
<td>T47D, IJG-1731 BT-20, MCF7cells</td>
<td>Induces proliferation and survival of tumor cells</td>
<td>(371)</td>
</tr>
<tr>
<td>IL-17</td>
<td>Human B-ALL</td>
<td>Promotes proliferation and resistance to daunorubicin-induced cell death</td>
<td>(372)</td>
</tr>
</tbody>
</table>

1.5.4 IL-17A signaling pathways

1.5.4.1 Gene transcription

The downstream signaling cascades from IL-17RA and IL-17RC have been studied mostly using primary fibroblast cells (291-293) (Figure 5). The binding of IL-17A, or its close family member IL-17F, to the IL-17RA-RC complex recruits the intracellular adaptor protein Act1, which is required for the activation of signaling pathways triggered by all known IL-17 family ligands (293, 373). As a lysine-63 (K63) E3 ubiquitin ligase, Act1 recruits and activates TNF receptor associated factor-6 (TRAF6) via ubiquitination. Upon ligand binding, IL-17R recruits a unique adaptor protein known as Act1 through a SEFIR-SEFIR interaction, Notably, TRAF6 is also a K63 E3 ligase, which recruits and facilitates transforming growth factor β-activated kinase (TAK)1-TAB (TAK1-binding protein) 2/3-dependent phosphorylation and activation of the inhibitor of nuclear factor-κB kinase (IKK) complex, including IKKα, IKKβ and IKKγ (or NF-kappa-B essential modulator, NEMO). Subsequently, the activated IKK phosphorylates the IκB subunit (e.g., IκBα), leading to its proteasomal degradation and the release of canonical NF-κB for rapid nuclear translocation and consequent gene transcription (291-293, 374). The molecular mechanism of how TAK1 is activated by ubiquitinated TRAF6 during IL-17 signaling is unclear; however, a lysine at position 63 is both necessary and sufficient for ubiquitin to activate TAK1, likely through the K63-linked polyubiquitination by TRAF6 (375).

Besides the canonical NF-κB pathway, IL-17RA/RC-Act1-TRAF6 signaling also induces selective activation of MAPK (ERK, p38 and/or JNK) pathways in different target cells, which leads to the activation of AP1 transcription factors (376-379). In particular, activated TAK1 can phosphorylate MAP2Ks (such as MKK6) (375), or activate IKK-dependent release and activation of the serine/threonine kinase, tumor progression locus (TPL) 2 (366), which leads to pro-inflammatory gene transcription. More recently, IL-17R-Act1-TRAF4-MEKK3-MEK5-ERK5 signaling has been reported to promote IL-17-induced gene transcription resulting in keratinocyte proliferation and tumorigenesis (370).
Figure 5. Schematic of IL-17/IL-17R signaling (291).
In addition, a microarray screen for IL-17A-induced genes identified that the activation of the *IL-6* promoter has an absolute requirement for the transcription factors C/EBP-β/δ following IL-17A and TNF-α stimulation (380). Further studies suggested that C/EBP-β and C/EBP-δ are indispensable for transcription from several gene promoters (e.g., *IL-6*), even with an intact NF-κB site (381, 382). Furthermore, as stated above, both IL-17A and IL-17F have synergistic effect with TNF in the transcriptional induction of proinflammatory cytokine genes, such as the *IL-6* and *CXCL1*, and the overexpression of either C/EBP-β or C/EBP-δ can replace the contribution of IL-17A in this additive signal (380). Nevertheless, C/EBP-β and C/EBP-δ seem to function redundantly, as reconstitution of cells lacking both C/EBP-β and C/EBP-δ with either transcription factor can restore IL-17A-dependent induction of IL-6 expression (380).

IL-17A also induces cytokine production through the PI3K/Akt pathway in epithelial cells and fibroblasts (383, 384). However, more comprehensive and solid biochemical data are needed to validate and illustrate how the PI3K/Akt pathway is involved in this process.

1.5.4.2 mRNA stability

Besides promoting gene transcription, a unique Act1-dependent, TRAF6-independent arm of the IL-17RA/RC signaling pathway has been shown to control the stabilization of mRNA transcripts encoding proinflammatory molecules (e.g., *CXCL1*) in both human (385) and mouse primary epithelial cell lines (386) (Figure 5). Around 8% of transcripts encoding proinflammatory cytokines and chemokines exhibit short half-lives due to AU-rich elements (AREs) located within their 3'-untranslated regions (3'-UTR) (387). These AREs can be recognized and bound by ARE-binding proteins for AU-mediated mRNA degradation (388). Therefore, the regulation of mRNA stability is an important mechanism to control the magnitude of inflammatory gene expression. For this function, after stimulation with IL-17A, inducible IκB kinase IKKε (also known as IKKi) forms a complex with Act1, which leads to the phosphorylation of Act1 and a conformational shift that favors the recruitment of TRAF2 and TRAF5, rather than TRAF6 (385, 388, 389). The Act1-TRAF2/5 complex further recruits the ubiquitously expressed RNA-binding protein human antigen R (HuR), which competes with an mRNA decay factor, the mRNA splicing regulatory factor 2 (SF2), for binding with the 3'-UTR, preventing the degradation of mRNAs (e.g., *CXCL1*). As a modest activator of the pro-inflammatory NF-κB pathway
(390), it has been noted that mRNA stabilization is the primary function of IL-17 in promoting inflammation, alone and in synergy with other stimuli (386). For instance, TNF-α-induced mRNA transcripts are intrinsically unstable, while IL-17 synergizes with the TNF-α-induced production of pro-inflammatory mediators IL-8 and IL-6 by maintaining the stability of the respective mRNAs (391).

1.6 Regulators of IL-17A signaling

1.6.1 Positive regulators

The inhibitor of NF-κB (IκB)-ζ, encoded by the NFKBIZ gene downstream of the non-canonical NF-κB signaling, is an autocrine transcription factor that facilitates IL-17-induced canonical NF-κB-dependent gene transcription (392-396). IκB-ζ also directly promotes IL-17 production in Th17 cells, which in turn, forms a positive feedback loop (397). In addition, IκB-ζ also suppresses the expression of miR-23b, an inhibitor of IL-17 signaling (see section 1.6.2) (398).

The IL-17R family member IL-17RD exhibits dual roles in mediating IL-17A/IL-17RA-dependent signaling. On one hand, IL-17RD facilitates the activation of IL-17A-induced p38-MAPK signaling and the expression of the neutrophil chemokine macrophage inflammatory protein (MIP)-2 (399). The loss of IL-17A-induced MIP-2 expression in IL-17RD-deficient mice is associated with dampened IL-17A-induced neutrophil infiltration in the lungs and the peritoneum, whereas exogenous MIP-2 administration restores neutrophilia in these mice. Currently, the molecular mechanism responsible for IL-17RD promotion of IL-17A-induced p38-MAPK signaling is unclear. On the other hand, IL-17RD is able to negatively regulate IL-17-induced expression of NF-κB-dependent pro-inflammatory genes, such as IL-6 and CXCL1 (see section 1.6.2) (399).

Among the six C/EBP family members, IL-17 only induces C/EBP-β and C/EBP-δ (373, 380). While C/EBPβ can be inducibly phosphorylated and lead to the inhibition of IL-17-dependent pro-inflammatory gene induction (see section 1.6.2) (400, 401), C/EBP-δ has not been reported to be involved in post-translational modifications. As a positive mediator of IL-17A-dependent transcription, the C/EBP-δ gene is subject to autoregulation, as its own enhancer contains a functional C/EBP binding element (402).
1.6.2 Negative regulators

IL-17RA signaling is tightly controlled by several negative regulators of the signaling cascade. At the receptor level, IL-17RD interacts with both IL-17RA and Act1 basally via a SEFIR-SEFIR interaction, sequestering them from binding TRAF6, which in turn prevents the Act1-dependent ubiquitination and activation of TRAF6 and thus negatively regulates IL-17A-induced activation of NF-κB and the expression of pro-inflammatory genes such as IL-6 and CXCL1 (373). In general, the dual functions of IL-17RD in IL-17A/IL-17R-dependent immunomodulation highlight the complexity of this signaling axis.

There are two mechanisms underlying an inhibitory effect of C/EBP-β in IL-17A/IL-17RA signaling, which are both mediated by the CBAD domain of IL-17RA (400, 401). Firstly, C/EBP-β protein exists in multiple isoforms (403), while IL-17 preferentially induces the full-length C/EBP-β isoform (known as LAP) (400, 403), one of the alternatively generated C/EBP-β isoforms contains only the DNA-binding domain, which in turn, is potentially a transcriptional repressor (380, 403). Secondly, it has been shown that IL-17R signalling activates ERK to phosphorylate Thr188 of C/EBPβ, which is required for sequential Thr179 phosphorylation of C/EBPβ by GSK3β. The dual phosphorylation of C/EBPβ results in inactivation, inhibiting IL-17-mediated downstream gene transcription via a negative feedback loop (401).

TRAFs, such as TRAF3 and TRAF4, act to disrupt downstream signaling complex formation after ligand binding (404, 405). Thus, TRAFs don’t affect the cytokine production downstream of IL-17 signaling (e.g., IL-6 and CXCL1) under homeostatic conditions (without exogenous ligand stimulation). In particular, TRAF3 inducibly binds to the CBAD motif in IL-17RA and thus competes with Act1 to interact with IL-17RA (404), while TRAF4 competes with TRAF6 for Act1 binding (405).

The micro-RNA, miR-23b, inhibits IL-1β-, TNF-α- or IL-17A-induced NF-κB activation via targeting the activities of TAB2/3 and IKK-α (398). Furthermore, IL-17A can down-regulate miR-23b expression, which in turn, promotes IL-17A signaling in an autocrine fashion (398). In contrast to miR-23b, the other micro-RNA inhibitor of IL-17A signaling miR-30a, targets Act1 expression, which inhibits both IL-17A-induced NF-κB and MAPK pathways (406).

More recently, the endoribonuclease monocyte chemoattractant protein-1-induced
protein (MCPIP)-1, also known as regnase-1, was reported to negatively regulate not only the IL-17A-induced mRNA stability of proinflammatory cytokines such as IL-6, but also the mRNAs of IL-17RA and IL-17RC (396). Notably, MCPIP1 expression can be induced by IL-17A, which acts as a negative feedback inhibitor. Furthermore, the RNA binding proteins roquin-1 and roquin-2 were shown to down-regulate mRNA of IL-6 (407). Indeed, roquins inhibit IL-6 production downstream of IL-17 signaling, which has a synergistic effect with MCPIP1 (396).

Deubiquitinating enzymes like USP25 and A20 regulate the ubiquitination status of TRAFs and place a brake on the signaling cascade (408-411). Upon ligand binding, USP25 deubiquitinates Act1-mediated K63-linked ubiquitination of TRAF5 and TRAF6, thereby turning off IL-17 signaling via inhibiting mRNA transcription as well as stability (408). Notably, A20 deubiquitinates TRAF6 and restricts the activation of NF-κB and MAPK pathways (409-411).

1.6.2.1 Biology of A20

A20, a widely expressed and inducible cytoplasmic protein encoded by the gene TNFα-induced protein 3 (TNFAIP3), was first reported as a negative regulator of the NF-κB pathway and has a vital role in controlling inflammation and apoptosis (412, 413). Although initially described as a negative feedback inhibitor of TNFα-induced signaling, A20 also inhibits Toll-like receptor (TLR), IL-1R, and Nod-like receptor pathways in addition to the IL-17R pathway (414-416). Notably, A20 is a NF-κB transcription dependent gene, which can be induced by multiple pro-inflammatory stimuli, such as TNF, IL-1β, bacterial LPS and IL-17A (409, 412).

Functionally, A20 is essential for the development and function of a variety of immune cells such as dendritic cells, B cells, T cells and macrophages (417). A20-deficient mice exhibit multi-organ inflammation and perinatal lethality due to uncontrolled NF-κB activity triggered by homeostatic TLR signaling (418, 419). More recently, genome-wide association studies revealed the association between single nucleotide polymorphisms (SNPs) at the TNFAIP3/A20 gene locus and multiple autoimmune and inflammatory diseases in humans, such as Crohn’s disease and rheumatoid arthritis (420, 421).
1.6.2.2 Molecular mechanisms of A20

Biochemically, A20 is a ubiquitin-editing enzyme that exhibits de-ubiquitinating, E3 ligase, and ubiquitin-binding activities (Figure 5). The N-terminal ovarian tumor domain of A20 is responsible for its de-ubiquitinating activity whereas the seven zinc fingers at the C-terminus mediate E3 ubiquitin ligase and ubiquitin-binding activities (416). While activation of NF-κB is controlled by both K48- and K63-polyubiquitination of upstream signaling proteins, A20 turns off NF-κB by modulating both types of ubiquitination (409, 413, 422). For example, A20 controls TNF-induced and IL-17A-induced NF-κB activation by removing Lys63-linked ubiquitin chains from TRAF6. In addition, A20 catalyzes Lys48-linked poly-ubiquityation of RIP1 via its E3 activity, which in turn triggers proteasome-mediated degradation of RIP1. A20 also inhibits IRF-3-dependent gene transcription (413, 415), TNF-induced apoptosis and IL-17A-induced IL-6 production via inhibition of the JNK pathway (409, 423). Furthermore, A20 inhibits Wnt signaling and reduced A20 expression is associated with human CRC development (424, 425). Given a vital role of A20 in controlling inflammation, it is conceivable that steady-state levels of A20 dictate the overall magnitude of inflammatory signals. While many pro-inflammatory stimuli can induce A20 production during inflammatory responses (412, 413, 415), it is less clear how A20 is maintained under steady-state conditions.

1.6.2.3 The role of A20 in cancer

The role of A20 in tumorigenesis has been studied; however, contradictory results were reported. For example, a tumor suppressor role for A20 in hematopoietic malignancies was generally accepted following the discovery that A20 is frequently inactivated due to somatic mutations and/or deletions in various lymphoid malignancies (426-429). Nevertheless, A20 is often overexpressed in leukemia, facilitating leukemic pathogenesis, cell proliferation and chemotherapy resistance (430-432). A functional paradox for A20 in solid tumors has also been suggested. On one side, A20 prevents hepatocellular carcinoma and colon cancer tumorigenesis (425, 433). On the other side, A20 over-expression is found in some other solid tumors, such as head and neck cancer, squamous cell carcinoma and aggressive breast cancer subtypes lacking either estrogen or progesterone receptors and is associated with a poor survival rate and chemo-resistance (434-436). Given that cancer arises and develops in the context of an in vivo tumor-specific
microenvironment, which orchestrates molecular and cellular events taking place in the course of tumor progression, these data support the notion that the role of A20 in the carcinogenesis of various cancers may depend on TME-specific A20 responses (162, 437). However, the intrinsic sources that maintain A20 levels in human neoplasms under steady state conditions are poorly understood.

1.7 Hypotheses and objectives

Given that IL-17RA and IL-17RC are differentially expressed by hematopoietic and non-hematopoietic cells (129), the ratio of IL-17RA/IL-17RC is postulated to control IL-17A-induced cytokine responses in a cell-type-dependent manner (129). However, the mechanism(s) by which IL-17R may regulate cell-type-dependent proliferation remains elusive. My first hypothesis is that tumor cells may rely on IL-17A signaling to directly control cellular proliferation in a cell-type-specific manner. Since intensive studies suggested that IL-17A-induced signals exhibited both pro-tumor and anti-tumor effects, the primary objective of this study was to define how tumor cells utilize IL-17A/IL-17R signals to mediate tumor-specific growth.

The increased levels of IL-17A and IL-17A-producing cells within the TME of different types of cancer suggest an important role for this cytokine signal in tumor progression. Previous research in Dr. Wang’s laboratory has developed a novel adenovirus-mediated transgene delivery system to over-express IL-17A or IL-17F, or deliver an IL-17RA antagonist (a soluble decoy fusion protein containing the extracellular domain of IL-17RA and Fc) to the tumor cells to understand the impact of IL-17A and IL-17F on tumor growth. Using a mouse B16 melanoma model, preliminary results indicated that over-expression of the IL-17RA antagonist at the tumor site inhibited tumor growth in C57BL/6 mice. Analysis of tumor-infiltrating leukocytes showed that the IL-17RA antagonist led to increases in CD4+ and CD8+ T cell populations and NK cells compared to other treatment groups. Conversely, over-expression of IL-17A resulted in reduced CD4+, CD8+ and NK cell infiltration into tumors. These results led us to hypothesize that tumor cell intrinsic IL-17A also plays an active role in shaping the immunosuppressive TME. The 2nd objective of my PhD research is to dissect the contribution of IL-17A/IL-17R signaling the regulation of the TME.
CHAPTER 2 MATERIALS AND METHODS

2.1 Cells and Cell lines

All human tumor cell lines including human breast cancer cell lines (MCF7, SKBR3, MDA-MB231 and MDA-MB468), colon cancer cell lines (HT29 and CaCo2), prostate cancer cell line PC3, ovarian cancer cell lines (OVCA429 and SKOV3), as well as lung carcinoma epithelial cell line A549 were originally purchased from the American Type Culture Collection (ATCC) (Manassas, VA USA). Mouse B16 melanoma cells were provided by Dr. Brent Johnston (Dalhousie University, Nova Scotia) and 4T1 mouse mammary carcinoma cells were obtained from Dr. Tim Lee (Dalhousie University). All tumor cell lines were maintained in complete Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 10 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 100 U/ml penicillin/streptomycin, and 2 mM of L-glutamine (Life Technologies, Waltham, MA USA). Primary human mammary epithelial cells (HMECs) (Lonza, CC-2551) were provided by Dr. David Hoskin (Dalhousie University). Primary human colon epithelial cells (HCECs) from ATCC (CRL-1831) were maintained in DMEM:F12 medium supplemented with 10% FBS, 30 ng/ml epidermal growth factor, 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 100 ng/ml hydrocortisone (all purchased from Sigma-Aldrich, Oakville, Ontario Canada) and 10 mM HEPES. Amphotropic Phoenix cells (Ampho-ФNX) were obtained from Dr. Craig McCormick (Dalhousie University) and cultured in complete MEM F11 medium. McCoy cells were obtained from ATCC. The cells were grown in McCoy medium (minimum essential medium; Earle’s salts, L-glutamine, non-essential amino acids (Invitrogen, Waltham, MA USA), 2.2 g sodium bicarbonate, 5% FBS (Sigma Aldrich), gentamicin (10 µg/ml) (Invitrogen) and fungizone (2 µg/ml) (Invitrogen).

To isolate the mouse embryonic fibroblasts (MEFs), T175 flasks were coated with 0.2% bovine gelatin (Sigma Aldrich) in sterile distilled water for 2 hrs. Pregnant mice were euthanized 2 weeks post-coitum. The uterine horns containing the embryos were removed, rinsed in 70% ethanol, then submerged in 5% bovine serum Roswell Park Memorial Institute (RPMI) medium. Using sterile technique, individual embryos were removed from the yolk sac in a Petri dish and the head and red organs were removed and discarded. The embryos were mechanically disrupted with glass slides until the pieces could be pipetted.
A mixture of 0.05% trypsin/ethylenediaminetetraacetic acid (EDTA, Wisent Bio Products, ST-BRUNO, Quebec Canada), 10 µg/ml DNase I (Sigma Aldrich), and 300 µg/ml collagenase II (Sigma Aldrich) (1 ml/embryo) was added to the suspension and then pipetted into a tube. The sample was incubated at 37°C for 20 min with gentle vortexing every 5 min. The reaction was stopped with at least one volume of complete DMEM and then pelleted (525 g, 10 min at 4°C). The supernatant was carefully aspirated with a pipette and the pellet was resuspended in complete DMEM. The cell suspension was plated onto the 0.2% bovine gelatin-coated flasks (3-4 embryos per flask) and then incubated at 37°C until confluent. Cells were then detached, filtered through a 70 µm cell strainer, and passaged for experiments.

Bone marrow derived dendritic cells (BMDCs) were generated from the femurs and tibia of naïve mice. Bone marrow was flushed with 5% bovine serum RPMI into Petri dishes containing 5-10 ml of 5% bovine serum RPMI. Samples were centrifuged at 525×g for 10 min at 4°C. The pellet was resuspended and red blood cells were lysed by incubation in 1 x Ammonium-chloride-potassium (ACK) buffer for 5 min at room temperature (RT) followed by addition of 5-10 ml 5% bovine serum RPMI. Samples were centrifuged for 10 min and resuspended in 10 ml complete RPMI medium and 20 ng/ml (200 U/ml) recombinant mouse GM-CSF (R&D Systems, Burlington, Ontario). The concentration of cells in single-cell suspensions was determined by trypan blue-dye exclusion method using a hematocytometer. On day 0, 3 x 10^6 bone marrow cells were seeded in 100-mm tissue culture dishes in 10 ml complete RPMI and incubated at 37°C, 5% CO₂. Cells were fed by adding an additional 10 ml complete RPMI at day 3. On day 6, loosely adherent cells were collected by gently pipetting the suspension media and used as the source of DCs.

2.2 Mice

C57BL/6 male and BALB/c female mice were purchased from Charles River Laboratories (Senneville, QC) and were normally used between 8 to 12 weeks of age. Mice were housed at the Izaak Walton Killam (IWK) Health Centre animal facility under pathogen-free conditions. All animal procedures were approved by the Dalhousie University Committee on Laboratory Animals.
2.3 Construction and use of retroviral vectors and DNA plasmids

Recombinant lentiviruses encoding shRNA sequences that target four different regions of mouse IL-17RA (OB320663, OB215726, OB15280 and OB3035) or IL-17RC (OB495966, OB495968, OB495970 and OB6972) were cloned into a pSMP vector (Open Biosystems) and confirmed by sequencing (GENEWIZ, Inc., South Plainfield, NJ USA). Approximately $0.8 \times 10^6$ Ampho-ΦNX cells per well were plated in 6-well plates to grow overnight. The Ampho-ΦNX cells are ready for transfection at approximately 80% confluency which occurs 16 hrs after culture. Approximately 0.5 µg of plasmid DNA encoding different shRNA constructs were mixed with 10 ul of 1 mg/ml polyethyleneimine (PEI) (40,000 MW, Polysciences Inc.) in 100 ul DMEM medium. The mixed constructs were vortexed 1 second intervals for 15 seconds and incubated at RT for 15 mins. During the incubation, Ampho-ΦNX cells were gently washed with pre-warmed phosphate buffered saline (PBS) and then transfected with the mixed constructs allowing virus production for 3 days. The virus-containing culture supernatants were collected and used to transduce B16 and 4T1 tumor cells. At one day before the transduction, tumor cells were seeded into 6-well plates ($0.25 \times 10^6$ per well), which normally reached about 40-50% confluency after 16 hrs culture and used for transduction. On the day of transduction, 2 ml of virus-containing culture supernatants were briefly centrifuged at 1000×g for 5 min to remove the cellular debris and the supernatants were subsequently incubated with cells in the presence of 8 µg/ml polybrene (Sigma Aldrich) for 2 hrs at RT and spun at 800×g. After spinning, cells in the 6-well plates were directly transferred to a 37°C incubator overnight. Subsequently, culture supernatants were removed and cells were grown with complete DMEM medium for an additional 24 hrs. Stable transfectants were selected by treating cells with 4 µg/ml puromycin (Bio Basic Inc.) for 7 days or until all non-transfected tumor cells died. Selected cells were subjected to a limiting-dilution-assay to obtain single-cell-derived subclones (438). Ten subclones of each of the 8 shRNA constructs (e.g., IL-17RA1.1 to IL-17RA1.10), as well as the pSMP control cells, were expanded for further characterization and analyses. For the B16 cells, IL-17RAKD3.1, IL-17RCKD4.5 and pSMP.5 were the best clones. For the 4T1 cells, IL-17RAKD4.6, IL-17RCKD4.8 and pSMP.4 were the best clones.

For reconstituting mouse IL-17RA, the full-length coding sequence of mouse IL-
17RA (NM_008359) was cloned into retroviral vector pBMN-IRES-Hygro, which was provided by Dr. Craig McCormick (Dalhousie University). The best stable RAKD subclone of B16 cells (B16-RAKD3.1) and B16-pSMP.5 transfectants were selected by 400 µg/ml hygromycin B (Life Technologies). Unlike the B16-RAKD3.1 clone that was generated by targeting 3’end un-translated region of IL-17RA, the viral vector used in the representative 4T1-RAKD4.6 clone targeted the coding sequence of IL-17RA, which would prevent the reconstitution of IL-17RA. Thus, the reconstitution was not performed in 4T1 cells.

In some experiments, GIPZ lentiviral shRNAs (Thermo Scientific, Waltham, MA USA) targeting JNK1 (V2LMM49133) and JNK2 (V3LMM472591, V3LMM515242 and V3LMM515241), were used to knockdown JNK1 or JNK2 in IL-17RCRD tumor cells. The lentivirus vector GIPZ has a green fluorescent protein (GFP) expression cassette, therefore, the cell transfection rate was observed directly under a fluorescent microscopy, which could reach up to 80%. At day 3 post-transfection, tumor cells were starved in serum-free medium for 14 hrs and then rescued with complete medium (CM) for 1 hr. Whole-cell extracts were harvested and the level of JNK1 or JNK2 protein was examined using Western blotting.

In some experiments, A20 reconstitution was conducted using plasmids encoding murine A20 or a deletion-mutant, which were purchased from the plasmid repository at BCCM/LMBP (Belgian Coordinated Collections of Micro-organisms and Laboratory of Molecular Biology–Plasmid collection). Lipofectamine 3000 Reagent (Life Technologies) was used for plasmid DNA transfection in tumor cells following the manufacturer's instructions.

2.4 Gene expression analysis

2.4.1 RNA extraction, reverse transcription-PCR and quantitative real-time PCR (qPCR)

Total RNAs were extracted from 3 x 10⁶ tumor cells using RNeasy columns (QIAGEN) and first strand cDNA was generated through reverse transcription-PCR using a QuantiTect Reverse Transcription kit (QIAGEN) following the manufacturer's instructions. PCR reactions were performed with gene-specific primers using PCR Master Mix (Promega) in an Eppendorf Mastercycler PCR machine. Primers were designed against the mRNA sequence of each gene of interest using Primer Premier Version 5
The properties of primers used in this study are listed in Table 4. The standard PCR cycling program in a 20 µl reaction volume was initially heated for 3 min at 95°C, processed through 30 cycles of sequential temperatures of 95°C (30 sec), 56°C (30 to 90 sec), 72°C (30 sec) and finally incubated for 10 min at 72°C, using an Eppendorf Mastercycler PCR machine. Pooled complementary DNA (cDNA) samples were used as template to assess the optimal annealing temperature of the individual primer pairs. The standard PCR cycling program was modified by replacing the annealing temperature step with a thermal gradient between 52°C and 64°C for 1 min extension time. Samples were stored at 4°C, prior to electrophoresis at 110 V on 0.8% agarose gels containing ethidium bromide.

For qPCR, cDNA was amplified in RT² SYBR® Green ROX qPCR Mastermix (QIAGEN) following the manufacturer's instructions using a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, USA). Each amplification was performed with no-cDNA control wells and positive control wells containing XpressRef™ Mouse Universal Total RNA (QIAGEN). The following thermal profile was used: 10 min at 95°C for HotStart DNA Taq Polymerase activation, followed by 40 amplification cycles of 15 sec at 95°C and 1 min 60°C (annealing-extension step). Dissociation curve analysis was performed after each run. All PCR components are denatured 1 min at 95°C, followed by complete annealing 2 mins at 65°C, followed by a gradual increase in temperature up to 95°C. Fluorescence intensity is monitored during this final temperature increase, resulting in the generation of a dissociation curve (or melting curve). A single peak in the dissociation curve of each primer pairs verifies the PCR specificity. GAPDH and β-actin were used as internal normalization controls for qPCR. The data were analyzed using the SDS software 2.2.2 from Applied Biosystems. In some assays, cells were treated with recombinant mouse IL-17A, IL-17F and IL-17E which were purchased from R&D Systems and reconstituted in sterile 4 mM HCl at a concentration of 100 µg/ml. Recombinant mouse IL-17C (eBioscience) was stored and used according to the manufacturer's protocol.
Table 4. Primers used in this study.

<table>
<thead>
<tr>
<th>Gene*</th>
<th>Sequence (5’→3’)</th>
<th>TM (°C)</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>mIL-17RA sense PCR</td>
<td>TTGCATGTTGAGTGGACCCCTGCA</td>
<td>61.5</td>
<td>698bp</td>
</tr>
<tr>
<td>mIL-17RA antisense PCR</td>
<td>ACGGCATACACCCACAGGGGA</td>
<td>62.9</td>
<td></td>
</tr>
<tr>
<td>mIL-17RA sense qPCR</td>
<td>ACGGTCTGCGGACTTGAT</td>
<td>60.4</td>
<td>140bp</td>
</tr>
<tr>
<td>mIL-17RA antisense qPCR</td>
<td>GCCTCGCGAGTTCTCTGTGTGA</td>
<td>58.5</td>
<td></td>
</tr>
<tr>
<td>mIL-17RC sense</td>
<td>AGATGCGCTGTCT CCTGTGC</td>
<td>57.1</td>
<td>243bp</td>
</tr>
<tr>
<td>mIL-17RC antisense</td>
<td>CAGCATCTGTCTCTGTGTGA</td>
<td>54.9</td>
<td></td>
</tr>
<tr>
<td>mIL-17RC isoform sense</td>
<td>GTGGTTCTGCGGATTTT</td>
<td>52.8</td>
<td>598bp</td>
</tr>
<tr>
<td>mIL-17RC isoform antisense</td>
<td>CATTGATCGAGGCGTTGTTT</td>
<td>53.7</td>
<td></td>
</tr>
<tr>
<td>mIL-17RD sense</td>
<td>GGCATAAGGAAAACACGTAACATAGCA</td>
<td>55.5</td>
<td>118bp</td>
</tr>
<tr>
<td>mIL-17 RD antisense</td>
<td>ACGCAAGAAGCCAGGAAACA</td>
<td>57.1</td>
<td></td>
</tr>
<tr>
<td>mIL-17A sense</td>
<td>CTCAGACTACCTCAACCGTTCCA</td>
<td>58.1</td>
<td>131bp</td>
</tr>
<tr>
<td>mIL-17A antisense</td>
<td>CAGCTCTCCTCCGCACT</td>
<td>58.1</td>
<td></td>
</tr>
<tr>
<td>mIL-17F sense</td>
<td>ACTGTTGATGTTGGACTTGCC</td>
<td>57.9</td>
<td>160bp</td>
</tr>
<tr>
<td>mIL-17F antisense</td>
<td>AGAAATGCGCTCAGTTTTGTTG</td>
<td>55.4</td>
<td></td>
</tr>
<tr>
<td>mIL-17C sense</td>
<td>AACGACCTGCGGACTTGCTACT</td>
<td>61.5</td>
<td>129bp</td>
</tr>
<tr>
<td>mIL-17C antisense</td>
<td>CCGATCTAGTCCCTCCGCA</td>
<td>61.2</td>
<td></td>
</tr>
<tr>
<td>mIL-17E sense</td>
<td>CCAGCAAAGGCAAGAAGAACCCE</td>
<td>58.8</td>
<td>179bp</td>
</tr>
<tr>
<td>mIL-17E antisense</td>
<td>CCGATCTAGTCCCTCCTGCAA</td>
<td>57.9</td>
<td></td>
</tr>
<tr>
<td>mA20 sense</td>
<td>AATCGGCTGCTTCTCTATGACTC</td>
<td>60.3</td>
<td>236bp</td>
</tr>
<tr>
<td>mA20 antisense</td>
<td>CTTTTCTGTCTCTACGGCTA</td>
<td>60.2</td>
<td></td>
</tr>
<tr>
<td>mJNK1 sense</td>
<td>GGAGGTAATGGATTTGGAGGA</td>
<td>58.1</td>
<td>119bp</td>
</tr>
<tr>
<td>mJNK1 antisense</td>
<td>ACGACGCGGAGAAGACGATG</td>
<td>59.0</td>
<td></td>
</tr>
<tr>
<td>mJNK2 sense</td>
<td>ACACGATAGATGTAGTTGGAAGGTGTCG</td>
<td>58.9</td>
<td>203bp</td>
</tr>
<tr>
<td>mJNK2 antisense</td>
<td>TTGCAAGGTTCTCCTCTGGTA</td>
<td>58.0</td>
<td></td>
</tr>
<tr>
<td>mGAPDH sense</td>
<td>CGATGCCCCCATGTTTGTGAT</td>
<td>58.2</td>
<td>249bp</td>
</tr>
<tr>
<td>mGAPDH antisense</td>
<td>GCAGGGATGATGTGTTG</td>
<td>55.8</td>
<td></td>
</tr>
<tr>
<td>hIL-17 RA sense</td>
<td>TCCGGCAGAGAATGCCA</td>
<td>60.1</td>
<td>84bp</td>
</tr>
<tr>
<td>hIL-17 RA antisense</td>
<td>GGAGATGCCGCTGTAGAAC</td>
<td>62.2</td>
<td></td>
</tr>
<tr>
<td>hIL-17 RC sense</td>
<td>GAGCGATAGCCTGGAGGCG</td>
<td>60.9</td>
<td>99bp</td>
</tr>
<tr>
<td>hIL-17 RC antisense</td>
<td>GCAGCGCGGAGAAGACTGAGC</td>
<td>60.9</td>
<td></td>
</tr>
<tr>
<td>hβ-actin sense</td>
<td>AGCGGAATAATGTGCCTG</td>
<td>58.8</td>
<td>309bp</td>
</tr>
<tr>
<td>hβ-actin antisense</td>
<td>CAGGGTACATGGTGTTG</td>
<td>58.4</td>
<td></td>
</tr>
</tbody>
</table>

* m: mouse, h: human, TM: melting temperature.
2.4.2 PCR microarray

For RT² Profiler™ PCR array of mouse chemokines & receptors (QIAGEN, PAMM-022A), cDNAs were generated from approximately 3 x 10^6 B16 tumor cells treated with 200 ng/ml recombinant IL-17A (R&D Systems) stimulation for 16hrs, or tumors isolated from C57BL/6 mice at day 12 post-inoculation. The same thermal profile described for qPCR was used in this experiment. RT² Profiler PCR Array Data Analysis version 3.5 (QIAGEN) was used for processing the raw data and auto-selecting the best housekeeping gene for normalization. This microarray pannel is customized with 84 inflammation-related genes and 5 housekeeping genes. Among the 5 housekeeping genes [β-actin, β2-microglobulin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-glucuronidase and heat shock protein 90 α (cytosolic) class B member 1], GAPDH was the most stable and was selected for normalization. Representative gene expression profiles were validated by qPCR. All the gene expression data were normalized to the level of GAPDH.

2.4.3 Droplet digital PCR (ddPCR)

ddPCR reactions were prepared using BioRad QX200 ddPCR EvaGreen Supermix (Bio-Rad, Mississauga, Ontario) following the manufacturer's instructions. Twenty microliters of each reaction mix were converted into droplets with 65 µl of Droplet Oil (Bio-Rad) in the QX200 droplet generator (Bio-Rad). Droplet-partitioned samples were then transferred to a 96-well plate, sealed and cycled in a C1000 deep well Thermocycler (Bio-Rad) under the following cycling protocol: 95°C for 5 min (DNA Taq polymerase activation), followed by 50 cycles of 95°C for 30 sec (denaturation), 60°C for 1 min (annealing) and 72°C for 1 min (elongation), followed by post-cycling steps of 4°C for 5 min hold, 90°C for 5 min (enzyme inactivation) and an infinite 10°C hold. The cycled plate was then transferred and read in the 6-carboxyfluorescein (FAM) and high-energy X-ray (HEX) channels using the QX200 Droplet reader (Bio-Rad) using “QuantaSoft” software (Bio-Rad) either the same day or the following day.

2.5 Cell proliferation assays

2.5.1 MTT assay

Tumor cells were plated in quadruplicate in a 96-well plate at a density of 5,000 cells per well. Cells were incubated at 37°C for a maximum of 72 hrs with or without serum
starvation to cell cycle synchronization. At the end of the assay, cells were incubated with 0.5 mg/ml MTT for 2 hrs and the purple formazan products were dissolved in 100 µl of dimethyl sulfoxide (DMSO). The plates were read on a plate reader (BioTek Synergy HT) at 570 nm with a reference reading at 630 nm. Optical density values collected 6 hrs post-seeding were used to calculate the fold-change in proliferation at different time points. In some assays, the cells were treated with different chemical inhibitors (Table 5) or DMSO vehicle. The inhibitors SB203580, FR180204, 420116 and SP600125 were purchased from EMD Millipore. KIN001-102 and BMS-345541 were purchased from Sigma Aldrich. All inhibitors were reconstituted in DMSO.

2.5.2 Ki67 staining

The proliferation rates of primary and tumor cells were determined based on expression of nuclear antigen Ki67. Cells were plated in 100 mm tissue culture dish at a density of 0.75 x 10^6 cells per dish, cultured in serum-free DMEM medium for 12 hrs and transferred into complete DMEM for 1-12 hrs. Cells were harvested and washed with 1 x PBS in 96-well plate. Meanwhile, the fixable viability dye eFluor506 (eBioscience) was thawed for 10 – 15 mins at RT. Cells were then resuspended in 100 ul 1 x PBS containing 1:1000 dilution of eFluor506 and incubated at 4°C for 30 mins in the dark. After staining, cells were washed once with fluorescence activated cell sorting (FACS) wash buffer (1% bovine serum in 1 x PBS). Following washing, 200 µl of Foxp3 Fixation/Permeabilization working solution (eBioscience) were added to each well and cells were fully resuspended by pipetting. Cells were then incubated in the dark for 30 mins at RT. Samples were centrifuged at 400 x g for 5 mins at RT, then the supernatant was discarded. Wells were washed twice with 200 µl 1 x Permeabilization Buffer (eBioscience, 10x concentrate diluted in dH2O). After washing, cells were blocked with 2% normal rat serum in 100 µl 1 x Permeabilization Buffer per sample for 15 mins at RT. After removing the supernatant, cell pellets were mixed with 50 µl 1:300 Ki67 PerCP-eFluor® 710 (eBioscience, clone: SolA15), diluted in 1 x Permeabilization Buffer, and incubated in the dark for 30 mins at RT. The wash was repeated twice with 200 µl of 1 x Permeabilization Buffer and cells were resuspended in 200 µl of FACS wash buffer. Data were collected using a BD LSR Fortessa flow cytometer.
Table 5. Chemical inhibitors used in this study and their properties.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Target pathway</th>
<th>Mode of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIN001-102</td>
<td>AKT</td>
<td>Isozyme selective Akt1/2 kinase inhibitor</td>
</tr>
<tr>
<td>BMS-345541</td>
<td>NF-κB</td>
<td>Highly selective I kappa B kinase (IKK) allosteric site inhibitor</td>
</tr>
<tr>
<td>SB203580</td>
<td>p38 MAPK</td>
<td>Competitive inhibition of ATP binding site of p38 MAPK</td>
</tr>
<tr>
<td>FR180204</td>
<td>ERK1/2 MAPK</td>
<td>ATP-competitive inhibition to ERK1/2</td>
</tr>
<tr>
<td>420116</td>
<td>JNK MAPK</td>
<td>(L)-form peptide with inhibition to JNK phosphorylation</td>
</tr>
<tr>
<td>SP600125</td>
<td>JNK/c-Jun MAPK</td>
<td>Competitive inhibition to JNK and c-Jun phosphorylation</td>
</tr>
</tbody>
</table>

Note: The inhibitors SB203580, FR180204, 420116 and SP600125 were purchased from EMD Millipore. KIN001-102 and BMS-345541 were purchased from Sigma.
2.5.3 Growth curve assay

In the growth curve assay, 0.25 x 10⁶ cells were seeded in a 60 mm dish. Cells were allowed to grow at 37°C. At different time points, cells were trypsinized and diluted 1:1 with 0.4% trypan blue stain. Ten microliters of the cell-stain mixture was then loaded onto a hemacytometer and viable cells were counted.

2.5.4 Cell cycle analysis

To conduct cell cycle analysis, 0.25 x 10⁶ tumor cells were synchronized in serum-free DMEM for 24 hrs and then cultured in complete DMEM medium in 6-well flat-bottom tissue culture plates for 24 or 48 hrs. Cells were harvest by trypsinization, washed, and resuspended in 0.5 ml ice-cold 1 x PBS. With gentle vortexing, 4.5 ml ice-cold 70% ethanol was added to fix the cells (final volume of 5 ml). The cells were further fixed by storing at -20°C for at least 24 hrs. Cells were then thawed, washed in 1 x PBS and (depending on cell number) resuspended in 0.5-1.5 ml of the cell cycle solution, which consists of 0.02 mg/ml propidium iodide (PI), 0.1% v/v Triton X-100, and 0.2 mg/ml DNase-free RNase A in 1 x PBS. Cells were incubated at RT for 30 mins. Data were collected with FACSCalibur on low flow (around 40 to 80 events per second) and DNA content in PI-stained cells was analyzed using ModFitLT V2.0 software (BD Biosciences).

2.6 Cytokine ELISA

The concentrations of cytokines and chemokines in culture supernatants were determined using enzyme-linked immunosorbent assay (ELISA) kits (eBioscience). The optimal concentration of each antibody was specified by the manufacturer.

Wells in 96-well flat-bottom ELISA plates (Greiner Bio-One, Monroe, NC USA) were coated with 50 µl of the specific capture antibody for against cytokine or chemokine of interest. The capture antibodies were all initially diluted in Coating Buffer (eBioscience). The plates were sealed and incubated overnight at 4°C. To wash the plates, 200 µl of 0.01% Tween-20/PBS (PBST) buffer was added to each well and then dumped out and patted dry on paper towel. Alternatively, an automatic plate washer was used for this process (BioTek, ELx405). After 5 washes, blocking buffer (100 µl) (Assay Diluent) (PBS containing 1% BSA) was added to each well and the plates were incubated for 2 hrs at RT. The plates were then washed 5 times as described above. The cytokine standards were prepared in a
1:2 serial dilution in Assay Diluent starting at 2,000 pg/ml. Eight dilutions were performed to generate a standard curve. Samples were diluted in Assay Diluent if the concentration of the cytokine being measured exceeded the upper limit of quantitation of the standard curve. Standards and samples were added to wells (50 µl each) and plates were incubated overnight at 4°C. After the incubation, the plates were washed 5 times with 200 ul/well of PBST. Following the washes, 50 µl of biotinylated detection antibody diluted in Assay Diluent was added to each well and the plates were incubated for 2 hrs at RT. Plates were washed 5 times and 50 µl of streptavidin-horse radish peroxidase (eBioscience) diluted in Assay Diluent was added to each well and incubated for 20 mins in the dark at RT. After seven washes with 200 µl/well PBST, 50 µl of 1x 3,3',5,5'-Tetramethylbenzidine substrate solution (eBioscience) was added to each well. Assays were monitored for color change and the reaction was stopped with 50 µl of 0.2M H₂SO₄. Within 30 mins, plates were read at 450 nm using a BioTek Synergy HT plate reader and the data was analyzed using Gen5 software (BioTek).

2.7 Western blotting

Approximately 2.5 x 10⁶ cells in 100 mm tissue culture dishes were washed twice with ice-cold 1 x PBS. Cells were then scraped into 1 ml ice-cold 1 x PBS and pelleted 500 x g for 3 mins at 4°C. The cell pellet was resuspended with 100–200 µl whole cell extraction buffer (20 mM HEPES [pH 7.4], 100 mM potassium chloride, 10 mM β-glycerophosphate, 50 mM sodium fluoride, 0.2% Triton X-100, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, and protease inhibitor cocktail [Sigma Aldrich]). Lysates were stored on ice for 15 mins with brief vortexing and spun at 12,000 x g for 3 mins. Supernatants were collected and protein concentrations were determined using the bicinchoninic acid (BCA) assay (Thermo Scientific) following the manufacturer's instructions. Sodium dodecyl sulfate (SDS) sample buffer was added to an aliquot of each extract and then boiled for 10 min. Protein samples (25 µg) were electrophoresed on SDS-polyacrylamide gel electrophoresis (PAGE) gels using the buffer system of Laemmli (439) (Mini PROTEAN electrophoresis system, Bio-Rad; 200 V, ~45 mins).

Polyacrylamide gels were transferred onto nitrocellulose membranes (Bio-Rad) with a wet transfer apparatus (Mini Trans-Blot, Bio-Rad) at 200 mA for 1 hr. All blots were
blocked in 1 x PBS with 5% BSA and 0.1% Tween at RT for 1 h. The blots were then probed with various primary antibodies as listed in Table 6. All primary antibodies were diluted in PBS/0.1% Tween-20 containing 5% BSA. After overnight incubation at 4°C, unbound antibodies were removed by washing 4 x 1 min with 1 x PBS with 0.1% Tween. Secondary antibodies conjugated with horseradish peroxidase were added for 1 hr at RT. The membranes were then washed 4 x 1 min with 1 x PBS with 0.1% Tween and 2 x 1 min with 1 x PBS. Quantitative western blots were developed using ECL Advanced Technology (GE Healthcare, Chicago, IL USA) and the reactivity was detected and visualized by chemiluminescence. The intensity of bands of interest was analyzed using ImageJ software (NIH).

2.8 Electrophoretic mobility shift assay (EMSA)

Nuclear protein extracts were prepared using a nuclear extract kit (Active Motif) per the manufacturer’s protocol. All preparation procedures were carried out at 4°C. Total protein concentration was determined using the bicinchoninic acid (BCA) assay (Thermo Scientific) following manufacturer's instructions. EMSA was performed using a double-stranded oligonucleotide probe specific for the NF-κB consensus sequence on the IL-6 promoter, 5′-AGTTGAGGGGACTTTCCCAGGC-3′ (Promega) (440). The oligonucleotides were labeled with 32P adenosine triphosphate (Perkin Elmer) using T4 kinase (Life Technologies) and purified using a Sephadex G-25M column (GE Healthcare). Ten micrograms of nuclear protein were added to 10 µl of binding buffer supplemented with 1 µg of poly-(dl-dC) (GE Healthcare) and incubated at RT for 15 mins before mixing with the labeled oligonucleotides. The reaction mixture was incubated at RT for 30 mins and subjected to electrophoresis on a 6% polyacrylamide gel in Tris–boric acid–EDTA buffer. Gels were vacuum-dried and subjected to autoradiography.
Table 6. List of antibodies used in western blotting and immunohistochemistry.

<table>
<thead>
<tr>
<th>Antibody name</th>
<th>Company (CAT#)</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Akt</td>
<td>Cell Signaling (9272)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-phospho-Akt (Ser473)</td>
<td>Cell Signaling (9271)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-phospho-Akt (Thr308)</td>
<td>Cell Signaling (9275)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-IκB-α</td>
<td>Cell Signaling (9242)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-phospho-IκB-α (Ser32/36)</td>
<td>Cell Signaling (9246)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-SAPK/JNK</td>
<td>Cell Signaling (9252)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-JNK1</td>
<td>Santa Cruz Biotech. (sc-1648)</td>
<td>1:200 (WB)</td>
</tr>
<tr>
<td>Anti-JNK2</td>
<td>Santa Cruz Biotech. (sc-827)</td>
<td>1:200 (WB)</td>
</tr>
<tr>
<td>Anti-phospho-SAPK/JNK (Thr183/185)</td>
<td>Cell Signaling (4668)</td>
<td>1:1000 (WB), 1:50 (IHC)</td>
</tr>
<tr>
<td>Anti-c-Jun</td>
<td>Cell Signaling (9165)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-phospho-c-Jun(Ser63)</td>
<td>Cell Signaling (2361)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-phospho-c-Jun(Ser73)</td>
<td>Cell Signaling (3270)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-A20/TNFAIP3</td>
<td>Cell Signaling (5630)</td>
<td>1:1000 (WB), 1:50 (IHC)</td>
</tr>
<tr>
<td>Anti-caspase-3</td>
<td>Cell Signaling (9662)</td>
<td>1:1000 (WB)</td>
</tr>
<tr>
<td>Anti-cleaved caspase-3</td>
<td>Cell Signaling (9664)</td>
<td>1:1000 (WB and IHC)</td>
</tr>
<tr>
<td>Anti-GAPDH</td>
<td>Cell Signaling (5174)</td>
<td>1:2000 (WB)</td>
</tr>
<tr>
<td>Anti-Ki67 (SolA15)-FITC</td>
<td>eBioscience (11-5698)</td>
<td>1:50 (IHC)</td>
</tr>
</tbody>
</table>

2.9 Flow cytometry

2.9.1 Extracellular staining

To determine the cell surface expression of IL-17RA and IL-17RC on stable transfected tumor cell lines, cells were analyzed by flow cytometry. Transduced tumor cells were washed with FACS wash buffer (1 x PBS supplemented with 1% BS), then to avoid non-specific Fc-mediated binding, each pellet was blocked using 50 µl of FACS wash buffer containing 10% rat serum, and incubated for 20 min at 4°C. After washing, cell pellets were resuspended in 50 µl of FACS wash buffer containing anti-mouse fluorescent conjugated monoclonal antibodies targeting either IL-17RA (PAJ-17R, eBioscience) or IL-17RC (FAB-2270A, R&D Systems) at recommended dilutions, and incubated for 20 min at 4°C. After staining, cells were washed and fixed with 200 µl/tube of fixation buffer (1% formalin in 1 x PBS), and transferred into flow cytometry mini-tubes.

To identify different cell types within a heterogeneous population based on surface antigens, instead of single color staining, washed cell pellets were resuspended in 50 µl of FACS wash buffer containing a cocktail of fluorescent conjugated antibodies that bind specific surface markers at appropriate dilutions and colors (Table 7). The same washing and fixation procedures were conducted as outlined above. All FACS data were acquired on a Becton Dickinson FACSCalibur then analyzed using FCS Express 4 Flow Research Edition (De Novo, Los Angeles, CA USA).

2.9.2 Intracellular staining

Intracellular staining identifies cells based on markers inside the cells. Cells were washed, resuspended in FACS wash buffer at a concentration of 1-2 x 10^6 cells/ml, and triplicate 100 µl samples were seeded in separate wells on a 96-well tissue culture plate. One hundred µl of complete RPMI supplemented with 1 ng/ml of phorbol myristate acetate (PMA), 1x Brefeldin A, and 1 µg/ml of Ionomycin was added to each well (final volume/well is 200 µl) and incubated for 4-5 hrs at 37°C. After incubation, 2 µl of 1 mM EDTA was added to each well and incubated for 5-10 mins at RT. Cells were then transferred to a V-bottom 96 well plate and washed with FACS wash buffer. For blocking, each well was supplemented with 20 µl of wash buffer containing 10% rat serum, incubated for 20 mins at 4°C, and washed. Extracellular staining was performed as above without the fixation step. After extracellular staining and wash, 100 µl of intracellular fixation buffer
was added to each well, followed by incubation in the dark for 20 mins at RT. Without washing, 100 µl of 1x permeabilization buffer was added to the mixture, which was centrifuged for 10 min (750 x g, 4°C). Washing was repeated using 200 µl of permeabilization buffer. Pellets were then resuspended in 50 µl of permeabilization buffer containing a cocktail of fluorescent conjugated antibodies against specific intracellular cytokines (IFN-γ, IL-17A, IL-4) at appropriate dilutions and colors (Table 7). Following incubation for 20 mins at 4°C, cells were washed using 100 µl of 1x permeabilization buffer, washed three times with wash buffer, mixed with 200 µl per tube of fixation buffer, and transferred into flow cytometry mini-tubes. Data were acquired on a Becton Dickinson FACSARia and analyzed using FCS Express 4 Flow Research Edition (De Novo).

2.9.3 Apoptosis assay

Apoptosis in cells was assessed using a PI/Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit (eBioscience) per the manufacturer’s protocol. B16 and 4T1 cultures were serum starved for 14 hrs and rescued with complete DMEM medium for 1 hr. The cells were then washed with ice-cold 1 x PBS and resuspended in 1 x binding buffer. Aliquots of 2 x 10⁵ cells were mixed with 5 µl Annexin V-FITC and 10 µl PI for 10 mins at RT in the dark. Fluorescence was detected within 4 hrs using flow cytometry. Flow cytometric analysis was performed on cells that were undergoing apoptosis (Annexin V⁺) (441).
Table 7. List of antibodies used in flow cytometry.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Conjugate</th>
<th>Clone</th>
<th>Company (CAT#)</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-IL-17RA</td>
<td>PE</td>
<td>PAJ-17R</td>
<td>eBioscience (12-7182-80)</td>
<td>1:150</td>
</tr>
<tr>
<td>Rat IgG2a Isotype Ctrl</td>
<td>PE</td>
<td>eBR2a</td>
<td>eBioscience (12-4321-83)</td>
<td>1:150</td>
</tr>
<tr>
<td>α-IL-17RC</td>
<td>APC</td>
<td>Polyclonal</td>
<td>R&amp;D Systems (FAB2270A)</td>
<td>15ul/test</td>
</tr>
<tr>
<td>Goat IgG Isotype Ctrl</td>
<td>APC</td>
<td>Polyclonal</td>
<td>R&amp;D Systems (IC108A)</td>
<td>15ul/test</td>
</tr>
<tr>
<td>a-Ki-67</td>
<td>PerCP-eFluor710 SolA15</td>
<td>eBioscience (46-5698-80)</td>
<td>1:300</td>
<td></td>
</tr>
<tr>
<td>α-CD4</td>
<td>Fite</td>
<td>RM4-5</td>
<td>eBioscience (11-0042-82)</td>
<td>1:200</td>
</tr>
<tr>
<td>α-CD3e</td>
<td>PerCP-Cy5.5</td>
<td>145-2C11</td>
<td>eBioscience (45-0031-82)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-CD8α</td>
<td>PE-Cy7</td>
<td>53-6.7</td>
<td>eBioscience (25-0081-82)</td>
<td>1:400</td>
</tr>
<tr>
<td>α-MHCII</td>
<td>APC-eFluor780 M5/114.15.2</td>
<td>eBioscience (47-5321-82)</td>
<td>1:800</td>
<td></td>
</tr>
<tr>
<td>α-NKp46</td>
<td>eFluor660</td>
<td>29A1.4</td>
<td>eBioscience (50-3351-82)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-CD8α</td>
<td>PE</td>
<td>53-6.7</td>
<td>eBioscience (12-0081-85)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-CD19</td>
<td>PE-Cy7</td>
<td>eBio1D3</td>
<td>eBioscience (25-0193-82)</td>
<td>1:500</td>
</tr>
<tr>
<td>α-CD45</td>
<td>Fite</td>
<td>30-F11</td>
<td>eBioscience (11-0451-85)</td>
<td>1:200</td>
</tr>
<tr>
<td>α-CD11c</td>
<td>APC</td>
<td>N418</td>
<td>eBioscience (17-0114-82)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-F4/80</td>
<td>PE</td>
<td>BM8</td>
<td>eBioscience (12-4801-82)</td>
<td>1:200</td>
</tr>
<tr>
<td>α-Ly-6C</td>
<td>PerCP-Cy5.5</td>
<td>HK1.4</td>
<td>eBioscience (45-5932-82)</td>
<td>1:300</td>
</tr>
<tr>
<td>α-CD11b</td>
<td>Fite</td>
<td>M1/70</td>
<td>eBioscience (11-0112-85)</td>
<td>1:200</td>
</tr>
<tr>
<td>α-Ly-6G</td>
<td>PE</td>
<td>1A8</td>
<td>BD Biosciences (551461)</td>
<td>1:200</td>
</tr>
<tr>
<td>α-Gr1(Ly-6G)</td>
<td>Biotin</td>
<td>RB6-8C5</td>
<td>eBioscience (13-5931-85)</td>
<td>1:400</td>
</tr>
<tr>
<td>α-CD80</td>
<td>Biotin</td>
<td>16-10A1</td>
<td>eBioscience (13-0801-82)</td>
<td>1:600</td>
</tr>
<tr>
<td>α-CD86</td>
<td>Biotin</td>
<td>GL1</td>
<td>eBioscience (13-0862-82)</td>
<td>1:600</td>
</tr>
<tr>
<td>α-CD40</td>
<td>Biotin</td>
<td>1C10</td>
<td>eBioscience (13-0401-82)</td>
<td>1:600</td>
</tr>
<tr>
<td>α-ICOS-L</td>
<td>Biotin</td>
<td>HK5.3</td>
<td>eBioscience (13-5985-82)</td>
<td>1:50</td>
</tr>
<tr>
<td>α-PD-L1</td>
<td>Biotin</td>
<td>1-111A</td>
<td>eBioscience (13-9971-82)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-PD-L2</td>
<td>Biotin</td>
<td>TY25</td>
<td>eBioscience (13-5986-81)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-MHCl</td>
<td>Biotin</td>
<td>28-14-8</td>
<td>eBioscience (13-5999-82)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-IL-4</td>
<td>PE</td>
<td>11B11</td>
<td>eBioscience (12-7041-81)</td>
<td>1:100</td>
</tr>
<tr>
<td>Rat IgG1 Isotype Ctrl</td>
<td>PE</td>
<td>R3-34</td>
<td>BD Biosciences (554685)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-IFN-γ</td>
<td>Alexa647</td>
<td>XMG1.2</td>
<td>eBioscience (RM90021)</td>
<td>1:100</td>
</tr>
<tr>
<td>α-IL-17</td>
<td>Alexa647</td>
<td>eBio17B7</td>
<td>eBioscience (51-7177-82)</td>
<td>1:100</td>
</tr>
<tr>
<td>Rat IgG1 Isotype Ctrl</td>
<td>Alexa647</td>
<td>43414</td>
<td>BD Biosciences (IC005R)</td>
<td>1:100</td>
</tr>
</tbody>
</table>
2.10 In vivo models

For the B16 melanoma model, $1 \times 10^6$ B16-pSMP, B16-RAKD or B16-RCKD cells suspended in 100 µl of supplement-free DMEM were injected subcutaneously into the hind leg of C57BL/6 male mice. Tumor growth was monitored and the volume was measured using an engineer’s caliper. Mice were sacrificed at days 8, 12 or 19 and the tumors were collected and weighed. For the 4T1 mammary carcinoma model, $1 \times 10^6$ of 4T1-pSMP, 4T1-RAKD or 4T1-RCKD cells were injected subcutaneously in the fourth mammary fat pad of female BALB/c mice. The tumor volume was determined at days 6, 12 and 18 post-inoculation. Mice were sacrificed using an overdose of CO$_2$ and lung metastases were quantified using a colony assay (see section 2.10.2). All tumor volumes were measured by an engineer’s caliper and calculated as $V = (W^2 \times L)/2$ (442). Tumor weight was determined after tumor resection on the day of the sacrifice.

2.10.1 Isolation of immune cells from organs of tumor-bearing mice

2.10.1.1 Tumor

At the time points indicated for each experimental model, tumors were resected from mice and weighed. Each tumor was minced in 2.5 ml of HBSS buffer using sharp scissors, then incubated for 20 mins at 37°C with an additional 2.5 ml of HBSS containing collagenase II enzyme (Bioshop, Burlington, ON) (final concentration of 150 µg/ml) to digest connective tissues. The tissue digest was filtered through a 70 µm cell strainer and the cells were washed twice using 5% bovine serum RPMI. Cells were counted and resuspended at a predetermined cellularity for immune profiling by flow cytometry analysis.

2.10.1.2 Lymph node

The inguinal draining lymph node was removed aseptically into 1 ml of HBSS. Lymphocytes were isolated by mashing the lymph node tissue with frosted slides. Cells were suspended in complete RPMI, filtered through a 70 µm cell strainer and counted. Cells were resuspended in a predetermined cellularity for immune profiling by flow cytometry analysis.

2.10.1.3 Blood samples

Blood was collected from the tail (50 µl per mouse) into a 75 µl micro-hematocrit
capillary tube containing 25 µl of 0.1 M EDTA. After collection, samples were diluted in a 1:3 ratio with PBS and centrifuged (300 x g, for 10 mins, at 4°C). The red blood cells within the pellet were lysed by mixing samples with 2 ml of ACK buffer. Following 5-7 mins of incubation, the reaction was stopped using 6 ml of 5% bovine serum RPMI. The cells were then washed with 5% bovine serum RPMI, pelleted (300 x g, for 10 mins, at 4°C), and resuspended in 1 ml of complete RPMI. Total cell number was determined by hemocytometer counting and leukocytes were suspended at a predetermined cellularity for immune profiling by flow cytometry analysis.

2.10.2 Quantification of lung metastases by colony assay

To recover 4T1 tumor cells that metastasized to the lung, a combination of mechanical and enzymatic digestion was performed to release cells from lung connective tissues. Lungs were removed after sacrifice, and swirled in HBSS to remove remaining blood. After mincing with scissors, lungs were digested in 5 ml of HBSS containing 1 mg/ml collagenase IV and 10 units of elastase. The tissue was digested for 75 min at 4°C on a rotating wheel. Lung cells were then filtered through 70 µm cell strainers and washed twice with RPMI containing 10% FBS. Single-cell suspensions were then re-suspended in complete RPMI supplemented with 60 µM 6-thioguanine to select for 4T1 cells that are resistant to this drug. Cells were seeded into 100 mm tissue culture plates and incubated at 37°C for 10-14 days until tumor colonies were visible. The colonies were then fixed with methanol for 5 mins and washed with distilled water. The fixed colonies were stained with 5 ml of 0.03% methylene blue stain and colonies that turned blue were counted. Data were expressed as total number of metastatic colonies per lung.

2.11 Immunohistochemistry (IHC) staining and Image J densitometry

For IHC staining of mouse tumor samples, 5 µm-sections were dewaxed and hydrated through graded ethanol, cooked in 10 mM citrate buffer at pH 6.0 in a pressure cooker/antigen retriever at 125°C for 30 mins (2100-Retriever, Electron Microscopy Sciences), then transferred into water to cool for 10 mins. After 5 mins of treatment in 3% H2O2, the slides were blocked with 10% normal goat serum (NGS) for 1 hr. The slides were dried and incubated with the primary antibody overnight at 4°C. The slides were washed three times and then incubated with the secondary antibody for 1 hr. Following
this, the slides were washed and dried, and then incubated with ABC solution (Vector Laboratories, Brockville, Ontario) at RT for 1 hr followed by the addition of DAB solution (Vector Laboratories) for 2 mins. The DAB solution was washed away and slides were counterstained with Mayer’s Haematoxylin for 2 mins followed by rinsing with tap water 2–3 times. The slides were then immersed in Scott’s solution for 2 mins, dehydrated and mounted with a coverslip.

For IHC staining of human tissue arrays, duplicate slides of a human melanoma tissue array ME481a (48 cases/48 cores), a human breast cancer and adjacent normal tissue array BC081120 (110 cases/110 cores), a human lung disease spectrum tissue array (99 cases/100 cores), and four sets of human colon tissue arrays, specifically COC1021 (102 cases/102 cores), CO952 (30 cases/95 cores), BC05023 (18 cases/54 cores) and T055 (6 cases/24 cores), were purchased from US Biomax Inc. (Rockville, MD USA). Each set of tissue array was immunostained with either polyclonal goat anti-hIL-17RA antibody (Abcam, ab133416) or goat IgG isotype control antibody (Sigma Aldrich) per my established protocol as stated above. Images of each sample at 50x, 100x and 1000x magnifications were captured using LEICA Application Suite (version 2.5.0 R1) on a LEICA DM2500 microscopy with LEICA DFC490 camera. The imaging conditions (e.g., exposure, saturation, gamma, gain, focus and light power, etc.) were optimized and used consistently for all samples for each set of the tissue array. Images captured at 50x magnification were subjected to densitometry analysis using ImageJ software with the minimum threshold (0–255) adjusted for each image to exclude background. The threshold values were used consistently between regions stained with anti-hIL-17RA and isotype control. The percent positive staining area and mean fluorescent intensity for each image were recorded and the value of isotype control sample was subtracted for the calculation.

2.12 Analysis of publicly available datasets

I searched the National Center for Biotechnology Information (NCBI)’s Genome Expression Omnibus (GEO) database for relevant studies published on or before May 31st, 2016. The search terms included “Cancer” and “TNFAIP3”. I then set five criteria to manually screen the 564 datasets identified in GEO-NCBI, including: (1) original papers containing independent data which have been published in a peer-reviewed journal, (2) basal level expression of A20 with no pre-treatments, (3) the sample size is above 20, (4)
the Affymetrix Human Genome U133 Plus 2.0 Array was used, which includes all genes of interest, (5) samples are from human patients or cell lines. After applying the five filters, a total of 34 datasets covering approximately 2185 samples from 12 types of solid cancers were identified and downloaded. Similarly, 30 datasets covering around 2083 solid malignancy samples were identified in Oncomine. All data obtained from Oncomine, but not GEO-NCBI, were pre-normalized and converted into Log2 values. Thus, to avoid biases resulting from artificially pooling unnormalized datasets, only the raw data retrieved from Oncomine were used to do the pooled analyses for specific cancer types. To analyze the effect of IL-17RA and A20 expression on prognosis of CRC patients, I downloaded the raw data for mRNA expression, copy number alteration and survival rate of TCGA Colorectal Adenocarcinoma dataset (633 patients) from cBioportal for Cancer Genomics (www.cbioportal.org) (443, 444) and Kaplan-Meier survival curves for CRC patients were generated using GraphPad Prism5 software.

2.13 Statistical analysis

Data were expressed as means ± the standard error of the mean. Statistical analyses were done using GraphPad Prism version 5.0 software program for Windows. Correlations between groups were analyzed by Pearson's and Spearman’s correlation coefficient. For normally distributed data, the two-tailed unpaired Student t test was used to determine the significance of the differences between two groups. For comparison of multiple groups, analysis of variance (ANOVA) was performed followed by post-hoc multiple comparisons of means. Dunnett’s post-hoc test was used for one-way ANOVA and Bonferroni’s post-hoc analysis was used for two-way ANOVA. For data does not have a normal distribution, nonparametric Mann Whitney test was used to determine the significance of the differences between two groups. Nonparametric Kruskal-Wallis test was performed for comparison of multiple groups, followed by Dunn’s post-hoc multiple comparisons of means. P values ≤ 0.05 were considered statistically significant. The following symbols were used to denote statistical significance: * P < 0.05, ** P < 0.01, *** P < 0.001.
CHAPTER 3 RESULTS

3.1 A novel role for IL-17R in repressing JNK1/JNK2 isoform-dependent tumor cell proliferation via the ubiquitin-editing enzyme A20

Parts of this chapter were included in the article “IL-17RC is critically required to maintain baseline A20 production to repress JNK isoform-dependent tumor-specific proliferation” Oncotarget. 2017;8:43153-68. https://doi.org/10.18632/oncotarget.17820 (445).

3.1.1 IL-17RC silencing in cancer cells directly alters tumor growth in a cell type dependent manner in vitro and in vivo

To examine the role of IL-17A/IL-17R in controlling cancer cell proliferation, I selected two well-characterized tumor cell lines B16 melanoma and 4T1 mammary carcinoma. IL-17RCKD clones were generated using several retroviral shRNA constructs cloned into the pSMP vector. Notably, all four shRNA constructs used were able to significantly reduce IL-17RC expression at mRNA and protein levels (Figure 6a/b). Representative clones that had >80% IL-17RC reduction and marginal change in IL-17RA expression were selected for further characterization. Compared to the pSMP control cells, the representative RCKD4.5 clone, produced significantly less CXCL1 upon IL-17A and IL-17F stimulation (Figure 6c), demonstrating a functional impairment of the IL-17A/F-induced signal transmission. Of interest, I noticed that B16-RCKD4.5 cells grew significantly slower than B16-pSMP control cells as measured by direct cell counting (Figure 6d) and MTT proliferation assay under normal culture condition and after serum starvation (Figure 6e). Correlation analysis revealed that cell proliferation was significantly and positively correlated with the level of IL-17RC expression in B16-RCKD clones (Figure 6f). When tumor cell clones were subcutaneously inoculated into C57BL/6 mice, the resulting B16-RCKD4.5 tumors were significantly smaller by volume and by weight compared to B16-pSMP tumors (Figure 6g). Together, my data suggest a positive role of IL-17RC in supporting the proliferation of B16 melanoma cells in vitro and in vivo.
Figure 6. Specific knockdown of IL-17RC expression in B16 melanoma cells attenuates tumor growth in vitro and in vivo.

B16 cells were transduced with retroviral vectors containing shRNAs against IL-17RC or scrambled sequences. IL-17RC expression by different B16 knockdown sub-clones was determined by qPCR, PCR (a) and flow cytometry (b). The threshold of gene expression for selecting the best knockdown is shown as a red line. (c) CXCL1 production upon IL-17A and IL-17F stimulation was assessed in culture supernatants by ELISA. Cell growth was measured by (d) direct cell counting and (e) MTT assay with or without serum starvation. (f) Proliferation of different KD strains was correlated with IL-17RC expression using Pearson and Spearman correlation analysis. (g) Weight and volume of B16-IL-17RCKD and B16-pSMP control tumors were determined in C57BL/6 mice after inoculation with 1 x 10^6 cells. All values are means ± SEM of 3 independent experiments for in vitro studies (a-f), or means ± SEM of n = 5-15 mice per group at each time point for in vivo studies (g). Statistical analyses were compared with the pSMP control; *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 6.

(a) IL-17RC mRNA level

(b) IL-17RC surface intensity

(c) B16 cells under IL-17A stimulation

(d) Growth curve by cell counting

(e) MTT proliferation assay

(f) Correlation Analysis

(g) Day 12 B16 tumor weight

(h) B16 tumor volume
RCKD clones with reduced IL-17RC at mRNA and protein levels were also generated using 4T1 cells (Figure 7a-c). Surprisingly, the loss of IL-17RC expression in 4T1 cells directly promoted tumor cell growth in culture. As shown in Figure 7d, the representative 4T1-RCKD4.8 clone displayed a 1.5- to 2-fold increase in proliferation rate in vitro compared to the 4T1-pSMP control. Furthermore, primary 4T1-RCKD tumors grown in BALB/c mice were approximately 2.5-fold larger than 4T1-pSMP tumors at day 18 post-inoculation (Figure 7e), and generated significantly more lung metastases (Figure 7f). Therefore, in sharp contrast to its role in B16 melanoma, IL-17RC is a negative regulator of 4T1 homeostatic proliferation and invasiveness in vitro and in vivo.

To investigate whether IL-17RC-controlled tumor growth was associated with altered apoptosis, flow cytometric analyses were conducted to measure the rates of serum starvation induced apoptosis in RCKD clones and pSMP controls. Notably, RCKD reduced the frequency of annexin V-positive B16 cells, but markedly increased the apoptosis of 4T1 cells (Figure 8a). I also measured caspase-3 activity via western blotting to verify the results (Figure 8b). Consistent with the flow cytometric analyses of annexin V staining, the levels of total and cleaved caspase-3 were reduced in B16-RCKD cells compared to B16-pSMP controls; in sharp contrast, the amount of cleaved caspase-3 was dramatically increased in 4T1-RCKD cells; however, the total caspase-3 level was comparable among 4T1-RCKD cells and 4T1-pSMP control cells. Similar to the in vitro observations, the level of cleaved caspase-3 was significantly increased in 4T1-RCKD tumor sections compared to their pSMP counterparts (Figure 8c). Therefore, my data suggest that IL-17RC has divergent roles in controlling homeostatic proliferation and stress-induced apoptosis in different tumor types. Notably, despite its impact on stress-induced apoptosis, IL-17RC-controlled homeostatic proliferation appears to ultimately dictate the invasiveness of the tumor cells in vitro and in vivo.
Figure 7. Specific knockdown of IL-17RC expression in 4T1 cells promotes tumor proliferation and tumor invasiveness in vitro and in vivo.

4T1 cells were transduced with retroviral vectors containing shRNAs against IL-17RC or scrambled sequences. (a-b) IL-17RA and RC mRNA and surface protein expression from a representative IL-17RCKD clone (RCKD4.8) and pSMP control of 4T1 cells were examined by RT-PCR and flow cytometry. The threshold of gene expression for selecting the knockdown clones is shown as a red line. (c) CXCL1 production upon IL-17A stimulation was determined by ELISA. (d) Cell growth was measured by direct cell counting and MTT assay with serum starvation treatment. (e,f) Tumor volume, weight and lung metastasis of 4T1-IL-17RCKD and 4T1-pSMP control tumors in BALB/c mice. All values are presented as the mean ± SEM of 3-5 independent experiments for in vitro studies (a-d), or the mean ± SEM of 5-10 mice per group at each time point for in vivo studies (e, f). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; statistical analysis was compared with the pSMP control.
Figure 7.

73

(a) 

(b) 

(c) 

(d) 

(e) 

(f) 

**Figure 7.**

(a) 4T1-pSMP and RCKD4.8

(b) IL-17RA and IL-17RC

(c) 4T1 cells under IL-17A stimulation

(d) Growth curve by cell counting

(e) 4T1 tumor volume

(f) Day 18 lung metastasis

***
Figure 8. IL-17RC silencing alters tumor cell apoptosis in vitro and in vivo in a tumor-dependent manner.

(a) Quantified results of Annexin V+ cell percentage in B16 and 4T1 culture after serum starvation for 14 hrs and recovery in CM for 1 hr. (b) RCKD and pSMP control subclones of B16 and 4T1 cells were serum starved for 14 hrs and recovered in CM for different periods of time as indicated. Whole-cell extracts were harvested and immunoblotted with the indicated antibodies to detect pro- and cleaved-caspase-3. GAPDH was used as a loading control. (c) Representative images and quantitative assessment of cleaved-caspase-3 protein level observed in day 18 4T1 tumors by immunohistochemistry. Values are means ± SEM of 4-6 replicates in two independent experiments (a,c). Statistical analyses were compared with the pSMP control; *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 8.

(a) Apoptosis of B16 cells

```
% Annexin V+ cells

<table>
<thead>
<tr>
<th></th>
<th>B16-pSMP</th>
<th>RCKD4.5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10</td>
<td>20</td>
</tr>
</tbody>
</table>
```

Apoptosis of 4T1 cells

```
% Annexin V+ cells

<table>
<thead>
<tr>
<th></th>
<th>4T1-pSMP</th>
<th>RCKD4.8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>20</td>
</tr>
</tbody>
</table>
```

(b) B16-pSMP B16-RCKD4.5 4T1-pSMP 4T1-RCKD4.8

<table>
<thead>
<tr>
<th></th>
<th>24 hrs starvation</th>
<th>5 min</th>
<th>15 min</th>
<th>30 min</th>
<th>60 min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro-Caspase-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cleaved Caspase-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(c) 4T1-pSMP RCKD4.8

```
1x 500x 1000x
```

Cleaved Caspase-3

```
<table>
<thead>
<tr>
<th></th>
<th>4T1-pSMP</th>
<th>RCKD4.8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive area %</td>
<td></td>
<td>**</td>
</tr>
</tbody>
</table>
```

**
3.1.2 IL-17RC silencing induces acquired-activation of distinct JNK isoforms in different tumor cells, which differentially regulates c-Jun-dependent homeostatic proliferation

To identify the specific signaling pathway(s) responsible for the altered homeostatic proliferation of B16 and 4T1 RCKD clones, well-characterized pharmacologic inhibitors were used to block NF-κB, PI3K-AKT and MAPK pathways in cell culture. Notably, the homeostatic proliferation of IL-17RCKD clones and pSMP controls of both B16 and 4T1 cells was significantly inhibited by KIN001-102 and BMS-34554 (Figure 9a/b), specific inhibitors for AKT and IKK, respectively, suggesting that AKT and NF-κB pathways provide survival signals for both B16 and 4T1 cells under steady-state conditions. However, B16 and 4T1 clones exhibited similar sensitivities to AKT and IKK inhibitors, indicating that IL-17RC-controlled cell proliferation is not mediated by AKT or NF-κB signals. Of interest, 4T1 and B16 clones displayed distinct sensitivities to inhibitors targeting the JNK/c-Jun pathway (Figure 9c/d), while they responded to the ERK and p38 inhibitors similarly (APPENDIX A). Specifically, L-form JNK inhibitor was able to inhibit proliferation of B16-pSMP cells, but not 4T1-pSMP cells; however, IL-17RC silencing resulted in reduced sensitivities to L-form JNK inhibitor in B16-RCKD cells, but markedly enhanced sensitivity of 4T1-RCKD cells (Figure 9c). Furthermore, the 4T1-RCKD clone was sensitive to the SP600125 JNK/c-Jun inhibitor, which exhibited no activity against 4T1-pSMP cells, but similar inhibition in B16-pSMP and B16-RCKD clones (Figure 9d). This highlights a role for IL-17RC in suppressing homeostatic JNK/c-Jun activation in 4T1 but not B16 cells.

To verify this finding, I examined total JNK/c-Jun and phospho-JNK/cJun levels by western blotting. As demonstrated in Figure 9e-h, phospho-JNK and phospho-c-Jun, as well as total JNK and c-Jun levels, were markedly increased in 4T1-RCKD cells compared to 4T1-pSMP control cells. Surprisingly, JNK phosphorylation, but not total protein level, was significantly increased in B16-RCKD cells. However, phospho-c-Jun and total c-Jun levels were significantly reduced in B16-RCKD clones compared to B16-pSMP clones (Figure 9g-h). In agreement with differential activation patterns of c-Jun in the two cell lines, the expression of cyclin D1, one of the c-Jun target genes, was also markedly reduced in B16-RCKD clone, but evidently increased in 4T1-RCKD cells, compared to their corresponding pSMP controls (Figure 9g). Collectively, my data demonstrate that IL-17RC
silencing results in acquired JNK-activities in B16 and 4T1 cells but distinct c-Jun activities, at both production/stability and functional activity levels, in the two tumor cell lines.

Given that the IL-17RC silencing induced consistent JNK-activation with distinct c-Jun activities and inverse proliferation patterns in the two tumor models, I questioned whether IL-17RC silencing induced activation of different JNK isoforms in B16 and 4T1 cell lines. Indeed, IL-17RC silencing in B16 cells significantly increased mRNA and protein levels of JNK2 (Figure 10a-c). Conversely, IL-17RC silencing in 4T1 cells induced marked upregulation of JNK1 (Figure 10a-c). To further verify whether the distinct c-Jun activities and proliferation profiles observed in RCKD clones of B16 and 4T1 cells were due to differential expression/activation of JNK1 and JNK2 isoforms, I used another retroviral vector pGIPz to deliver shRNAs targeting endogenous Jnk1 or Jnk2 in B16-RCKD and 4T1-RCKD cells (Figure 10d/e). While both JNK1 and JNK2 shRNAs displayed specific targeting effects in both B16-RCKD and 4T1-RCKD clones (Figure 10d/e), the JNK1 shRNA increased Jnk2 mRNA and JNK2 protein in 4T1 cells (Figure 10d/e), indicating a potential role of JNK1 in repressing JNK2 expression under steady-state conditions. Importantly, the level of phospho-JNK in B16-RCKD and 4T1-RCKD clones was markedly attenuated by JNK2 and JNK1 shRNA, respectively (Figure 10e), reinforcing the notion that IL-17RC silencing induces differential acquired-activation of distinct JNK isoforms in the two tumor cell lines. Despite differential expression/activation of JNK isoforms in B16 and 4T1 cells, JNK1 shRNA was able to completely remove total and phospho-c-Jun signals, demonstrating a critical role of JNK1 in maintaining baseline c-Jun activities. Conversely, JNK2 shRNA enhanced total and phospho-c-Jun (S73) levels in B16-RCKD and, possibly, 4T1-RCKD cells, indicating a potential role of JNK2 in suppressing baseline c-Jun activities (Figure 10e). Importantly, JNK1 silencing consistently attenuated the proliferation of both B16-RCKD and 4T1-RCKD cells, whereas JNK2 silencing increased the proliferation of both cell lines (Figure 10f). Notably, the apoptosis rates were not significantly affected by JNK1/JNK2 silencing in both cell lines (Figure 10g). Taken together, my data suggest that IL-17RC silencing induces tumor-specific expression and activation of JNK1 and JNK2 isoforms, which have opposing roles in controlling downstream c-Jun activity and c-Jun-dependent homeostatic proliferation.
Figure 9. IL-17RC silencing results in acquired-JNK activation but distinct c-Jun activities in B16 and 4T1 cells.
(a-d) IL-17RCKD and pSMP clones of B16 melanoma and 4T1 mammary cancer cells were treated with DMSO or one of the inhibitors indicated for 48 hrs. Cell proliferation was then measured by MTT assay. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; statistical analysis was compared with the DMSO control. ##p ≤ 0.01; ###p ≤ 0.001; statistical analysis was compared with the pSMP control line. All values are means ± SEM of 4-6 replicates in two independent experiments. (e-h) Whole-cell extracts were harvested and immunoblotted to detect total or phosphorylated proteins as indicated. GAPDH was used as a loading control. Scanning densitometry of relative phospho (p)-JNK, total JNK, p-cJun and total cJun protein levels at 30 mins post CM recovery were performed.
Figure 9. Continued.
Figure 9. Continued.

(g) Table showing the expression levels of various proteins over time in different cell lines. The proteins include p-c-Jun (S63) and (S73), Total c-Jun, Cyclin D1, and GAPDH.

(h) Graphs showing the 30-minute c-Jun activity in B16 and 4T1 cells. The graphs compare the relative levels of p-c-Jun (S63) and (S73) to GAPDH for B16-pSMP, B16-RCKD, 4T1-pSMP, and 4T1-RCKD.
Figure 10. IL-17RC silencing induces acquired activation of different JNK isoforms in different tumor cells, which differentially regulate c-Jun activities and homeostatic cell proliferation.

(a) JNK1 and JNK2 mRNA levels were determined by qRT-PCR in pSMP and RCKD subclones of B16 and 4T1 tumor cells. (b) Whole-cell extracts were harvested and immunoblotted to detect total JNK1 and JNK2 protein. GAPDH was used as a loading control. (c) Scanning densitometry of relative JNK1 and JNK2 protein levels at 30 mins post CM recovery were performed. (d-g) RCKD subclones of B16 and 4T1 cells were transiently transfected with JNK1 and JNK2 shRNA. (d) JNK1 and JNK2 mRNA levels were determined by qRT-PCR 3 days after transfection. (e) Day 3 transfected cells were serum starved for 14 hrs and rescued with CM for 1 hr. Whole-cell extracts were harvested and immunoblotted to detect total or phosphorylated proteins. GAPDH was used as a loading control. (f) Day 3 transfected cells were seeded and cultured for an additional 3 days. Cells were then collected for flow cytometric analysis of their proliferation rate. For each sample, 20,000 events were collected and the time of collection was recorded. PI was used to exclude the dead cells. The PI- live cell count for each sample was divided by the respective time of collection to quantify the cell proliferation rate. (g) Quantified results of Annexin V+ cell frequency in B16 and 4T1 cultures. Values are means ± SEM of 4-6 replicates in two independent experiments. Statistical analyses were compared with the vector control cells; *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 10.
3.1.3 IL-17RC is required for maintaining basal A20 level that restrains homeostatic activation of JNK and NF-κB pathways

Having demonstrated a role for IL-17RC in restraining activation of JNKs in both B16 and 4T1 tumors, I questioned whether this observation was due to the loss of a critical negative control. By comparing the published information regarding baseline versus IL-17-induced signaling, I found that most of the negative regulators require ligand binding to actively interfere with IL-17A signaling. While several of these inhibitors are IL-17A-dependent transcripts, A20 seems to be the only IL-17A-dependent autocrine regulator identified under homeostatic conditions, which forms an intrinsic negative feedback loop to block IL-17A signaling (409) (Figure 5). Given the critical role of A20 in negatively regulating multiple pathways, I examined A20 expression in RCKD and pSMP clones of B16 and 4T1 cells. As demonstrated in Fig. 11, A20 mRNA levels in RCKD clones of both B16 and 4T1 tumors were consistently reduced by four different IL-17RC-targeting shRNA constructs (Figure 11a). Notably, the basal level of A20 in B16-pSMP cells was significantly lower than that in 4T1-pSMP cells. In agreement with the mRNA profile, A20 protein levels were also consistently reduced in RCKD clones compared to pSMP cells under regular CM conditions or after 24 hrs of serum starvation (Figure 11b), highlighting a critical role of IL-17RC in maintaining basal production of A20. In accordance with a role of A20 in negatively regulating the NF-κB pathway (413), NF-κB activity, as measured by the phospho-IκB-α level and EMSA assays, demonstrated that the nuclear translocation of NF-κB was markedly and persistently elevated in RCKD clones compared to pSMP counterparts (Figure 11b/c).

To further verify that IL-17RC-controlled A20 was responsible for acquired-JNK activation in RCKD clones, I transfected RCKD clones with a plasmid carrying full length A20 or the empty plasmid vector and examined the intracellular signaling molecule profile by western blot. While the A20 plasmid effectively restored A20 levels in RCKD clones, A20 reconstitution also reduced the level of phopho-IκBα, total and phospho-JNK1 and JNK2 at 72 hrs post-transfection in both B16-RCKD and 4T1-RCKD cells (Figure 11d/e), confirming that acquired homeostatic activation of both NF-κB and JNK pathways in RCKD clones was due to reduced A20 production. Since the ZnF4-5 domain of A20 is critical for K48-mediated ASK1 degradation that inhibits TNF-induced JNK-c-Jun
activation (423), I used a ΔZnF4-5 mutant (~65kDa) plasmid to determine whether A20 may also utilize this mechanism in controlling homeostatic JNK activation. Notably, the ΔZnF4-5 mutant exhibited clear functional impairment in reducing JNK phosphorylation compared to WT A20 counterparts in both B16-RCKD and 4T1-RCKD clones, suggesting that A20 inhibits homeostatic JNK activation mainly through the ZnF4-5 domain. In comparison, the ΔZnF4-5 mutant exhibited less consistent functional alterations in controlling homeostatic NF-κB activity compared to WT A20 (Figure 11d).

3.1.4 The IL-17RC-A20 axis is required to selectively repress cytokine production downstream of NF-κB and JNK/c-Jun pathways

Having demonstrated that NF-κB and JNK pathways are up-regulated in RCKD cells, I hypothesized that, in addition to controlling homeostatic proliferation, the IL-17RC-A20 axis may also control secretion of pro-inflammatory cytokines downstream of NF-κB and JNK pathways under steady state conditions and upon cytokine stimulation. To this end, I cultured 4T1-pSMP control and 4T1-RCKD cells in the presence or absence of recombinant IL-17A and measured the levels of GM-CSF and IL-6 in the culture supernatants as representative cytokines downstream of NF-κB and JNK pathways. Given an impaired CXCL1 production by RCKD cells upon IL-17A stimulation observed in my initial characterization experiments (Figure 7c), I also measured CXCL1 as a control. Notably, the levels of IL-6 and GM-CSF, but not CXCL1, showed a clear trend toward enhanced basal production in 4T1-RCKD cells compared to the pSMP control cells. Despite a very low level of IL-17RC expression on the surface of RCKD cells, 4T1-RCKD cells actually produced significantly more IL-6 and GM-CSF, but not CXCL1, upon IL-17A stimulation (Figure 12a). A similar experiment was conducted using mouse embryonic fibroblasts (MEFs) isolated from C57BL/6 mice and A20-knockout (A20KO) mice. As shown in Figure 12b, A20KO MEFs produced significantly more IL-6 and a trend toward higher GM-CSF compared to WT counterparts. In comparison, a marked reduction of CXCL1 was observed in A20KO MEFs under steady-state condition while they produced similar amounts upon IL-17A stimulation. Collectively, my data suggests that, in addition to controlling tumor-specific proliferation, the IL-17RC-A20 axis has a regulatory role in selectively repressing production of pro-inflammatory cytokines including IL-6 and GM-CSF, but not CXCL1.
Figure 11. IL-17RC is required to maintain basal production of A20 and repress homeostatic activities of JNK1 and JNK2.
(a) A20 mRNA level determined by qRT-PCR in pSMP and RCKD subclones of B16 and 4T1 tumor cells. (b) Whole-cell extracts were harvested and immunoblotted to detect total or phosphorylated proteins as indicated. GAPDH was used as a loading control. (c) Nuclear proteins were extracted from RCKD and pSMP cells of B16 and 4T1 cells and subjected to EMSA using $^{32}$P-labeled NF-κB DNA probes. (d) RCKD cells were transfected with plasmid vector, plasmids expressing A20 or A20 with a mutant ΔZnF4-5 domain. After 72 hrs, whole-cell extracts were harvested and immunoblotted to detect phosphorylated or total proteins as indicated. GAPDH was used as the loading control. (e) Scanning densitometry of relative protein levels was performed. Values are means ± SEM of at least two independent experiments. Statistical analyses were compared with the respective vector control cells (white bar). *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 11.
Figure 12. The IL-17RC-A20 axis selectively represses cytokine production downstream of NF-κB and JNK/c-Jun pathways.

(a) IL-17RCKD and scramble control 4T1 cell lines were cultured or stimulated with recombinant IL-17A as indicated. Cytokine ELISAs were performed using the day-three culture supernatants. (b) WT and A20KO MEFs were stimulated with or without 50 ng/ml recombinant IL-17A. Cytokine ELISAs were performed using the day-three culture supernatant. Values are means ± SEM of 3-5 replicates in at least two independent experiments. Statistical analyses were compared with the pSMP vector control in panel a, or WT cells in panel b. **p < 0.01; ***p < 0.001.
3.1.5 IL-17RA silencing in B16 melanoma and 4T1 mammary carcinoma cells enhances tumor cell growth *in vitro* and *in vivo*

Since both IL-17RC and IL-17RA are obligate receptors for IL-17A signaling, I created IL-17RAKD clones of B16 melanoma cells to examine the role of IL-17RA in controlling cancer cell behavior. Using 4 retroviral shRNA constructs, a total of 38 single clones were selected, expanded and characterized for IL-17RA/RC levels by RT-PCR and flow cytometry. A representative clone B16-RAKD3.1, which exhibited a 90% reduction in IL-17RA and no change in IL-17RC expression was selected (Figure 13a/b). As expected (292, 293), IL-17A and IL-17F stimulation induced significantly less CXCL1 production from B16-RAKD3.1 cells compared to the B16-pSMP control, demonstrating a functional impairment in IL-17A/F-induced signal transmission (Figure 13c). In contrast to B16-RCKD cells, B16-RAKD clones exhibited significantly enhanced proliferation compared to the B16-pSMP control. This observation was consistent among all clones regardless of where the shRNA target sequences were located and whether the cells were cultured directly in CM or after serum starved (Figure 13d). The observation was further verified by Ki67 staining (Figure 13f) and direct cell counting (Figure 13g). The correlation analysis revealed that cell proliferation was significantly and inversely correlated with the IL-17RA level in B16-RAKD clones (Figure 13e), highlighting a critical role for IL-17RA-mediated signals in negatively controlling homeostatic proliferation of B16 melanoma cells *in vitro*.

I also generated RAKD clones from 4T1 mammary carcinoma cells and observed the same phenotype and growth patterns as B16-RAKDs. The representative 4T1-RAKD4.6 clone, which had an approximately 80% reduction in IL-17RA but intact IL-17RC, displayed significantly elevated proliferation compared to the 4T1-pSMP control (Figure 14). Notably, while RCKDs in both of my cancer cell line models exhibited altered apoptotic rates, RAKD clones exhibited comparable levels of apoptosis to the corresponding pSMP controls (Figure 15).
Figure 13. Knockdown of IL-17RA expression in B16 melanoma cells promotes tumor growth in vitro.

B16 cells were transduced with retroviral vectors containing shRNAs targeting different regions of IL-17RA or the pSMP control vector. (a, b) IL-17RA and IL-17RC expression measured by flow cytometry and qRT-PCR on representative clones. (c) CXCL1 production determined by ELISA following IL-17A or IL-17F stimulation. (d) Growth of IL-17RAKD and pSMP clones under normal and serum-starved condition measured by MTT assay. (e) Correlation analysis between growth rate and IL-17RA expression. (f) Cells were starved with serum medium for 12 hrs and then cell proliferation, as measured by Ki67 staining, was assessed by flow cytometry 1 hr and 12 hrs after addition of complete medium. (g) Cell growth measured by direct cell counting. All values are means ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; compared with the pSMP control.
Figure 13.

(a) IL-17RA MFI

(b) IL-17RA mRNA

(c) IL-17A Stimulation

(d) MTT Assay

(e) Correlation Analysis

(f) Growth Curve of B16 Cells
Figure 14. Characterization of IL-17RA knockdown clones of 4T1 cells in vitro.
(a) IL-17RA and IL-17RC expression in representative 4T1 clones measured by RT-PCR and flow cytometry. (b) Cell growth measured by MTT assay. (c) Cell growth measured by direct cell counting. (d) Cells were starved with serum-free medium for 12 hrs and then cell proliferation, as measured by Ki67 staining, was assessed by flow cytometry 1 hr and 12 hrs after addition of complete medium. All values are means ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; compared with the pSMP control.
Figure 15. Flow cytometric analysis of PI-Annexin-V to quantify IL-17RA-associated apoptosis in B16 and 4T1 cells.
(a) Dot plots of 4T1-RAKD and control cells in complete DMEM medium with 10% FBS, or serum starved for 12hrs and rescued with CM for 1hr or 4hrs. The results shown are representative of three independent experiments. (b) Quantification of Annexin V+ B16 and 4T1 clones in culture after serum starvation for 12hrs and rescue with complete medium for 1hr. Values are means ± SEM of 3 independent experiments.
Subsequently, I subcutaneously inoculated B16 tumor cells into C57BL/6 mice and monitored the kinetics of tumor growth for a period of 19 days. Consistent with in vitro data, B16-RAKD3.1 cells grew into significantly larger tumors by volume and/or weight at days 12, 16 and 19 post-inoculation, compared to the control B16-pSMP cells (Figure 16a), indicating that in contrast to IL-17RC signaling in B16 cells, IL-17RA-mediated signaling has a significant role in restraining tumor progression in vivo. In comparison, 4T1-RAKD4.6 cells grew into significantly larger primary tumors compared to 4T1-pSMP cells (approximately 2.5-fold larger at day 18 post-tumor inoculation), and generated significantly more lung metastases compared to the control cells (Figure 16b). The slightly higher growth rate of 4T1-RAKD tumors compared to the 4T1-RCKD tumors may be the result of the increased apoptotic rate in 4T1-RCKD tumor cells (Figure 8). Together, in contrast to the role of IL-17RC in controlling tumor-specific proliferation, my data demonstrate that the reduction or loss of IL-17RA expression in tumor cells uniformly enhances cell proliferation and invasiveness of tumor cells in vitro and in vivo.
Figure 16. Knockdown of IL-17RA expression promotes tumor growth in vivo.
(a) Tumor volume and weight following inoculation of B16-IL-17RAKD and B16-pSMP control cells into C57BL/6 mice. (b) Tumor volume, weight and lung metastasis following inoculation of 4T1-IL-17RAKD and 4T1-pSPM control cells in BALB/c mice. All values are means ± SEM of 3 independent experiments. n = 5-10 mice per group for each time point.
3.1.6 Baseline IL-17RA level restrains tumor cell proliferation by inhibiting homeostatic JNK/c-Jun activation

Once again, I utilized pharmacologic inhibitors to identify the specific signaling pathway(s) which may be responsible for the hyper-proliferation of 4T1-RAKD3.1 and B16-RAKD3.1 clones and further examined the NF-κB, MAPK and PI3K-AKT pathways in cultured cells with or without exogenous IL-17A (Figure 17a). The homeostatic proliferation of B16-pSMP and 4T1-pSMP control lines was significantly reduced in the presence of AKT and IKK inhibitors, but not MAPK inhibitors; however, the effects of AKT and IKK inhibitors were either completely (B16-pSMP) or partially (4T1-pSMP) reversed by stimulation with exogenous IL-17A. These results indicate that AKT and NF-κB activities induced by endogenous IL-17A act as modest pro-proliferation signals in pSMP clones. Interestingly, the IKK inhibitor was also suppressive in both B16-RAKD3.1 and 4T1-RAKD3.1 clones, and the level of suppression was not affected by exogenous IL-17A (Figure 17a), indicating that the NF-κB activity in RAKDs is primarily induced by IL-17RA-independent signaling. The AKT inhibitor was suppressive in B16-RAKD3.1, but not 4T1-RAKD3.1, and the level and pattern of suppression were not affected by exogenous IL-17A, suggesting that AKT is activated by IL-17RA-dependent and IL-17RA-independent signaling pathways, depending on the cell type, and not responsible for hyper-proliferation of RAKD3.1 clones. Remarkably, consistent with the hyper-proliferative 4T1-RCKD3.1 clone, both B16-RAKD3.1 and 4T1-RAKD3.1 clones also displayed obvious sensitivities to JNK and c-Jun inhibitors, which were not observed in control pSMP counterparts (Figure 17a).

Cell cycle analysis was conducted to understand the involvement of the JNK pathway in the hyper-proliferation of RAKD3.1 clones. Compared to B16-pSMP control cells, a significantly higher frequency of B16-RAKD3.1 cells accumulated in the G1 phase after serum-starvation and progressed into S phase upon recovery in complete medium (Figure 17b), indicating that the hyper-proliferation of RAKD3.1 clones is primarily due to enhanced G1-to-S phase transition. Notably, inhibiting the JNK/c-Jun pathway with SP600125 effectively eliminated the differences between B16-RAKD3.1 and B16-pSMP cells entering S phase (Figure 17c). Together, though distinct proliferation patterns have been observed in IL-17R KDs, my data demonstrated that IL-17R silencing uniformly induced
the activation of JNK signaling and JNK-mediated G1-to-S phase cell cycle control in both cancer cell lines.

3.1.7 Baseline IL-17RA level is required for maintaining the basal production of A20 that controls aberrant activation of JNK and hyper-proliferation

I next determined whether JNK activation induced by IL-17RA silencing was due to impaired basal production and/or function of the endogenous IL-17A-induced regulatory signaling molecule A20. Though some results from IL-17RCKD clones were presented in previous sections, I purposely included them herein as internal controls to provide a direct comparison between IL-17RA verses IL-17RC signals. A20 mRNA levels were consistently upregulated by IL-17A and IL-17F, but not IL-17C or IL-17E, in both B16 and 4T1 cells (Figure 18a). Furthermore, A20 mRNA levels were reduced in both RAKD and RCKD clones compared to pSMP counterparts in B16 and 4T1 cells, highlighting the importance of IL-17RA/RC in maintaining A20 homeostasis (Figure 18b). In comparison, C/EBPβ had irregular expression patterns among different clones of B16 and 4T1 cells, suggesting that IL-17RA/IL-17RC selectively control A20 but not C/EBPβ. In agreement with the mRNA profile, A20 protein levels were consistently reduced in KD clones under serum-starvation and regular culture conditions (Figure 18c/d), indicating that baseline IL-17R is essential for basal production of A20. Notably, RAKDs exhibited a trend toward greater A20 mRNA loss compared to RCKDs; however, this is not reflected by A20 protein level, suggesting that A20 expression may also be controlled at post-transcriptional levels by other IL-17R-independent signals. Unlike A20 expression, basal levels of phospho-JNK in RAKD and RCKD clones of 4T1 and B16 cells were significantly increased compared to pSMP counterparts (Figure 18c/e). B16-RAKD and B16-RCKD cells displayed quicker kinetics and enhanced intensities of JNK phosphorylation upon CM recovery compared to the B16-pSMP clone. In comparison, 4T1-RAKD and 4T1-RCKD had constitutive JNK phosphorylation compared to the 4T1-pSMP control. Indeed, the 4T1-pSMP clone had negligible phospho-JNK levels in all samples (Figure 18c/e). To examine whether the JNK isoform-dependent proliferation may also explain hyper-proliferation of B16-RAKDs, I blotted for both JNK isoforms. Surprisingly, JNK1 and JNK2 were both upregulated in RAKDs compared to their respective B16 and 4T1 pSMP clones (Figure 18c). Given the hyper-proliferation phenotype of RAKDs, these data support the notion that the IL-17R-
silencing induced pro-proliferative JNK1 activity is dominant compared to the anti-proliferative JNK2.

In accordance with a role of A20 in negatively regulating the NF-κB pathway, the NF-κB activity as measured by phospho-IκB-α and EMSA assays indicated that the NF-κB nuclear translocation was markedly and persistently elevated in RCKD clones, but only marginally increased in RAKD clones compared to pSMP counterparts (Figure 18f/g).

In order to validate the role of IL-17R/A20 axis in controlling JNK-dependent proliferation \textit{in vivo}, I immunoblotted 4T1 tumor sections for Ki67, A20 and phosphor-JNK staining (Figure 19). Both 4T1-RAKD and 4T1-RCKD tumors exhibited around 3-fold higher Ki67\(^+\) expression intensity and percentage area staining, than the 4T1-pSMP control tumors. Consistent with my \textit{in vitro} results, the hyper-proliferative nature of IL-17R-KD tumors was associated with markedly reduced A20 expression and enhanced activation of JNK. Together, the profile of intracellular signaling molecules provides solid evidence that the baseline IL-17A/IL-17R signal is essential for maintaining basal levels of A20, which actively restrains baseline JNK activation in RAKD and RCKD clones, as well as the NF-κB activity in RCKD clones.

I also examined whether the IL-17R-A20 axis may control the proliferation of primary cells. Bone marrow-derived dendritic cells (BMDC) and mouse embryonic fibroblasts (MEF) from an IL-17RA- or IL-17RC-deficient mice all displayed significantly reduced A20 levels compared to their wild type (WT) counterparts (Figure 20). BMDC from IL-17RA\(^-\), IL-17RC\(^-\), and WT mice exhibited different proliferation capacities with the order of IL-17RA\(^-\)>IL-17RC\(^-\)>WT (Figure 20b). MEF proliferation assays indicated that MEF from IL-17RA\(^-\) and IL-17RC\(^-\) mice had significantly higher rates of proliferation compared to WT MEF upon CM recovery (approximately 40\% in RAKO, 20\% in RCKO and 8\% in WT) while serum starvation stopped MEF proliferation (approximately 0.9\% Ki67\(^+\)) (Figure 20c/d). These results demonstrate that baseline IL-17R level is required for basal production of A20 in primary cells and controlling homeostatic proliferation of primary hematopoietic and non-hematopoietic cells.
Figure 17. Baseline IL-17RA level restrains tumor cell proliferation via inhibiting homeostatic JNK/c-Jun activation.

(a) IL-17RAKD and pSMP control lines of B16 melanoma and 4T1 breast cancer cells were cultured with or without IL-17A (50 ng/ml) stimulation. Cells were treated with DMSO or one of the inhibitors (2 µM AKT inhibitor, 5 µM IKK inhibitor, 10 µM ERK inhibitor, 10 µM p38 inhibitor, 5 µM L-form JNK inhibitor or 10 µM JNK/c-Jun inhibitor) for 48 hrs. Cell proliferation was measured by MTT assay. The absorbance value in each treatment condition was normalized relative to the MTT value in the seeding control. (b/c) Cell cycle analysis in B16-pSMP and B16-RAKD3.1 cells. (b) Cells were synchronized for 24 hrs in serum-free medium or cultured in complete medium for an additional 48 hrs prior to PI staining and analysis of DNA content. (c) To assay the role of JNK/c-Jun, B16-RAKD3.1 cells were starved in serum-free medium for 24 hrs and recovered in complete medium, DMSO-containing medium or SP600125-containing medium for 48 hrs. Values are means ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; compared with the respective control (white bar) using one-way or two-way ANOVA.
Figure 17. B16-pSMP
(a) B16-pSMP
Medium alone rIL-17A (50 ng/ml)
Relative proliferation level to the seeding control
1 2 3 4 5 6 7 1 2 3 4 5 6 7
(b) Serum-free Med Complete Med
% Cell Population
G1 S G2 G1 S G2 G1 S G2
1 2 3 4 5 6 7
(c) Med DMSO SP600125
% Cell Population
G1 S G2 G1 S G2 G1 S G2
(d) Med IL-17A IL-17F
% Cell Population
G1 S G2 G1 S G2 G1 S G2

1: DMSO;
2: AKT inhibitor (KIN001-102);
3: IKK inhibitor (BMS-345541);
4: ERK inhibitor (FR180204);
5: p38 inhibitor (SB203580);
6: L-form JNK inhibitor (420116);
7: JNK/c-Jun inhibitor (SP600125).
Figure 18. IL-17RA/RC silencing leads to reduced A20 production and enhanced activation of JNK and NF-κB pathways.

(a) B16 melanoma and 4T1 mammary carcinoma cells were starved with serum-free DMEM for 14 hrs and allowed to recover in complete DMEM medium with or without exogenous 200 ng/ml IL-17 ligands for 30 mins. Gene expression was determined by qRT-PCR with 6 replicates from 2 independent experiments. Values were compared with the respective CM treated group (black bar). (b) A20 and C/EBPβ mRNA levels were determined by qRT-PCR in pSMP, RAKD and RCKD subclones of 4T1 and B16 tumor cells. (c) Whole-cell extracts were harvested from serum starved and recovered cells and immunoblotted to detect total or phosphorylated proteins as indicated. GAPDH was used as a loading control. (d, e) Scanning densitometry of relative A20 and p-JNK protein levels at 60 min post CM recovery were performed. (f, g) Nuclear proteins were extracted from RAKD, RCKD and control cells of B16 and 4T1 cells and subjected to EMSA using 32p-labeled NF-κB DNA probes. Values are means ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; *** p < 0.001; compared with the respective control cell line (black bar) using one-way ANOVA.
Figure 18.

(a) [Graph showing data for B16 and 4T1 cells with A20 and other markers.]

(b) [Graph showing data for A20 in B16 and 4T1 cells.]

(c) [Table showing protein expression levels for B16 and 4T1 cells across different conditions.]
Figure 18. Continued.

(d) A20 Protein in B16

(e) p-JNK in B16

(f) RAKD3.1 RCKD4.5 B16-pSMP

(g) NF-κB activity in B16

(h) NF-κB activity in 4T1
Figure 19. IL-17RA/RC silencing leads to reduced A20 production and enhanced activation of JNK \textit{in vivo}.

Mice were inoculated with $1 \times 10^6$ 4T1 mammary carcinoma cells. On day 18, tumors were harvested and prepared for immunohistochemistry. Sections were stained with antibodies against Ki67, A20 and phosphorylated JNK. Staining was developed using ABC and DAB solutions (Vector Laboratories, Brockville, Ontario). Slides were counterstained with Mayer’s Haematoxylin and staining intensity was determined. Original magnification was 400x. Values are means ± SEM of 3 independent experiments. *$p < 0.05$; **$p < 0.01$; ***, $p < 0.001$; compared with the respective control cell line (black bar) using one-way Kruskal-Wallis test.
Figure 20. BMDC and MEF with IL-17RA or IL-17RC deficiency show reduced basal expression of A20 and increased proliferation.

(a) A20 mRNA levels in GM-CSF-induced BMDCs and MEF cells from WT, IL-17RAKO and IL-17RCKO mice. (b) BMDCs were labeled by Cell Proliferation Dye eFluor® 670 staining and the cell proliferation was measured at 4 days post culturing in GM-CSF-containing medium. (c) MEF cells were starved in serum-free medium for 12 hrs and the cell proliferation via Ki67 staining was measured at 1 hr after addition of complete medium. Data are presented as mean ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; compared with the WT control using one-way ANOVA.
Figure 20. (a) A20 mRNA level in BMDC and MEF.

(b) BMDC proliferation assay.

(c) Serum-Free medium vs. Complete Culture Medium.

(d) MEF.
3.1.8 Reconstitution of IL-17RA in RAKD clones restores parental proliferation, A20 expression and JNK activity

Given the opposing proliferation phenotypes in IL-17RAKD and IL-17RCKD B16 cells, I conducted reconstitution experiments to rule out the possibility of off-target effects. To this end, I transduced B16-RAKD3.1 and B16-pSMP cells with a viral vector expressing full-length of IL-17RA (pBMN-RA) in order to restore or over-express IL-17RA. The pBMN vector (pBMN-Ctrl) lacking a transgene sequence was used as a negative control. As anticipated, pBMN-RA, but not pBMN-Ctrl, restored IL-17RA expression in B16-RAKD3.1 cells to an extent that was comparable to B16-pSMP cells transduced with the pBMN-Ctrl vector (Figure 21a), suggesting a complete reconstitution of IL-17RA in B16-RAKD cells. The pBMN-RA transduction in B16-pSMP doubled the mRNA expression of IL-17RA; however, it was not able to further increase surface IL-17RA expression (Figure 21b), indicating a tight post-transcriptional regulation of IL-17RA under steady-state conditions. Importantly, IL-17RA reconstitution successfully attenuated hyper-proliferation of B16-RAKD clones and restored the proliferation profile back to the parental level (Figure 21c). Furthermore, IL-17RA reconstitution effectively eliminated IL-17RA-silencing-induced sensitivities to L-form JNK inhibitor and reduced the responsiveness to SP600125 JNK/c-Jun inhibitor in MTT proliferation assays (Figure 21d). Notably, IL-17RA reconstitution restored the basal mRNA expression and protein levels of A20 to the levels observed in pSMP control cells (Figure 21e/f). Associated with these observations, the aberrant activation of JNK/c-Jun was attenuated to the pSMP control level (Figure 21f). While these observations allow us to rule out a possible off-target effect of my technology, the complex phenotype of IL-17RAKD and IL-17RCKD suggests that JNK isoform expression is controlled via complex mechanisms.
Figure 21. Reconstitution of IL-17RA in RAKDs is able to restore the parental rate of proliferation and associated A20 expression and JNK/c-Jun activity.

IL-17RA was reconstituted into B16-RAKD and pSMP control cells with a viral vector expressing full-length of IL-17RA (pBMN-RA). (a, b) The IL-17RA and IL-17RC levels in different subclones of B16 cells were detected by qRT-PCR and flow cytometry. (c, d) The proliferation of different subclones and their responsiveness to JNK inhibitors was measured via MTT assay. The data was normalized to the MTT response of the respective seeding controls. The % of proliferation inhibition was calculated relative to the respective DMSO control. (e, f) A20 mRNA levels in different subclones were determined by qRT-PCR and western blot. (f) Whole-cell extracts were harvested and immunoblotted to detect phosphorylated or total proteins of A20, JNK, c-Jun and GAPDH. Values are means ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. Statistical analyses were compared using one-way ANOVA.
Figure 21.
Given that A20 is the key molecule required for controlling JNK activation in IL-17RC signaling (Figure 11d), I verified this in IL-17RA signaling. I transfected RAKD and pSMP control cells with the plasmid carrying full length A20 or the empty plasmid vector alone (Figure 22a/b). Notably, in both B16 and 4T1 models, A20 transfection in RAKD cells effectively restored A20 protein levels. In addition, the JNK/c-Jun activity at 48 and 72 hrs post-transfection were markedly reduced, as indicated by reduced phosphorylation of JNK and c-Jun. Along with the restored A20 expression, the cellular proliferation of RAKD cells was restrained to the normal level observed in the pSMP control. Together with the RCKD results, the A20 reconstitution experiments in RAKDs further demonstrate that the IL-17R-A20 axis is required for restraining homeostatic proliferation via inhibiting aberrant JNK/c-Jun activation.

3.2 Loss of IL-17RA expression in cancer cells promotes an immunosuppressive TME

3.2.1 IL-17RA silencing in B16 melanoma cells induces an immunosuppressive TME

Having demonstrated a role for IL-17R signaling in mediating cancer cell proliferation in vitro and in vivo, I next questioned how tumor cells may utilize IL-17R signaling in shaping the TME. Using the B16 melanoma model, I first isolated and examined the tumor-draining lymph nodes (DLNs), the primary site for inducing anti-tumor immune responses. To my surprise, IL-17RA silencing in B16 melanoma cells induced comparable immune induction in DLNs compared to the pSMP control despite increased tumor size (Figure 23a), suggesting an active immunosuppression may be associated with the IL-17RAKD tumors. Indeed, while the overall cell density did not differ among the groups, the density of tumor-infiltrating CD4+ Th cells, CD8+ Tc cells, and NK cells was markedly reduced in RAKD tumors, and to a lesser extent, in RCKD tumors compared to the controls (Figure 23b). Notably, the frequency of MHCII+CD19+ B cells in the DLNs, as well as their density in the TILs, were both decreased significantly in the RAKD, but not RCKD tumors, compared to the pSMP controls. Together, the general resemblance with minor differences in the immune profile, suggested that IL-17RA and IL-17RC signaling in tumor cells may utilize both common and differential mechanisms to restrain the suppressive TME.
Figure 22. Reconstitution of A20 in RAKD clones is able to restore the normal rate of proliferation and associated JNK/c-Jun activity.

(a/c) IL-17RAKD and pSMP control of B16 and 4T1 cells were transfected with plasmids containing A20 or a control vector for 48hrs and 72hrs. Whole-cell extracts were harvested and sequentially immunoblotted with the indicated antibodies to detect phosphorylated and total levels of A20, JNK, c-Jun and GAPDH proteins. (b/d) The proliferation rate of different subclones was measured by MTT assay 72 hrs after transfection. The data was normalized to the respective seeding control. Values are means ± SEM of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 23. IL-17RA silencing in B16 melanoma cells promotes an immunosuppressive TME

Mice were inoculated subcutaneously in the hind flank with 1 x 10^6 B16 melanoma cells. (a) DLNs and (b) tumors were collected 12 days post-innoculation. Total CD45^+ leukocytes and the frequency in DLNs or density in tumors of CD4^+ Th cells, CD8^+ Tc cells, CD19^+ B cells and NKp46^+ NK cells were obtained by flow cytometric analysis. Data are presented as the mean ± SEM. *p<0.05 versus pSMP control as determined by Kruskal-Wallis test with Dunn’s post-hoc analysis.
Figure 23.

(a) Draining lymph nodes (DLNs)

(b) Tumor infiltrating leukocytes (TILs)

- Total Cell Count in DLNs
- CD45^+CD3^+ T cells
- CD45^+CD3^+CD4^+ Th cells
- CD45^+CD3^+CD8^+ Tc cells
- CD45^+MHCI^+CD19^+ B cells
- CD45^+CD3^NKp46^+ NK cells
3.2.2 Loss of baseline IL-17RA expression in B16 melanoma cells induces pro-inflammatory cytokine production in vitro and in vivo

Given that cells with an attenuated IL-17R/A20 signaling are sensitive to IL-17A stimulation and exhibited elevated production of proinflammatory cytokines in vitro, including IL-6 and GM-CSF, but not CXCL1 (Figure 12), I questioned what other proinflammatory cytokines and chemokines are subject to this regulatory mechanism. To this end, I screened 84 inflammation-related genes along with 5 housekeeping genes, using the RT² Profiler™ PCR Array (QIAGEN). I first screened the gene expression profiles in vitro using B16-pSMP and B16-IL-17R KD cells following 16hrs treatment with 200 ng/ml IL-17A (Figure 24a). I found three genes, CXCR5, IL-6 and the angiogenesis factor thymidine phosphorylase (Tymp) (446), were highly up-regulated in both RAKD and RCKD compared to pSMP control, suggesting that these genes are restrained by IL-17R expression. Furthermore, the expression levels of CXCL1, CCL25 and CCBP2 (or ACKR2, atypical chemokine receptor 2) were reduced in both RAKD and RCKD clones, indicating these genes may be induced by the IL-17 signal to favor inflammatory responses. Together, these two clusters of gene alteration may result from the IL-17/IL-17R induced signal and the IL-17R/A20-repressed signal. To validate whether the IL-17R/A20 controlling mechanism may also apply for in vivo settings, I performed a micro-array on bulk tumor samples collected at day 12 post-innoculation with B16-RAKD and B16-RCKD clones (Figure 24a/b). Several ligands and receptors were upregulated or downregulated > 2-fold in the IL-17R KD samples compared to the pSMP controls. To validate the microarray data and examine the dynamics of gene expression profiles of the in vivo tumor samples, I further collected tumor samples at day 8, 12, 19 post-innoculation and performed qRT-PCR using the pre-validated primers (Bio-Rad) targeting 16 different genes. As shown in Fig. 24a/b, consistent with the observation of in vitro samples, proinflammatory cytokines IL-6, as well as IL-1β, were highly upregulated within the in vivo IL-17RAKD tumors, and to a lesser extent, the IL-17RCKD tumors compared to the pSMP controls. In addition, Tymp exhibited significant upregulation in both IL-17RA and IL-17RC KD tumors, confirming the impact of IL-17R-downregulation in the production of pro-inflammatory cytokines and pro-tumor molecules. In addition to the genes which exhibited similar alteration pattern in vitro and in vivo, I found serval gene profiles were altered only in in
vivo tumors, highlighting the role of TME in shaping the functional role of the IL-17/IL-17R/A20 axis in tumor development. For instance, the anti-tumor cytokine of the type 1 response, IFNγ, was severely downregulated only in early cancer development at day 8 post-inoculation of both IL-17R KD tumors (Figure 24a/b). Furthermore, there was a 3-fold increase of Mill1, CXCL14 and CXCL10 in the IL-17RAKD tumors, but not IL-17RCKD tumors, suggesting the differential impact of IL-17RA and IL-17RC signaling in regulating the TME.

Given the inflammatory and immunosuppressive TME observed in the IL-17R KD tumors, especially in the IL-17RAKD tumors, I further examined the immune profile in the DLNs (Figure 24c). Surprisingly, there was a 2- to 3-fold increase of IFNγ-producing APCs and CD8+ Tc cells in the IL-17RAKD DLNs compared to the pSMP controls, which suggests that the IL-17RKD-induced immune dysfuntion is restricted within the TME. Of note, no alteration of type 2 (e.g., IL-4) and type 17 (e.g., IL-17) immune responses was detected.
Figure 24. Loss of baseline IL-17RA in B16 melanoma cells selectively induces pro-inflammatory cytokine production *in vitro* and *in vivo*.

(a) Total RNA was extracted from either approximately $3 \times 10^6$ B16 cells treated with 200 ng/ml IL-17A stimulation for 16 hrs, or *in vivo* B16 tumors that were isolated from mice at day 8, 12 and 19 post-inoculation. RNA was reverse-transcribed into cDNA. Target genes amplified by a QIAGEN RT² Profiler™ PCR array of mouse chemokines & receptors. Gene expression levels were confirmed by qPCR using pre-validated primers (Bio-Rad). All the gene expression results were normalized to the level of the housekeeping gene GAPDH. The relative level of gene expression compared to the control group is shown.

(b) List of chemokine and chemokine receptor genes differentially regulated by IL-17RA and IL-17RC signals.

(c) Intracellular cytokine staining for IFNγ was performed on lymphocytes isolated from DLNs on day 8, 12 and 19 post-inoculation with tumor cells. *p < 0.05; **p < 0.01; ***p < 0.001. Statistical analyses were compared using Kruskal-Wallis test.
<table>
<thead>
<tr>
<th>Array ID</th>
<th>Gene name</th>
<th>In vitro</th>
<th>In vivo</th>
<th>Biological function</th>
</tr>
</thead>
<tbody>
<tr>
<td>F02</td>
<td>Darc</td>
<td>3.83</td>
<td>0.49</td>
<td>Non-specific receptor for many chemokines such as IL-8, GRO, RANTES, MCP-1 and TARC.</td>
</tr>
<tr>
<td>A11</td>
<td>Ccl24</td>
<td>0.22</td>
<td>0.89</td>
<td>Chemotactic for resting T-lymphocytes, and eosinophils. Lower for neutrophils. Binds to CCR3.</td>
</tr>
<tr>
<td>D07</td>
<td>Cxcl11</td>
<td>0.52</td>
<td>0.25</td>
<td>Chemotactic for neutrophils. Pro-inflammation and exerts its effects on endothelial cells in an autocrine fashion.</td>
</tr>
<tr>
<td>B01</td>
<td>Ccl26</td>
<td>9.3</td>
<td>0.09</td>
<td>Chemotactic for eosinophils and basophils. Binds to CCR3.</td>
</tr>
<tr>
<td>A01</td>
<td>C5ar1</td>
<td>0.92</td>
<td>0.89</td>
<td>3.34 Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a.</td>
</tr>
<tr>
<td>G10</td>
<td>Tymp</td>
<td>1.21</td>
<td>1.18</td>
<td>0.13 0.22 Thymidine Phosphorylase, this gene encodes an angiogenic factor.</td>
</tr>
<tr>
<td>A05</td>
<td>Ccl12</td>
<td>0.57</td>
<td>0.48</td>
<td>Specifically attracts eosinophils, monocytes and lymphocytes.</td>
</tr>
<tr>
<td>D08</td>
<td>Cxcl10</td>
<td>0.59</td>
<td>0.11</td>
<td>Chemotactic for monocytes and T-lymphocytes. Binds to CXCR3.</td>
</tr>
<tr>
<td>D12</td>
<td>Cxcl14</td>
<td>0.82</td>
<td>0.94</td>
<td>2.59 1.12 Potent chemoattractant for neutrophils, and weaker for dendritic cells.</td>
</tr>
<tr>
<td>F08</td>
<td>IL-1b</td>
<td>1.58</td>
<td>1.08</td>
<td>2.35 1.63 Pro-inflammation, thymocyte proliferation, B-cell maturation and proliferation, and fibroblast growth factor activity.</td>
</tr>
<tr>
<td>F07</td>
<td>IL-6</td>
<td>1.67</td>
<td>1.61</td>
<td>2.57 1.4 Pro-inflammation, B-cell maturation and proliferation.</td>
</tr>
<tr>
<td>N/A</td>
<td>IL-27</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A N/A Promotes Th1 cell commitment and IFNγ production. Inhibits Th2 and Th17 differentiation.</td>
</tr>
<tr>
<td>N/A</td>
<td>IFNγ</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A N/A Potent activator of macrophages and NK cells with antiviral and antitumor effects.</td>
</tr>
<tr>
<td>N/A</td>
<td>Mill1</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A N/A MHC class I-like glycoprotein encoded outside the MHC, associated with β2-microglobulin.</td>
</tr>
<tr>
<td>N/A</td>
<td>Itgax</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A N/A Also known as Integrin, αX (complement component 3 receptor 4 subunit), or CD11c</td>
</tr>
<tr>
<td>H3</td>
<td>GAPDH</td>
<td>1</td>
<td>1</td>
<td>1 1 Has glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities in glycolysis and nuclear functions</td>
</tr>
</tbody>
</table>

Figure 24, Continued.
3.2.3 The inflamed TME of B16-RAKD tumors converts host-derived CD45+ cells into MHCII+PD-L1+ immunosuppressive cells

Given the broad reduction of different effector cell subsets, I hypothesized that the immunosuppression may be triggered in IL-17RAKD tumors by coinhibitory signals on the APCs within the TME. To this end, I further gated the TILs by their expression levels of CD45 and MHCII (Figure 25a). As expected, the CD45+ immune cells exhibited small cell size on the FSC, while the CD45- populations that consist of structural cells and tumor cells have relatively larger sizes and higher cellular complexities as indicated by SSC. Surprisingly, there was no significant difference in the frequency of CD45+MHCII+ APCs among groups. However, the B16-RAKD tumors exhibited a significantly increased frequency of CD45-MHCII+ cells in the TME. I further examined the origin of these CD45-MHCII+ cells by innoculating the B16-RAKD cells into wild-type and GFP-knockin mice. Notably, the enriched CD45-MHCII+ cells were also GFP+ (Figure 25b), suggesting that these cells were host-derived cells rather than tumor cells. Subsequently, I further screened the co-stimulatory/inhibitory signals on the CD45-MHCII+ cells, including CD80, CD86, CD40, PD-L1, PD-L2 and Icos-L. Remarkably, CD45-MHCII+ cells in the TME of B16-RAKD tumors, but not B16-RCKD or the B16-pSMP tumors, markedly increased co-inhibitory PD-L1 expression (Figure 25c), which is consistent with an immunosuppressive profile. All other co-stimulatory/inhibitory signals were not altered in B16-RAKD tumors compared to the controls.
Figure 25. B16-RAKD tumors are enriched with host-derived CD45^+MHCII^+PD-L1^+ cells

Mice were inoculated subcutaneously in the hind flank with B16 melanoma cells. Tumor-derived cells were collected 12 days after tumor cell inoculation. (a) The gating strategy and frequencies of CD45^-/MHCII^- cells were shown. (b) B16-RAKD cells (1 x 10^6) were inoculated subcutaneously into the wild-type and GFP-knockin C57BL/6 mice. On day 12 TILs were harvested and analyzed by flow cytometry. Live CD45^- cells were gated via the Fixable Viability Dye eFluor™ 506 (eFluor506^-) to identify whether CD45^+MHCII^+ cells were derived from the tumor cells or the host recipient and (c) the expression of PD-L1 was examined.
3.2.4 B16-RAKD tumors are enriched with PD-L1/PD-L2+ M2 macrophages

Given that there was no alteration in the frequency of CD45+MHCII+ cells in IL-17R KD tumors compared to the pSMP controls (Figure 25a), I further assessed the different APC subpopulations, including CD11c+ DCs, F4/80+ macrophages, and CD19+ B cells. As shown in Figure 26, all three APC subpopulations exhibited comparable frequencies among different groups, suggesting that the quantity of APCs is dispensable for the immunosuppression observed in the IL-17R KD tumors. Nevertheless, CD45+MHCII+ APCs in the B16-RAKD tumors, but not B16-RCKD tumors, had markedly increased the expression of PD-L1 and PD-L2. The tumor-infiltrated APCs showed comparable expression levels of both CD80 and CD86 in B16-RAKD and B16-RCKD tumors, while no detectable expression of Icos-L and CD40 was observed. Further sub-population analyses on the APCs suggested that the elevated PD-L1/L2 expression was due to enriched M2 polarization, but not DCs or B cells. Consistent with the severe immunosuppression in the B16-RAKD, and to a lesser extent in B16-RCKD tumors, the PD-L1/PD-L2 expression levels on tumor-infiltrating macrophages were B16-RAKD > B16-RCKD > B16-pSMP. Taken together, these data suggested that the loss of IL-17RA and IL-17RC in tumor cells triggers an immunosuppressive TME phenotype through both common (pro-inflammatory cytokine production and the quality of tumor-infiltrating macrophages), as well as distinct mechanisms (CD45+MHCII+PD-L1+ host-derived cells uniquely enriched in B16-RAKD tumors).
Figure 26. Enriched PD-L1/L2^+ M2 polarization in the TME of B16-RAKD tumors. Mice were inoculated subcutaneously in the hind flank with 1 x 10^6 B16 melanoma cells. TILs were collected 12 days after tumor cell inoculation. Live CD45^+MHCII^+ APCs were gated via the Fixable Viability Dye eFluor™ 506 (eFluor506®). The gating strategy and frequencies of CD19^+ B cells, F4/80^+ macrophages and CD11c^+ DCs are shown. The expression of CD80, CD86, CD40, PD-L1, PD-L2 and Icos-L was analyzed by flow cytometry.
Figure 26. Gate on R2: CD45^+ MHCII^+ TILs

**B16-pSMP**
- CD19: 82.28%
- RAKD3.1: 81.28%
- RCKD4.5: 78.68%

**F4/80^+**
- CD19: 93.00%
- RAKD3.1: 96.25%
- RCKD4.5: 91.11%

**Isotype**
- pSMP
- RAKD
- RCKD

**Gate on CD45^+ MHCII^+**

**PD-L1**
- B16-pSMP
- F4/80

**CD80**
- Isotype
- pSMP
- RAKD
- RCKD

**CD40**
- Isotype
- pSMP
- RAKD
- RCKD

**PD-L2**
- Isotype
- pSMP
- RAKD
- RCKD

**ICOSL**
- Isotype
- pSMP
- RAKD
- RCKD
3.2.5 Loss of baseline IL-17RA expression in 4T1 breast carcinoma cells promotes Gr1^CD11b^ cells and immunosuppression in blood cells

To validate the immunosuppressive phenotype of IL-17RAKD tumors deserved in the B16 melanoma model, I inoculated 4T1 subclones into BALB/c mice and blood samples were collected from mice at different time points post-inoculation. Peripheral leukocytes were analyzed by flow cytometry. I found that CD11b^Gr1^ myeloid cells accounted for approximately 14% of peripheral leukocytes in naïve mice. Upon 4T1 cell inoculation, CD11b^Gr1^ cells progressively increased to 50-60% by day 6 and remained at this level at day 18 (Figure 27). Notably, IL-17RA KD 4T1 cells significantly increased the frequency of CD11b^Gr1^ myeloid cells in the blood to 80% at day 18 post-inoculation. Conversely, the frequency of circulating lymphocytes (T cells, B cells, and NK cells) was markedly reduced compared to the pSMP control group. Since myeloid cells are a heterogeneous population of granulocytic and monocytic cells, I further analyzed subpopulations in my model. I found that the main subpopulation induced by 4T1 tumors were granulocytic cells (CD11b^Ly6C^{low}Ly6G^+), but not monocytic cells (CD11b^Ly6C^{+}Ly6G^{-/low}), which increased in frequency and absolute cell number. Given that both IL-17RAKD and IL-17RCKD tumors exhibited increased tumor growth in the 4T1 model, I expected a similar immunosuppressive phenotype within 4T1-RCKD tumors. However, in sharp contrast, the IL-17RC KD in 4T1 cells significantly reduced the frequency of CD11b^Gr1^ cells in blood as early as six days following tumor injection, suggesting that the IL-17RC signal may mediate immunosuppression through distinct mechanism(s). To confirm the causal link between the increased CD11b^Gr1^ cells and the decreased effector cells (e.g., T cells), a suppression assay using co-cultured cell populations is needed. Furthermore, although the IL-17A-induced immunosuppressive TME of 4T1 tumors has been reported in previous work in our lab using adenovirus to overexpress IL-17A (187), further studies will be required to validate and explore the IL-17RA versus IL-17RC signals in shaping the immunosuppression in 4T1 tumors.
Figure 27. IL-17RAKD 4T1 cells preferentially induce the expansion of granulocytic myeloid cells in peripheral blood.

Mice were inoculated subcutaneously in the fourth mammary fat pad of female BALB/c mice with 1 x 10^6 4T1 mammary carcinoma cells. Frequency and cell density of granulocytic and monocytic subpopulations in CD45^+ peripheral blood leukocytes are shown. All values are means ± SEM of n = 10 mice per group per at each time point. Statistical analyses were compared with the pSMP control using Kruskal-Wallis test; *p < 0.05; **p < 0.01; ***p < 0.001.
3.3 Prognostic value of IL-17RA and A20 in cancer patients

Given the role of baseline IL-17R expression in maintaining A20 homeostasis in murine cells, I questioned whether my finding could be verified in human cancers. If yes, which cancer types are likely to adopt a regulatory mechanism that is controlled by the IL-17R/A20 axis, and can the IL-17RA/A20 axis be used as a prognostic and/or predictive marker for human cancers. To this end, I performed gene copy number and expression analyses on datasets from clinical studies and human cell lines, together with human tissue arrays, to establish a comprehensive picture of the relationship between IL-17/IL-17R and A20 expression in various human neoplasms.

3.3.1 IL-17RA is co-expressed with A20 and bi-directionally altered in a subset of human cancers

Given that IL-17RA and IL-17RC have differential tissue distribution (321), I first determined whether the somatic copy number levels of IL-17RA and IL-17RC are altered in human cancers. To this end, I queried publicly available TCGA datasets in cBioportal and conducted cross-cancer genome-wide analysis of somatic copy number alterations (CNA) for IL-17RA and IL-17RC. I found bi-directional CNA of IL-17RA and IL-17RC in 22 and 24 out of 32 human cancer types, respectively (Figure 28a). Besides amplification or gain of copies, many cancer types also showed deletions of IL-17RA and/or IL-17RC. Among all examined cancer types, IL-17RA exhibited higher frequencies of deletion compared to IL-17RC, especially in chronic inflammation associated cancers of the mucosal system, including esophageal cancer, lung cancer, stomach (gastric) cancer, CRC, cervical cancer, breast cancer and melanoma, suggesting a role for IL-17RA in cancer biology and a molecule with strong prognosis. Notably, while most cancer types are associated with both gain and deletion of IL-17RA and IL-17RC, a cohort of CRC patients (n = 633) showed a predominant IL-17RA and IL-17RC deletion profile. I sub-grouped these patients based on their IL-17R and A20 CNA profiles. While the majority of the CRC patients carried a normal diploid profile, patients with co-deletion of IL-17RA/A20 (n = 43), or IL-17RC/A20 (n = 21), were identified in this CRC-TCGA dataset (Figure 28b).
Figure 28. Somatic copy numbers of IL-17RA and IL-17RC are bi-directionally altered in a fraction of human cancers in a cancer-type-specific manner.

(a) Cross-cancer analyses of IL-17RA/RC copy number alteration (CNA) frequency in 32 TCGA studies from cBioportal. Blue indicates deep loss of gene copy number, possibly a homozygous deletion. Red indicates a high-level amplification of gene copy number. (b) CNA of A20 grouped by CNA of IL-17RA or IL-17RC in CRC-TCGA dataset from cBioportal. N = 633. Each dot represents 10 patients. ACC, adrenocortical carcinoma; AML, acute myeloid leukemia; GBM, glioblastoma multiforme; PCPG, pheochromocytoma and paraganglioma; ccRCC, clear cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; pRCC, papillary renal cell carcinoma; Lung squ, lung squamous cell carcinoma; DLBC, diffuse large b-cell lymphoma; Uterine CS, uterine carcinosarcoma.
I downloaded and analyzed the mRNA gene expression data for IL-17RA and A20 from two additional searchable human cancer databases, Oncomine (Table 8) and GEO-NCBI (Table 9). A total of 59 datasets covering 20 types of cancer and normal tissues were identified based on my selection criteria (see Materials and Methods section). The two databases are highly complementary with only 5 overlapping datasets. In agreement with what I have in cBioportal datasets, IL-17RA mRNA expression also displayed bi-directional alterations in different cancer types (Table 8, 9). For example, melanoma samples exhibited a very broad range of IL-17RA expression (APPENDIX B) and no change observed in samples compared to normal counterparts (Table 8, 9). Breast and lung cancers were found to have decreased expression in some datasets, but significantly increased expression or no change in other datasets. Nevertheless, while IL-17RA expression is highly upregulated in pancreatic cancer to favor the IL-17R-dependent inflammatory responses, the downregulation of IL-17RA expression is consistently and significantly observed in all CRC datasets in both database systems (Table 8, 9).

Based on my novel finding that IL-17R expression is critically required for maintaining A20 homeostasis in cancer cells, I further examined the correlation of IL-17RA and A20 in different human cancers. Indeed, the mRNAs of IL-17RA and A20 were consistently co-expressed in many clinical samples, especially colorectal, gastric, lung and pancreatic cancers (Table 8, 9). Nevertheless, in some other cancer types, such as breast, adrenal, liver, thyroid, vulva cancers and melanoma, no significant co-expression pattern was consistently observed (Table 8, 9). Furthermore, IL-17RA and A20 are negatively correlated in prostate and head-neck cancers, suggesting the co-expression of IL-17RA and A20 is a tumour-specific phenomenon, which might be influenced by the IL-17R/A20 axis within the specific TME. Overall, the level of A20 was significantly correlated with IL-17RA expression in 17 out of 33 GEO-NCBI datasets (51.5%) and 11 out of 15 cancer types in Oncomine analyses (73.3%), which strongly supports my finding that IL-17R is critical in maintaining the homeostatic level of A20 in many human cancer types.

3.3.2 IL-17RA is significantly co-expressed with A20 and reduced in human CRC samples

Consistent with genome-wide CNA analysis presented above, CRC samples were repeatedly found to have significant co-expression between A20 and IL-17RA from
various datasets (Table 8, 9 and Figure 29), demonstrating that the IL-17R/A20 axis may play an important role in human CRC development.

The GEO-NCBI dataset GDS2947 contains 32 colorectal adenomas and 32 paired normal colorectal tissues, an ideal dataset for examining how the IL-17R and A20 may change during CRC development in an unbiased manner. Importantly, the overall levels of both IL-17RA and A20 were significantly reduced in CRC samples compared to their normal counterparts (Figure 29a), supporting a notion that the specific CRC tumor microenvironment reduces IL-17RA expression leading to attenuated baseline A20 production. Nevertheless, 7 and 4 out of 32 paired samples exhibited an increase in the IL-17RA and A20 levels in CRC, respectively, suggesting tumor-specific regulation of the IL-17RA/A20 axis. The Oncomine analysis which compiled all 5 available CRC studies exhibited a reduced overall IL-17RA level of CRC samples compared to normal colorectal tissues (Figure 29b), as well as a significant co-expression of IL-17RA and A20 (Pearson R=0.4803, P<0.0001; Spearman R=0.4878, P<0.0001). Importantly, the significant co-expression of IL-17RA and A20 was in agreement with the CRC-TCGA dataset from cBioportal (Pearson R= 0.3655, p< 0.0001; Spearman R= 0.3398, p= 0.0001) (Figure 29c). Together, CRC samples from all three databases consistently showed a clear co-reduction of IL-17RA and A20, highlighting a potential role of the IL-17RA/A20 axis in CRC development. Subsequently, I examined whether other pro-inflammatory signals, such as IL-1R1, TNFR1, MyD88 and TLR4 may also associate with the basal level of A20. My analyses indicated that IL-1R1, TNFR1 and MyD88 mRNA expression levels were significantly but relatively weakly correlated with A20 expression, whereas TLR4 appeared to be inversely correlated. Thus, my data strongly suggests that baseline IL-17RA level has a predominant role in maintaining basal A20 level in human CRC.
Figure 29. IL-17RA is significantly co-expressed with A20 and reduced in CRC patients.

(a) Relative mRNA expression of IL-17RA and A20 in normal and cancer tissues was quantified using the GEO-NCBI (GDS2947) database. (b) IL-17RA and A20 expression levels in a total of five CRC studies are quantified from Oncomine datasets and their co-expression was determined by Pearson and Spearman correlation analysis. (c) IL-17RA expression from the CRC-TCGA dataset were correlated with respective A20 expression levels. (d) Correlations of A20 with IL-17RA, IL-1R1, TNFR1, MyD88 and TLR4 mRNAs that are quantitated using the GEO-NCBI (GDS2947) dataset. Statistical analyses on relative expressions were compared with the respective normal tissue using an unpaired student t test for panel b, and paired student t test for panel a. *p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 29.

(a) IL-17RA in Colorectal Tissue (GDS2947) A20 in Colorectal Tissue (GDS2947)

(b) IL-17RA in Colorectal Tissue (Oncomine) Correlation in Colorectal Tissue (Oncomine)

(c) Correlation in CRC-TCGA

(d) IL-17RA & A20 correlation (GDS2947) IL-1R1 & A20 correlation (GDS2947) TNFR1 & A20 correlation (GDS2947) MyD88 & A20 correlation (GDS2947) TLR4 & A20 correlation (GDS2947)

Pearson R: 0.4674, P < 0.0001
Spearman R: 0.4500, P < 0.0001

Pearson R: 0.2902, P < 0.0001
Spearman R: 0.2799, P < 0.0001

Pearson R: 0.5603, P < 0.0001
Spearman R: 0.3473, P < 0.0001

Pearson R: 0.2746, P < 0.0001
Spearman R: 0.2941, P < 0.0001

Pearson R: 0.3750, P < 0.0001
Spearman R: 0.4320, P < 0.0001
Table 8. Gene expression of Oncomine datasets used in this study

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Dataset Count</th>
<th>Sample Count</th>
<th>P &amp; R Values of IL-17RA &amp; A20 Correlation</th>
<th>IL-17RA Expression in Cancer</th>
<th>Dataset Source</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>30</td>
<td>4505</td>
<td>&lt;0.0001, 0.3479 &lt;0.0001, 0.3241</td>
<td>0.0001, **, ↓</td>
<td>Oncomine</td>
<td></td>
</tr>
<tr>
<td>Adrenal cancer</td>
<td>1</td>
<td>65</td>
<td>0.7956, 0.0328</td>
<td>0.3140</td>
<td>Oncomine (447)</td>
<td></td>
</tr>
<tr>
<td>Brain cancer</td>
<td>2</td>
<td>281</td>
<td>&lt;0.0001, 0.2681 &lt;0.0001, 0.3160</td>
<td>0.0099, **, ↑</td>
<td>Oncomine (448, 449)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>3</td>
<td>99</td>
<td>0.2719, 0.1115</td>
<td>0.3397, -0.0970</td>
<td>Oncomine (450-452)</td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>5</td>
<td>396</td>
<td>&lt;0.0001, 0.4803 &lt;0.0001, 0.4878</td>
<td>&lt;0.0001, **, ↓</td>
<td>Oncomine (424, 453-455)</td>
<td></td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>2</td>
<td>96</td>
<td>&lt;0.0001, 0.4507</td>
<td>&lt;0.0001, 0.4876</td>
<td>Oncomine (456, 457)</td>
<td></td>
</tr>
<tr>
<td>Head-Neck cancer</td>
<td>2</td>
<td>79</td>
<td>&lt;0.0001, -0.4389 &lt;0.0001, -0.4334</td>
<td>0.6149</td>
<td>Oncomine (458, 459)</td>
<td></td>
</tr>
<tr>
<td>Liver cancer</td>
<td>1</td>
<td>75</td>
<td>0.8157, -0.0274</td>
<td>0.8709, 0.0191</td>
<td>Oncomine (460)</td>
<td></td>
</tr>
<tr>
<td>Lung cancer</td>
<td>3</td>
<td>452</td>
<td>&lt;0.0001, 0.8443</td>
<td>&lt;0.0001, 0.7530</td>
<td>Oncomine (461-463)</td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>1</td>
<td>86</td>
<td>0.0475, 0.2144</td>
<td>0.0607, 0.2031</td>
<td>Oncomine (464)</td>
<td></td>
</tr>
<tr>
<td>Multi-cancer</td>
<td>1</td>
<td>84</td>
<td>0.0516, 0.2131</td>
<td>0.0228, 0.2482</td>
<td>Oncomine (465)</td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>2</td>
<td>130</td>
<td>&lt;0.0001, 0.6079 &lt;0.0001, 0.5390</td>
<td>&lt;0.0001, **, ↑</td>
<td>Oncomine (466, 467)</td>
<td></td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>2</td>
<td>40</td>
<td>0.0106, 0.3999</td>
<td>0.0083, 0.4114</td>
<td>Oncomine (468, 469)</td>
<td></td>
</tr>
<tr>
<td>Renal cancer</td>
<td>1</td>
<td>67</td>
<td>0.0053, 0.3369</td>
<td>0.0573, 0.2334</td>
<td>Oncomine (470)</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>2</td>
<td>36</td>
<td>0.4105, 0.1415</td>
<td>0.2867, 0.1825</td>
<td>Oncomine (471, 472)</td>
<td></td>
</tr>
<tr>
<td>Uterus cancer</td>
<td>1</td>
<td>77</td>
<td>0.0077, 0.3015</td>
<td>0.0065, 0.3079</td>
<td>Oncomine (473)</td>
<td></td>
</tr>
<tr>
<td>Vulva cancer</td>
<td>1</td>
<td>19</td>
<td>0.0795, 0.4122</td>
<td>0.0726, 0.4211</td>
<td>Oncomine (474)</td>
<td></td>
</tr>
</tbody>
</table>

Note: N/A, not applicable. ↑, up-regulation. ↓, down-regulation.
### Table 9. Gene expression of GEO-NCBI datasets used in this study

<table>
<thead>
<tr>
<th>Dataset ID</th>
<th>Sample Type</th>
<th>Sample Count</th>
<th>Sample Case</th>
<th>Sample Nationality</th>
<th>P value of IL-17RA</th>
<th>Pearson P value of A20 Correlation</th>
</tr>
</thead>
<tbody>
<tr>
<td>GDS4456</td>
<td>Bladder cancer</td>
<td>93</td>
<td>New York, USA</td>
<td>N/A</td>
<td>0.3166</td>
<td>0.0148, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0121, *</td>
<td>0.623</td>
</tr>
<tr>
<td>GDS3096</td>
<td>Breast cancer</td>
<td>47</td>
<td>Maryland, USA</td>
<td>N/A</td>
<td>0.1497</td>
<td>0.0728</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.9299</td>
<td>0.993</td>
</tr>
<tr>
<td>GDS2550</td>
<td>Breast cancer</td>
<td>47</td>
<td>Boston, USA</td>
<td>0.0336, †</td>
<td>0.5278</td>
<td>0.0298, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0657</td>
<td>0.0159, *</td>
</tr>
<tr>
<td>GDS3139</td>
<td>Breast cancer</td>
<td>29</td>
<td>Boston, USA</td>
<td>0.0094, †</td>
<td>0.7707</td>
<td>0.0331, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.4868</td>
<td>0.7604</td>
</tr>
<tr>
<td>GDS3716</td>
<td>Breast cancer</td>
<td>42</td>
<td>Boston, USA</td>
<td>N/A</td>
<td>0.6849</td>
<td>0.264</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.6541</td>
<td>0.0662</td>
</tr>
<tr>
<td>GDS4761</td>
<td>Breast cancer</td>
<td>91</td>
<td>Sweden</td>
<td>N/A</td>
<td>0.0051, **</td>
<td>&lt;0.0001, ***</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001, ***</td>
<td>N/A</td>
</tr>
<tr>
<td>GDS2416</td>
<td>Cervical cancer</td>
<td>33</td>
<td>Toronto, Canada</td>
<td>N/A</td>
<td>0.2545</td>
<td>0.5447</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0002, ***</td>
<td>0.1797</td>
</tr>
<tr>
<td>GDS3233</td>
<td>Cervical cancer</td>
<td>61</td>
<td>New York, USA</td>
<td>0.1872</td>
<td>0.1084</td>
<td>0.0002, ***</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.8936</td>
<td>0.4854</td>
</tr>
<tr>
<td>GDS3292</td>
<td>Cervical cancer</td>
<td>38</td>
<td>New York, USA</td>
<td>0.8600</td>
<td>0.8777</td>
<td>0.7782</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.8011</td>
<td>0.4694</td>
</tr>
<tr>
<td>GDS4664</td>
<td>Cervical cancer</td>
<td>39</td>
<td>Groningen/Netherlands</td>
<td>N/A</td>
<td>0.0417, *</td>
<td>0.0139, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.7632</td>
<td>0.1089</td>
</tr>
<tr>
<td>GDS2947</td>
<td>Colorectal cancer</td>
<td>64</td>
<td>Viterbo, Italy</td>
<td>&lt;0.0001, †, #</td>
<td>0.0378, *</td>
<td>0.0281, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reverse, 0.0022, **</td>
<td>0.0038, **</td>
</tr>
<tr>
<td>GDS4379</td>
<td>Colorectal cancer</td>
<td>62</td>
<td>N/A</td>
<td>N/A</td>
<td>0.4354</td>
<td>0.6497</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0221, *</td>
<td>0.0078, **</td>
</tr>
<tr>
<td>GDS4381</td>
<td>Colorectal cancer</td>
<td>64</td>
<td>Durham, USA</td>
<td>N/A</td>
<td>&lt;0.0001, ***</td>
<td>0.1124</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1073</td>
<td>&lt;0.0001, ***</td>
</tr>
<tr>
<td>GDS4382</td>
<td>Colorectal cancer</td>
<td>34</td>
<td>Tokyo, Japan</td>
<td>0.0119, †, #</td>
<td>0.3806</td>
<td>0.679</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1133</td>
<td>0.9014</td>
</tr>
<tr>
<td>GDS4515</td>
<td>Colorectal cancer</td>
<td>49</td>
<td>Finland</td>
<td>0.0035, †</td>
<td>0.5376</td>
<td>0.9922</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0518</td>
<td>0.5833</td>
</tr>
<tr>
<td>GDS4516</td>
<td>Colorectal cancer</td>
<td>104</td>
<td>Tokyo, Japan</td>
<td>N/A</td>
<td>0.1745</td>
<td>0.4946</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.5437</td>
<td>0.0221, *</td>
</tr>
<tr>
<td>GDS4718</td>
<td>Colorectal cancer</td>
<td>44</td>
<td>Tokyo, Japan</td>
<td>N/A</td>
<td>0.0448, *</td>
<td>0.8147</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.467</td>
<td>0.2672</td>
</tr>
<tr>
<td>GDS4513</td>
<td>Colon cancer</td>
<td>53</td>
<td>Berlin, Germany</td>
<td>N/A</td>
<td>0.0015, **</td>
<td>0.0111, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.8304</td>
<td>0.0008, ***</td>
</tr>
<tr>
<td>GDS4589</td>
<td>Endometrial cancer</td>
<td>103</td>
<td>Durham, USA</td>
<td>0.0087, †</td>
<td>0.5648</td>
<td>0.0005, ***</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.5679</td>
<td>0.0002, ***</td>
</tr>
<tr>
<td>GDS4198</td>
<td>Gastric cancer</td>
<td>70</td>
<td>Australia</td>
<td>N/A</td>
<td>0.052</td>
<td>0.0344, *</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0248, *</td>
<td>0.0789</td>
</tr>
<tr>
<td>GDS2771</td>
<td>Lung cancer</td>
<td>192</td>
<td>USA/Germany/Ireland</td>
<td>0.0072, †</td>
<td>&lt;0.0001, ***</td>
<td>&lt;0.0001, ***</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.1428</td>
<td>0.9848</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dataset ID</th>
<th>Sample Type</th>
<th>Sample Count</th>
<th>Sample Case</th>
<th>P value of IL-17RA in Cancer</th>
<th>Pearson P value of A20 Correlation</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>GDS3837</td>
<td>Lung cancer</td>
<td>120</td>
<td>Taiwan</td>
<td>0.0032, ↓, #</td>
<td>0.057</td>
<td>&lt;0.0001, ***</td>
</tr>
<tr>
<td>GDS4794</td>
<td>Lung cancer</td>
<td>65</td>
<td>Japan</td>
<td>0.0046, ↓, #</td>
<td>0.0715</td>
<td>&lt;0.0001, ***</td>
</tr>
<tr>
<td>GDS3966</td>
<td>Melanoma</td>
<td>83</td>
<td>Massachusetts, USA</td>
<td>N/A</td>
<td>0.7739</td>
<td>0.0004, ***</td>
</tr>
<tr>
<td>GDS4281</td>
<td>Melanoma</td>
<td>29</td>
<td>Genoa, Italy</td>
<td>N/A</td>
<td>0.6841</td>
<td>0.0317, *</td>
</tr>
<tr>
<td>GDS3341</td>
<td>Nasopharyngeal cancer</td>
<td>41</td>
<td>Taiwan</td>
<td>0.0388, ↑ Reverse, 0.0028, **</td>
<td>0.7148</td>
<td>0.6853</td>
</tr>
<tr>
<td>GDS3592</td>
<td>Ovarian cancer</td>
<td>24</td>
<td>Atlanta, USA</td>
<td>0.0010, ↑</td>
<td>0.1025</td>
<td>0.0183, *</td>
</tr>
<tr>
<td>GDS4102</td>
<td>Pancreatic cancer</td>
<td>52</td>
<td>Rochester, USA</td>
<td>0.7217</td>
<td>0.0617</td>
<td>0.0001, ***</td>
</tr>
<tr>
<td>GDS4103</td>
<td>Pancreatic cancer</td>
<td>78</td>
<td>Romania/Germany</td>
<td>0.0453, ↑</td>
<td>&lt;0.0001, ***</td>
<td>&lt;0.0001, ***</td>
</tr>
<tr>
<td>GDS4329</td>
<td>Pancreatic cancer</td>
<td>24</td>
<td>Belgium</td>
<td>0.1868, #</td>
<td>N/A</td>
<td>0.0029, **</td>
</tr>
<tr>
<td>GDS4109</td>
<td>Prostate cancer</td>
<td>79</td>
<td>New York, USA</td>
<td>N/A</td>
<td>0.4338</td>
<td>0.1517</td>
</tr>
<tr>
<td>GDS4824</td>
<td>Prostate cancer</td>
<td>21</td>
<td>Boston, USA</td>
<td>0.0105, ↓</td>
<td>0.3425</td>
<td>0.7269</td>
</tr>
<tr>
<td>GDS1096</td>
<td>Normal tissues</td>
<td>36</td>
<td>Japan</td>
<td>N/A</td>
<td>0.0005, ***</td>
<td>0.0035, **</td>
</tr>
</tbody>
</table>

**Note:** N/A, not applicable. ↑, up-regulation. ↓, down-regulation. #, statistical analyses were compared with the respective normal tissue using paired t test.
3.3.3 IL-17RA protein is significantly reduced in high grade CRC tumors, correlating with a poor clinical outcome

To identify the clinical impact of alterations in the IL-17RA-A20 axis in CRC, I analyzed the CRC-TCGA dataset from cBioportal for Cancer Genomics (Figure 30). Importantly, CRC patients with either shallow heterozygous or homozygous copy number (CN) deletions of IL-17RA (n = 198) exhibited a significantly poorer overall 5-year survival rate (p = 0.01) compared to the patients with normal IL-17RA levels (n = 373) (Figure 30a). An absolute 5-year survival rate in this cohort of CRC patients with an IL-17RA-deletion or normal IL-17RA was calculated as 44% and 66%, respectively. Patients with an IL-17RA CN deletion had an estimated median survival of 51.45 months. Those patients without deletions did not reach 50% mortality by 60 months. In agreement with the CNA profile, CRC patients with downregulation of IL-17RA mRNA, albeit a small sample size (n = 12), also exhibited significantly decreased OS (p = 0.0004) compared to those without mRNA alterations (n = 597). Similar to IL-17RA, CRC patients with a CN deletion of A20 (n = 73) also displayed a poor overall 5-year survival rate compared to their normal counterparts (p = 0.01) (Figure 30b). Importantly, patients with a double-deletion of IL-17RA and A20 (n = 43) had a reduction in median survival of 45.37 months (Figure 30c), suggesting a synergistic value of IL-17RA and A20 in CRC prognosis. Finally, patients with CN deletion of IL-17RC alone (n = 84) or in combination with A20 (n = 21) displayed significantly worse clinical outcomes compared to their normal counterparts (Figure 30d). Notably, patients with CN amplification of IL-17RA, IL-17RC and/or A20 showed a trend, but no significance due to small number, toward worse overall survival compared to their counterparts with a normal CN profile.

Finally, I wanted to verify IL-17RA protein expression in human tissue arrays by IL-17RA immunohistochemical staining (Figure 31). Four different CRC tissue arrays with clear histological grading assessments were subjected to IL-17RA staining. Colon tissue derived from normal human colon or normal tissue adjacent to the tumor samples were included in all tissue arrays. These controls had comparable IL-17RA staining and were grouped together in my analyses. Notably, only marginal IL-17RA staining was detected on inflammatory cellular infiltrates. I found that IL-17RA staining was comparable between low grade (I and II) CRC samples and normal/adjacent samples. However, IL-
17RA staining was significantly decreased in high grade CRC tumors in both female and male patients (Figure 31a/b). Of note, IL-17RA staining level displayed an interesting distribution profile in different stages of CRC (Figure 31c/d). In normal/adjacent tissue samples, approximately 70% had a normal range (7-29%) of IL-17RA staining, and the remaining 30% of samples showed a low range of IL-17RA staining (0-7%). This distribution profile was highly maintained in stage I CRC samples, but bi-directionally altered in later stages of CRC samples. One one hand, samples with a high range of IL-17RA staining (>30%) were consistently observed in stage II, III and IV, as well as metastatic tumors. On the other hand, the fraction of low range IL-17RA staining in stage III samples was markedly increased, which accounted for at least 50% of stage III samples I examined. Of interest, there was no single stage IV sample or metastatic sample expressing a low range of IL-17RA. While the data may indicate a stage-dependent control of IL-17RA expression, it is possible that low sample size might be responsible for the observation.

The location of CRC tumors is recognized as a criteria for establishing prognosis in all stages of diseases (503, 504). To this end, I compared IL-17RA protein expression between right colonic (ascending colon) and left colonic (descending colon and sigmoid colon) samples (Figure 31e). In agreement with the clinical observation that left colon CRC patients have poor clinical outcomes (505), tumor samples in left colon showed significantly reduced IL-17RA staining compared to tumors on the right colon. Collectively, IL-17RA expression was consistently demonstrated to be bi-directionally altered at the CN, mRNA and protein levels in CRC tumor samples. Given the deletion of IL-17RA is associated with high grade CRC tumors and poorer overall 5-year survival, IL-17RA/A20 status could be used as a potential prognostic biomarker in CRC.
Figure 30. Altered IL-17R/A20 copy number level in CRC patients is associated with poor survival rate.

Five year overall survival of patients with CRC is analyzed with IL-17RA CNA, IL-17RA mRNA, A20 CNA, IL-17RA/A20 CNA, IL-17RC CNA, and IL-17RC/A20 CNA.
Figure 31. IL-17RA protein level is significantly reduced in high grade CRC tumors. (a-d) Quantitative results and representative images of IL-17RA protein levels observed in normal and cancerous colon tissues by immunohistochemistry. The solid red line indicates the median in panel b/c/e. Statistical analyses were compared using Kruskal-Wallis test for b/c or Mann Whitney test for (e). ND. no significant differences. *p < 0.05; ** p < 0.01.
Figure 31.

(a) α-IL-17RA

Isotype Ctrl

(b) Expression by grade & sex

Female
Male

IL-17RA+ (%)

(c) Expression by stage

(d) Distribution by stage

(Adenocarcinoma)

(e) Expression by location

(Adenocarcinoma)

Expression by stage

Distribution by stage

Expression by location
CHAPTER 4 DISCUSSION

4.1 Summary of major findings

The current study offers important insights into the controversial role of the IL-17/IL-17R axis in tumorigenesis. In contrast to the classic IL-17A-induced proinflammatory responses, which are often implicated in inflammation and cancer development, I found that the loss of baseline IL-17/IL-17R signaling also favors disease progression. Using a model system implementing loss or gain of IL-17R expression in cancer cells, herein I have demonstrated that baseline IL-17R level maintains A20 homeostasis, which restrains JNK/c-Jun-dependent cellular proliferation and the inflammatory pathology of tumorigenesis. The role of IL-17R/A20 in controlling cell proliferation and proinflammatory cytokine/chemokine production also applied to primary BMDCs and MEFs.

Besides the direct regulation on cancer cells, I also demonstrated that the IL-17R/A20 axis may influence immunosuppression at the tumor sites. I discovered that B16 melanoma cells lacking IL-17R expression promote proinflammatory cytokine production in vitro and in vivo, which is associated with PD-L1+/L2+ M2 polarization within the TME, along with attenuated accumulation of T cells, B cells and NK cells. Unique to the IL-17RA, but not IL-17RC signal, the inflamed TME also converted CD45+ host-derived cells into potentially immunosuppressive MHCII+PD-L1+ cells.

Importantly, I have also provided clinical evidence for co-expression of IL-17RA and A20 in human neoplasms. Of note, I identified the down-regulation of the IL-17RA/A20 axis in a variety of human cancer types. In particular, high grade CRC samples have significantly attenuated IL-17RA expression which is associated with poor overall 5-year patient survival.

4.2 Implications and relevance of major findings

4.2.1 Baseline verses induced IL-17/IL-17R/A20 signaling

Constitutive activation of various transcription factors, including NF-κB and AP-1, is commonly observed in human malignancies (39, 506); however, the molecular mechanisms and consequences underlying deregulation of these transcription factors remain incompletely understood. In the present study, I have provided compelling in vitro and in vivo evidence to demonstrate a novel scenario in which aberrant activation of NF-
κB and JNK/c-Jun in cancer cells is triggered by the loss of baseline IL-17R expression, and an anti-inflammatory molecule—A20 (see Figure 32 for my model).

Using a shRNA knockdown approach, I have demonstrated in two different cancer cell lines that the biological impact of attenuating IL-17R expression is more than just losing conventional IL-17A-induced signaling pathways (e.g., reduced CXCL1 production). Tumor cells with IL-17RA silencing are hyper-proliferative due to aberrant JNK activation that promotes G1-to-S phase cell cycle transition. In addition to aberrant JNK activation, IL-17RC silencing in tumor cells further promotes constitutive NF-κB activation. My findings are in sharp contrast with the prevailing understanding that IL-17A induces NF-κB and JNK activation (291-293, 366, 409). I have identified that baseline IL-17R level is imperative in maintaining basal production of A20, a key signaling molecule that negatively controls NF-κB and JNK activity. Therefore, for the first time, my study has united two distinct signals (pro-inflammatory and anti-inflammatory) into a single regulatory system and revealed an elegant “yin-yang” collaborative mechanism for controlling aberrant activation of transcription factors. Notably, this “yin-yang” mechanism of proliferation control is not restricted to tumor cells, but was also evident in primary hematopoietic and non-hematopoietic cells. However, loss of this proliferation control in primary cells is not sufficient for early tumor initiation. As demonstrated in a recent study, IL-17RA-deficiency in enterocytes significantly reduced the incidence of adenoma, despite that increased crypt hyperplasia in IL-17RA-deficient gut compared to WT control (507). In this sense, my approach of blunting IL-17RA expression in already transformed tumor cell lines provides an excellent model system to accurately examine the impact of IL-17RA in regulating the invasiveness of tumor cells and disease progression.
Figure 32. Proposed model for JNK1/JNK2 isoform-dependent tumor proliferation controlled by baseline IL-17/IL-17R level.

Under steady-state conditions, IL-17-dependent signaling and, to a lesser extent, IL-17R-independent signaling are required for maintaining baseline A20 production, which serves as a negative regulator for restraining the activation of both JNK1 and JNK2. When baseline IL-17R level is severely diminished, basal A20 production is reduced, leading to aberrant production/stability and functional activities of JNK1 and/or JNK2 in a cell type-dependent manner. When JNK1 is present as the dominant isoform, JNK1 induces c-Jun phosphorylation and promotes c-Jun-dependent proliferation; conversely, when JNK2 is present as the dominant isoform, JNK2 degrades c-Jun and suppresses c-Jun-dependent cellular proliferation.
While A20 is widely recognized for its role in controlling inflammation and apoptosis (413, 415, 422), it is less appreciated that A20 also has a role in controlling homeostatic cell proliferation. Consistent with my finding, A20-deficient mice and mice with epidermis-specific A20-deficiency both exhibit thickening of epidermal and dermal layers as the result of uncontrolled proliferation of keratinocytes (418, 508). In 2014, Vereecke et al. reported that combining intestinal epithelial cell (IEC)- and myeloid-specific A20 deletion induces ileitis and severe colitis, associated with epithelial hyper-proliferation and continuous epithelial cell death in vivo; however, the molecular mechanism was still unclear (509). A two-phase model has been proposed to describe A20-mediated cytokine regulation. A20 expression is induced in the first phase by inflammatory stimuli like TNF-α, IL-1β, LPS and IL-17A and then acts as a feedback inhibitor of inflammatory pathways in the second phase (510). My study has extended this model to include basal IL-17R-dependent signaling controlling baseline A20 production and A20-dependent responses under steady-state conditions. Consistently, a recent study by Dr. Kolls’s group has provided supporting evidence (319). They found that while conditional deletion of IL-17R in the mouse enteric epithelium caused reduced expression of α-defensins, Pigr, and Nox1, which are required to control gut commensal bacteria, other anti-microbial peptides, including members of regenerating-islet derived (Reg) 3 family (Reg3α/β/γ), were markedly increased in these mice, along with increased intestinal and systemic GM-CSF cytokine production and increased susceptibility to autoimmune responses (319). Although an increased load of enteric segmented filamentous bacteria is likely to be an important trigger for over-expression of Reg3α/β/γ and GM-CSF in the gut (319), I believe the loss of IL-17R-A20 regulation contributes to selective up-regulation of certain anti-microbial peptides and pro-inflammatory cytokines in this model.

Multiple intracellular molecules have been reported to directly or indirectly interact with IL-17R under resting conditions. Gaffen’s group has identified interactions of both IL-17RA and IL-17RC with anaphase-promoting complex protein 5 and anaphase-promoting complex protein 7 under steady-state conditions, which also directly interacts with A20 (410). Of note, the anaphase-promoting complex/cyclosome is a multi-subunit E3 ubiquitin ligase that targets more than 30 proteins for ubiquitin-dependent proteasome degradation and has an essential role in controlling the cell cycle (511). anaphase-
promoting complex protein 5 and anaphase-promoting complex protein 7 also interact directly with the transcription co-activators CBP/p300, stimulating intrinsic CBP/p300 acetyltransferase activity to potentiate transcription of target genes, including A20 (512). Notably, the general transcription apparatus and the CBP/p300 coactivators are indeed constitutively associated with the core promoter of A20 under basal conditions, which allows basal production of A20 (415). Collectively, my results, in conjunction with other published studies, suggest that a basal level of A20 production may be maintained through a mechanism involving anaphase-promoting complex protein 5 and anaphase-promoting complex protein 7 and CBP/p300. Of importance, once A20 levels are maintained, IL-17R is unlikely to be required for the biological activities of A20 since reconstituted A20 was able to inhibit NF-κB and JNK activity in the absence of IL-17R. Furthermore, it is intriguing to speculate whether other non-IL-17R inflammatory receptors including TNFR, IL-1R and TLR may also control tumor-specific proliferation in the manner that I have demonstrated for IL-17R.

In addition to restraining homeostatic JNK activation, the basal levels of A20 may also control IL-17A-induced JNK activation. Existing evidence indicates that IL-17A-induced signaling pathways, including the JNK pathway, are subjected to regulation, and thus are only inducible in selective cell types (376-379). For example, IL-17A directly induces production of signaling molecules A20 and C/EBPβ at mRNA and protein levels and phosphorylation of C/EBPβ (18-22), which in turn negatively modify the magnitude of IL-17A-induced signaling. It is possible that the JNK activity in IL-17A-stimulated cells is controlled by the balance of stimulatory and inhibitory signals. In sharp contrast, JNK inhibition controlled by the baseline IL-17R-A20 axis is widely conserved in primary and neoplastic cells with distinct origins. Furthermore, baseline IL-17R has highly selective target molecules such as A20 but not C/EBP proteins, indicating that IL-17A likely utilizes different signaling pathways in stimulating versus maintaining basal A20 production. In my hands, although IL-17A was able to induce NF-κB activation and A20 production in both B16 and 4T1 cells, it only induced JNK activation in B16 but not 4T1 cells (Figure 33). The selective IL-17A-induced activation of JNK in B16 cells is likely due to the lower basal levels of A20 in B16 cells compared to 4T1 cells, since 4T1 and B16 cells exhibited comparable JNK activation upon TGFβ stimulation (Figure 33). Therefore, different from
A20-mediated regulation of the NF-κB pathway, which only restricts the second phase of classic NF-κB activation as predicted by a mathematical model (513), A20 is able to control both the first and second phases of JNK activation. Most importantly, while my data indicate that both homeostatic activation of JNK and NF-κB pathways are restrained by the IL-17R-A20 axis, it is the JNK pathway and not the NF-κB pathway that is responsible for controlling homeostatic tumor-dependent proliferation.

4.2.2 The role of JNK isoforms in the functional IL-17/IL-17R paradox in cancer

The role of different JNK isoforms and the JNK-c-Jun axis in controlling cell cycle progression, cell proliferation and cell apoptosis has been extensively studied. My data is highly consistent with the notion that JNK1 and JNK2 have opposing roles in controlling cell cycle progression and cell proliferation, with JNK1 and JNK2 being positive and negative regulators of these processes, respectively. Relevant to my study, specific gene knockdown of JNK1, but not JNK2, inhibits the growth of human melanoma cell lines (514). JNK2 inhibits oncogene-induced breast cancer development in vivo by preventing cell cycle progression and DNA repair in breast cancer cells (515). The opposing roles of JNK1 and JNK2 in regulating c-Jun dependent cell cycle progression was first observed in fibroblasts, erythroblasts and hepatocytes lacking JNK1 and/or JNK2 expression (279). However, the notion of JNK2 functioning as a negative regulator of c-Jun was challenged by the observation that JNK2 is fully able to phosphorylate c-Jun upon stimulation-induced activation (282). Notably, in addition to activation of their substrates, the JNKs cause degradation of various substrate proteins, including c-Jun, ATF2, and p53, under non-stimulatory conditions (516). The substrate degradation process is dependent on binding of the JNKs to the substrates and occurs in the absence of substrate phosphorylation (516). Biochemically, JNK2 has a 25-fold higher binding affinity for c-Jun than JNK1, which is the major JNK isoform that binds to and constitutively degrades c-Jun under steady-state conditions (279, 517). Upon stimulation, JNK1 becomes the major isoform to preferentially bind to c-Jun and induce c-Jun activation and c-Jun-dependent responses (279). Therefore, the specific role of JNK1 and JNK2 in regulating c-Jun-dependent cell proliferation is context-dependent and stimulation-dependent. The opposing roles of JNK1 and JNK2 in controlling tumor cell proliferation are mediated through distinct molecular
mechanisms and more applicable under steady-state conditions and, potentially, developing tumors during equilibrium phase.

4.2.3 IL-17R alteration and its prognostic value in human cancer management

CRC is caused by a successive accumulation of mutations in oncogenes, tumor suppressor genes and genes related to DNA repair mechanisms (518, 519). The three major pathogenic mechanisms leading to the disease are chromosomal instability, microsatellite instability (MSI), and epigenetic instability that is responsible for the CpG island methylator phenotype. Currently, the most widely used biomarkers in CRC are the determinations of MSI and KRAS mutations in tumor samples, which are used for diagnostic, classification and therapy management purposes (35). MSI is caused by a deficient mismatch repair system and occurs in approximately 15% of CRC. As a stage-dependent biomarker of CRC, MSI frequently occurs in early rather than late-stage disease. MSI-high CRCs exhibit a higher mutational load and are more immunogenic with a better prognosis (520). Nevertheless, in late-stage and metastatic CRC, MSI-high seems to confer a negative prognosis. Like MSI in CRC prognosis, KRAS mutation also exhibits certain prognostic limitations, since 40-60% of CRC patients with wild-type KRAS tumors do not respond to anti-EGFR antibody therapy (521). Given the drawbacks of the current clinical screening methods for CRC (e.g., colonoscopy), such as invasiveness, low specificity and sensitivity and high cost, the identification of novel molecular predictive and/or prognostic biomarkers with more specific, sensitive features and less invasiveness, has become an essential issue to improve cancer detection, treatment allocation and patient outcome.
Figure 33. IL-17A triggers A20 and NF-κB induction and cell-type-dependent JNK activation.

B16 or 4T1 tumor cells were treated with or without 50 ng/ml IL-17A or 5 ng/ml TGF-β for the time indicated. Whole-cell extracts were harvested and immunoblotted to detect total or phosphorylated proteins as indicated. GAPDH was used as a loading control.
Chronic inflammatory conditions, such as inflammatory bowel disease (IBD), can drive the development of CRC (55). The axis of Th17 cells and their signature product proinflammatory cytokine IL-17, is highly increased and thought to contribute to the pathogenesis of IBD and CRC (522). Indeed, extensive mouse studies using either azoxymethane (AOM) and dextran sulfate sodium (DSS), with deliberately induces inflammation (523, 524), or spontaneous intestinal tumorigenesis in adenomatous polyposis coli ApcMin mice confirmed this idea (507, 525). Furthermore, IL-17 neutralizing antibody prevented colitis and CRC initiation triggered by human enterotoxigenic Bacteroides fragilis bacteria (526). However, the pathogenic role of IL-17 is challenged by the most recent findings that IL-17 inhibits intestinal epithelial permeability during DSS-mediated injury (527) and colitis in mice deficient in the multiple drug resistance gene Abcb1a−/− (318). The inconsistent results in the mouse models highlight the need to examine the role of IL-17 in human CRC.

To examine the clinical relevance of IL-17R-downregulation in human cancers, I used a TCGA database to examine correlations between the genomic CNAs, transcriptomic mRNA levels and their associations with clinical and histopathological parameters in 633 CRC patients. In addition, we validated IL-17RA expression by immunohistochemical staining of human CRC tissue arrays. While confirming that excessive IL-17/IL-17R signaling promotes inflammatory responses associated with a trend towards poor clinical outcome, my work adds to the existing knowledge in two important ways: 1. Baseline IL-17R level is essential in maintaining anti-inflammatory A20 homeostasis in human CRC; 2. IL-17RA/A20-downregulation is a novel and potent prognostic signature associated with poor overall survival in CRC patients. My gene ontology enrichment analysis of gene targets either positively or negatively correlated with IL-17RA/A20 mRNA expression in CRC-TCGA database and clearly separated the IL-17R-dependent genes into two clusters. While the IL-17RA/A20 axis induces pro-inflammatory responses, inducing cytokine secretion, immune cell proliferation, activation and recruitment, it also negatively represses gene transcripts responsible for mitochondrial metabolism and protein synthesis (see Figure 34 for my model). Indeed, as a method to detect healthy mitochondrial activity in cells (528), the MTT assay has been used to show IL-17R-attenuation-induced cellular proliferation in my study. Altered energy metabolism is a hallmark of cancer (39). How
energy metabolism is regulated by baseline IL-17R level in cancer cells is intriguing and needs to be explored. Taken together, the gene transcriptional profile extended my proposed dual character of IL-17R signaling in cancer development as a “yin-yang” collaborative mechanism.

My human CRC tissue array suggested that the most aggressive stage IV and metastatic tumors didn’t have IL-17RA-downregulation. This observation could be the result of the fatal effect of losing IL-17RA/A20 control during cancer growth and progression, or an increased IL-17RA level of early stage tumors to gain stem-cell like quiescent phenotypes. Given the potent inhibitory effect of A20 in restraining pro-survival signals, such as NF-κB and JNK (409, 416, 423), the down-regulation of IL-17RA/A20 in the dedifferentiation of CRC may allow the tumors to achieve an anti-apoptotic property and uncontrolled proliferation during disease development. Notably, hematopoietic stem cells that lack A20 display a loss of quiescence and hyperproliferation (529). Further studies with paired samples collected from early stage, e.g., stage II, and stage IV CRC patients would provide valuable insight regarding this question. In addition, future studies that aim to dissect the potential involvement of IL-17RA-A20 axis in stem cell biology would be valuable in understanding its role in proper maintenance of hematopoietic stem cell homeostasis. Together with my reported detrimental role of IL-17/A20 downregulation in murine cancer models and the current protective role of baseline IL-17RA/A20 axis in human cancers, my data draw caution on the utility of IL-17A neutralizing antibodies in cancer immunotherapy.
Figure 34. IL-17RA/A20 axis restrains mitochondrial metabolism and protein synthesis while inducing inflammation in CRC.

(a) Gene ontology enrichment analysis of gene targets either positively or negatively correlated with IL-17RA/A20 mRNA expression in CRC-TCGA database. (b) Revised model on the role of the IL-17R/A20 axis in predicting clinical outcomes in CRC patients. The intensity of IL-17A/IL-17R signaling can be divided into increased signaling (left), baseline signaling (middle), or reduced/no signaling (right). The increased signaling commonly occurs when exogenous or paracrine IL-17A is present, which stimulates NF-κB and MAPK pathways. However, IL-17A concurrently stimulates the production of signaling molecules including A20, which negatively regulate IL-17A-induced proinflammatory NF-κB and MAPK activation. The moderate IL-17A-induced inflammatory responses in CRC patients are associated with a trend towards poor overall survival. Under resting conditions, endogenous IL-17A/IL-17R level is required to specifically maintain basal production of A20 and restrains basal NF-κB and MAPK activities. When baseline IL-17A/IL-17R level is severely diminished, basal A20 production and A20-dependent suppression are markedly reduced. As such, IL-17R-independent signals trigger aberrant mitochondrial metabolism and protein synthesis in cancers, which are associated with poor overall survival of CRC patients.
Figure 34.

(a) Gene Transcripts Negatively Correlate with IL-17RA/A20

(b) Gene Transcripts Positively Correlate with IL-17RA/A20

<table>
<thead>
<tr>
<th>Gene Function</th>
<th>IL-17RA/A20 Gain</th>
<th>IL-17R/A20 diploid</th>
<th>IL-17R/A20 deletion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF-κB MAPK activation</td>
<td>A20</td>
<td>Good clinical outcomes</td>
<td>Aberrant NF-κB and JNK activities triggered</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Increased leukocyte adhesion, Increased angiogenesis, Increased inflammatory responses, Poor 5-year survival</td>
<td>Good clinical outcomes</td>
<td>Increased tumor permeability</td>
</tr>
<tr>
<td>NF-κB and JNK activities maintained</td>
<td>Normal gut barrier, Restained tumor proliferation, Restained tumor metabolism, Restained protein synthesis</td>
<td>Good clinical outcomes</td>
<td>Increased tumor permeability</td>
</tr>
<tr>
<td>homeostatic</td>
<td></td>
<td>Good clinical outcomes</td>
<td>Aberrant tumor permeability</td>
</tr>
<tr>
<td>IL-17A</td>
<td></td>
<td>Good clinical outcomes</td>
<td>Increased protein synthesis</td>
</tr>
<tr>
<td>IL-17 receptor A</td>
<td></td>
<td>Good clinical outcomes</td>
<td>Aberrant tumor permeability</td>
</tr>
<tr>
<td>IL-17 receptor C</td>
<td></td>
<td>Good clinical outcomes</td>
<td>Increased protein synthesis</td>
</tr>
</tbody>
</table>

For further details on the gene functions and their correlations with IL-17RA/A20, please refer to the accompanying text.
The molecular mechanism of copy number deletion and downregulation of IL-17RA expression in CRC is unclear so far. Nevertheless, IL-17RA level alteration could result from multiple conditions dependent on the differentiation stage and cell type, as well as the tumor-specific microenvironment. For example, KRAS mutations in neoplastic epithelial cells directly induces IL-17RA expression and IL-17A production (245, 246). Under steady-state conditions, IL-17RA expression on tumor cells appears to be tightly regulated by an intrinsic mechanism since I was not able to over-express it. Members of γc-family of cytokines, IL-15 and IL-21, have been reported to increase IL-17RA expression in the murine HT-2 T cell line, whereas IL-2 is able to suppress IL-17RA expression (530). In addition, pro-inflammatory stimuli, including TNFα, poly(I:C) and LPS, induced IL-17RA/RC expression on synovial fibroblasts isolated from human arthritis patients (409, 412). Given the emerging role of the human microbiome in tumorigenesis (531), further investigation of the relationship and impact of the gut microbiome in regulating IL-17R-dependent immunologic dysregulation and cancer is clearly warranted. Moreover, vasoactive intestinal peptide, which ameliorates or prevents several inflammatory and autoimmune disorders in animal models (532-540), and IL-22 have been suggested to antagonize the pro-inflammatory stimuli signals and down-regulate IL-17RA/RC expression (541, 542). In conjunction with a recent finding that CRC patients have a significantly higher serum level of IL-22 and anti-IL-22 antibody markedly attenuated tumor growth in an animal model (541), it is reasonable to speculate that IL-22-induced down-regulation of IL-17RA might be involved in mediating IL-22-dependent CRC progression.

I found that IL-17RA is more prone to CNA in cancers than IL-17RC (Figure 28). Indeed, with limited alteration in IL-17RC expression, it failed to correlate with A20 levels in the CRC-TCGA dataset (Figure 35a). Furthermore, A20 mRNA is significantly co-expressed with IL-17A and IL-17F, but not IL-17C or IL-17E (IL-25), highlighting the critical role of IL-17A/IL-17R axis in maintaining A20 homeostasis in human CRC (Figure 35b). Consistent with the data from human samples, while 4T1 mouse breast cancer cells exhibited ~400 fold higher IL-17RA mRNA expression than B16 melanoma cells (Figure 35c), IL-17A and IL-17F markedly induced A20 expression in both 4T1 and B16 cell lines (Figure 18a). Nevertheless, IL-17C and IL-17E could only induce A20 in 4T1, but not B16
cells, suggesting the important role of the local cytokine milieu in controlling the tumor-type-specific IL-17R-induced responses. I conducted ddPCR to examine the involvement of baseline IL-17 family ligands in repressing the IL-17R-suppressed signal (Figure 35d). I found that B16 cells secreted marginal IL-17C and IL-17F, with no detectable level of IL-17A and IL-17E. Furthermore, mRNA for IL-17 family ligands were not detected in the 4T1 cultures. Further ELISA experiments also failed to detect any ligand secretion in day 3 cell culture supernatants. Given the consistent observation that IL-17RA-attenuation induces cellular proliferation in both B16 and 4T1 models, it is more likely that the baseline IL-17 family ligands are dispensable for this phenotype. In future studies, however, it would be valuable to determine the impact of the functional domain of IL-17R in maintaining A20 using truncated IL-17R constructs. While an IL-17R mutant lacking the extracellular ligand-binding domain can validate the involvement of IL-17 family ligands, mutants with the deletion of different intracellular domains will be required to further dissect the functional domain(s) of IL-17R in A20 homeostasis.
Figure 35. Significant association between IL-17A-F/IL-17R axis with A20 alteration. 
(a, b) mRNA expression levels were quantified from RNA-Seq data in the CRC-TCGA dataset from cBioportal. Correlation analyses of A20 mRNA expression with IL-17RA, IL-17RC, IL-17A, IL-17F, IL-17C and IL-17E (IL-25) mRNA levels. (c) Mouse cell lines were either untreated or starved in the serum-free DMEM for 14 hrs and recovered in complete DMEM medium with or without exogenous mouse recombinant IL-17 family ligands (200 ng/ml, 30 mins). Total RNA was extracted from approximately 3 x 10^6 cells of different mouse cell lines. RNA was reverse-transcribed into cDNA and amplified by quantitative real-time PCR and (d) digital droplet PCR. The gene expression was normalized to the expression of the housekeeping gene GAPDH. (c, d) All values are means ± SEM of 3 independent experiments. Statistical analyses were compared with the pSMP control for panel (d) using one-way ANOVA.
Figure 35.

(a) Pearson r = 0.3655, p < 0.0001
Spearman r = 0.3398, p = 0.0001

(b) Pearson r = 0.1546, p = 0.0024
Spearman r = 0.2209, p < 0.0001

(c) 2^Act

(d) Relative copies per 1,000 copies of GAPDH
I observed co-expression of IL-17RA and A20 in clinical tumor samples; however, the co-expression was not detected in two datasets of human cancer cell lines, i.e., the NCI-60 cancer cell line panel (GDS4296) in GEO-NCBI (Table 10) (543) and the Cancer Cell Line Encyclopedia (CCLE) from cBioportal (Table 11) (544). Specifically, NCI-60 covers human cancer cell lines from 9 different tissues of origin, including breast, central nervous system (CNS), colon, leukocytes, skin, non-small cell lung (NSCL), ovary, prostate, and kidney. In the NCI-60, while A20 expression is significantly correlated with IL-17RA in ovarian cancer and melanoma, A20 homeostasis is dependent on other pro-inflammatory signals in the other cancer types, such as IL-1 and TNF signals in breast cancer, TNF signals in renal and prostate cancer and TLR4 signals in NSCLC. Interestingly, TLR-MyD88 signals are negatively correlated with A20 expression in leukemia and prostate cancer. Notably, A20 didn’t exhibit a clear co-expression with any signals examined in leukemia or CNS cancer; nevertheless, it is significantly correlated with IL-17RA level in all leukemia subsets (Pearson R=0.6226, P=0.0132; Spearman R=0.7143, P=0.0028), except acute promyelocytic leukemia HL-16.

The CCLE panel contains a massive parallel sequencing dataset covering 947 human cancer cell lines that compiling gene expression and chromosomal copy number. In the CCLE dataset, IL-17RA/A20 co-expression was observed in cancer cell lines originating from autonomic ganglia and the upper aerodigestive tract, but not from other tissues. Possible explanations of this inconsistency include the limitation that molecular signatures of cancer cell lines in culture may do not capture all aspects of cellular activity in the TME (545). The intratumor heterogeneity and molecular differences among cells within an individual tumor have clinical implications and highlight the need to use integrative samples and models to provide a greater predictive power. In addition, given that the co-expression pattern is disrupted in lung cancer patients from GDS2771 in GEO-NCBI, which were all collected from current and former smokers, patient lifestyle background (e.g., cigarette smoker) may be another factor that influences the intrinsic correlation of IL-17RA and A20 (546, 547). Moreover, limited sample size (e.g., GDS4824 of prostate cancer, n = 21 and GDS3592 of ovarian cancer, n = 24) (Table 9), and/or potential intrinsic stimuli, such as hormone receptor signaling in breast cancers (435), may alter the expressions of IL-17RA and/or A20 and also contribute to inconsistencies. Importantly,
the paired analyses of normal vs cancer samples obtained from the individual patients with CRC clearly exhibited down-regulation of IL-17/A20 as well as their intrinsic co-expression pattern, which strongly highlights the importance of this regulatory control mechanism in clinical settings.

Furthermore, I found that both IL-17RA and IL-17RC mRNA levels were significantly decreased in human colon cancer cell lines compared to primary HCEC (Figure 3). Nevertheless, while A20 expression is significantly attenuated in the human colon cancer line, HT29, compared to the primary HCEC, there is a 7-fold increase in the A20 mRNA level in another human colon cancer line, CaCo2 (Figure 3). Indeed, the high level of A20 in CaCo2 cells was associated with significantly weaker pro-inflammatory cytokine production of both IL-6 and IL-8 under IL-17A stimulation (Figure 3). Given that HT29 and CaCo2 have distinct gene mutation backgrounds with respect to BRAF, PIK3CA and TP53 (548), co-expression of IL-17RA and A20 may be biased by patient (cell line)-specific regulation.
Table 10. A20 correlation analysis grouped by cancer types in NCI-60 cancer cell line panel (GDS4296)

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Sample Count</th>
<th>Test Method</th>
<th>P and R values of A20 correlation</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>174</td>
<td>Pearson</td>
<td>0.8656; 0.0129</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.4162; 0.0620</td>
</tr>
<tr>
<td>Leukemia</td>
<td>18</td>
<td>Pearson</td>
<td>0.5482; 0.1516</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.5758; -0.1414</td>
</tr>
<tr>
<td>Leukemia</td>
<td>15</td>
<td>Pearson</td>
<td>0.7870; 0.0763</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.4514; -0.7000</td>
</tr>
<tr>
<td>(excludes HL-16)</td>
<td></td>
<td>Spearman</td>
<td>0.0037; 0.0076</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>15</td>
<td>Pearson</td>
<td>0.0041; 0.7460</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.0037; 0.7000</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>21</td>
<td>Pearson</td>
<td>0.5339; -0.1438</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.5072; 0.1532</td>
</tr>
<tr>
<td>Melanoma</td>
<td>26</td>
<td>Pearson</td>
<td>0.6366; -0.0972</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.1815; -0.2704</td>
</tr>
<tr>
<td>CNS cancer</td>
<td>18</td>
<td>Pearson</td>
<td>0.1915; 0.3227</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.1279; 0.3725</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>21</td>
<td>Pearson</td>
<td>0.5298; -0.1453</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.6827; -0.0948</td>
</tr>
<tr>
<td>Renal cancer</td>
<td>23</td>
<td>Pearson</td>
<td>0.3315; -0.2120</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.2132; -0.2698</td>
</tr>
<tr>
<td>NSCLC</td>
<td>26</td>
<td>Pearson</td>
<td>0.8680; 0.0342</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.5982; 0.1084</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>6</td>
<td>Pearson</td>
<td>0.8763; -0.0826</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spearman</td>
<td>0.2132; -0.2698</td>
</tr>
</tbody>
</table>

**Note:** CNS, central nervous system. NSCLC, non-small cell lung cancer.

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Sample Count</th>
<th>P &amp; R Values of IL-17RA &amp; A20 Correlation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample</td>
<td>Count</td>
<td>Pearson</td>
</tr>
<tr>
<td>All</td>
<td>967</td>
<td>0.0006, 0.1124</td>
</tr>
<tr>
<td>Autonomic Ganglia</td>
<td>17</td>
<td>0.0892, 0.4248, 0.0130, 0.5882</td>
</tr>
<tr>
<td>Biliary Tract</td>
<td>7</td>
<td>0.2772, -0.4787, 0.2000, -0.5714</td>
</tr>
<tr>
<td>Bone</td>
<td>25</td>
<td>0.7923, 0.05545, 0.4696, 0.1515</td>
</tr>
<tr>
<td>Breast</td>
<td>58</td>
<td>0.7902, -0.03570, 0.8533, 0.02482</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>52</td>
<td>0.9726, -0.004889, 0.7116, -0.05251</td>
</tr>
<tr>
<td>Endometrium</td>
<td>24</td>
<td>0.5317, -0.1342, 0.5572, -0.1261</td>
</tr>
<tr>
<td>Hematopoietic and lymphoid tissue</td>
<td>174</td>
<td>0.4928, -0.05233, 0.5944, -0.04064</td>
</tr>
<tr>
<td>Kidney</td>
<td>21</td>
<td>0.1258, 0.3448, 0.2158, 0.2818</td>
</tr>
<tr>
<td>Large Intestine</td>
<td>50</td>
<td>0.2246, 0.1748, 0.3161, 0.1447</td>
</tr>
<tr>
<td>Liver</td>
<td>27</td>
<td>0.4949, -0.1372, 0.3113, -0.2024</td>
</tr>
<tr>
<td>Lung</td>
<td>164</td>
<td>0.8595, -0.01393, 0.8327, -0.01662</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>24</td>
<td>0.2361, -0.2514, 0.3016, -0.2200</td>
</tr>
<tr>
<td>Ovary</td>
<td>50</td>
<td>0.1134, -0.2267, 0.3246, -0.1422</td>
</tr>
<tr>
<td>Pancreas</td>
<td>44</td>
<td>0.2313, 0.1842, 0.4275, 0.1227</td>
</tr>
<tr>
<td>Pleura</td>
<td>10</td>
<td>0.2698, 0.3866, 0.3487, 0.3333</td>
</tr>
<tr>
<td>Prostate</td>
<td>7</td>
<td>0.8592, -0.08324, 0.4976, 0.3214</td>
</tr>
<tr>
<td>Skin</td>
<td>58</td>
<td>0.0816, 0.2306, 0.0611, 0.2475</td>
</tr>
<tr>
<td>Soft Tissue</td>
<td>20</td>
<td>0.3269, -0.2311, 0.5781, -0.1323</td>
</tr>
<tr>
<td>Stomach</td>
<td>37</td>
<td>0.1999, 0.2157, 0.4002, 0.1425</td>
</tr>
<tr>
<td>Thyroid</td>
<td>12</td>
<td>0.2471, -0.3623, 0.1309, -0.4615</td>
</tr>
<tr>
<td>Upper Aerodigestive Tract</td>
<td>30</td>
<td>0.0223, -0.4158, 0.0166, -0.4339</td>
</tr>
<tr>
<td>Urinary Tract</td>
<td>23</td>
<td>0.3672, -0.1972, 0.3057, -0.2233</td>
</tr>
</tbody>
</table>
Figure 36. A20 restrains IL-17A-induced proinflammatory cytokine production in human colon cell lines.

(a,b) Total RNA was extracted from approximately 3 x 10^6 cells of different human cell lines. RNA was reverse-transcribed into cDNA and amplified by polymerase chain reaction (PCR) and quantitative real-time PCR. The gene expression was normalized to the expression of the housekeeping gene β-actin. HCEC: human colon epithelial cells; HT29 and CaCo2: human colon cancer cell line. (c) Human IL-8 and IL-6 production were determined by ELISA following stimulation with 50 ng/ml of recombinant mouse IL-17A. Values are means ± SEM of 6 replicates from two independent experiments. Statistical analyzes were compared with HCEC using Kruskal-Wallis test. *p < 0.05; ** p < 0.01; *** p < 0.001.
4.3 Limitations of experimental system

4.3.1 Apoptosis versus proliferation

The review by Hanahan and Weinberg entitled “The Hallmarks of Cancer” characterizes sustaining proliferation and resistance of apoptosis as two of the first six traits of cancer (38). As such, the design and development of cancer chemotherapies and other treatments have generally been evaluated based on their ability to inhibit proliferation and induce cell death. Nevertheless, these two hallmarks of cancer do not necessarily co-exist in cancer cells. In a large cohort of 791 breast cancer patients with long-term follow-up (range, 8.9-36.5 years), tumors exhibited high levels of apoptosis and increased cellular proliferation (549). Indeed, other clinical studies have suggested that other cancers exhibit increased frequency of proliferation and apoptosis, rather than evasion of apoptosis (273, 550). The harsh microenvironment of the tumor core, such as hypoxia, nutrient deprivation and low extracellular pH, is not a favorable condition for cancer cells to thrive (65). Nevertheless, cancer is not merely a mixture of neoplastic cells. The crosstalk among the cancer cells, stromal and immune cells, remodels the TME to favor an immune suppressive phenotype, which supports tumor cell proliferation over the rate of cell death, which in turn, leads to tumor growth and progression.

In my B16 and 4T1 cancer cell line models, the rate of cellular proliferation and apoptosis exhibited the same trend in alteration, which is consistent with clinical observations. I identified that cellular proliferation under IL-17R signaling is c-Jun-dependent and is alerted through entry modification at the G1-to-S phase of cell cycle. Indeed, it has been proposed that mutations of the Rb tumor suppressor lead to increased E2F family of DNA-binding transcription factors (E2F) activity, and this promotes both G1-to-S phase transition and apoptosis in cancer cells (551-553). Another new theory of increased cellular turnover of both proliferation and apoptosis in cancers proposed that the apoptosis of cancer tissues drives the surviving cancer cells to proliferate in an uncontrolled way through a process named “Compensatory Growth” (Figure 3) (273, 274). In the present study, the siRNA knockdown of either JNK1 or JNK2 altered cellular proliferation but not apoptosis (Figure 10f), suggesting the IL-17R-attenuation-induced JNK/c-Jun-dependent proliferation is independent of apoptosis. Further studies will be required to determine the
role for JNK isoforms in apoptosis under IL-17R-dependent versus IL-17R-independent signaling pathways.

4.3.2 Lentiviral-shRNA/siRNA delivery system

In the present study, I used a lentiviral-shRNA/siRNA delivery system to knockdown genes of interest. The main reason for choosing the lentivirus delivery system over other systems, such as plasmid DNA or adenovirus, is due to the ability of lentiviruses to infect both dividing and non-dividing cells and integrate into the host genome to achieve stable and sustained gene knockdowns (554). Nevertheless, the main drawback of the lentivirus-based delivery system is off-target effects. To confirm that my observation was not biased by any off-target effect, I examined IL-17R knockdown in multiple primary and cancer cells. Consistent results were observed and the full-length reconstitution of IL-17RA restored the proliferation rate, as well as JNK/c-Jun activities to the control level. To further validate my results, strategies to overcome or avoid the off-target effects using newly developed genome-editing systems, such as CRISPR/Cas9 (555), would be needed.

4.3.3 Online database and human tissue array analyses

In interpreting the results, some limitations of this study should be addressed. Firstly, the compiled analyses of multiple database and subgroup IHC analyses of CRC tissue array were performed based on a fraction of all the possible data to be pooled, so selection bias may have occurred and my results may be overinflated. Thus, additional large scale studies on IL-17RA/A20 interaction are needed to validate my findings. Secondly, in the pooled analyses of online datasets, different ethnicities were grouped in other population and the patient-specific regulation of gene expression profile may bring in some heterogeneity. Moreover, the gene-environment interactions including diet, microbiota, alcohol drinking, cigarette consumption, inflammation and other lifestyle factors, should also be considered in future studies.

4.4 Proposed future directions

While my study unmasked a role for repression of baseline IL-17R level in cancer progression and its clinical implication, there are many questions that remain to be answered. In my study, the endogenous level of A20 was maintained by baseline IL-17R level; however, the molecular mechanism is unclear. It would be interesting to determine
the functional domain of IL-17R, which are required for A20 homeostasis. Furthermore, while the expression levels of IL-17 family ligands are under the limit of detection by ddPCR, direct evidence to support the notion that IL-17 family ligands are dispensable for the IL-17R-repressing signal is missing. Further studies using truncated IL-17R lacking the extracellular domain for ligand binding will be required to validate this finding.

While I identified a critical role for IL-17R in A20 homeostasis, A20 can be induced by a variety of proinflammatory stimuli (409, 412). This may raise a question as to whether other pro-inflammatory signals are able to compensate for the IL-17R-A20 axis and override IL-17R silencing-induced A20 reduction and JNK isoform-dependent cell proliferation in vivo. However, this may not be the case in my study. Although the loss of IL-17R triggered elevated production of proinflammatory cytokines, such as IL-6 and GM-CSF in B16 and 4T1 cells, IL-17R KD clones in both tumor models exhibited consistent invasiveness in vitro and in vivo. Nevertheless, this remains to be determined experimentally.

In my study, IL-17RC signaling in the two cancer cell line models, B16 and 4T1, exhibited opposing effects on proliferation via an unclear mechanism. This finding is novel in the context of recent literature suggesting a TME-specific role of IL-17 signaling in cancers (136). Nevertheless, the mechanism underlying this intrinsic phenotype of cells from various origins is intriguing. My preliminary work on the screening of IL-17RC isoform expression in B16, 4T1 and MEF cells suggested that these cells express both full-length IL-17RC and another isoform with a deletion of exon 7 and part of exon 8 (ΔExon7/8) (Figure 37). Notably, the truncated ΔExon7/8 isoform of IL-17RC fails to bind with either IL-17A or IL-17F (307), suggesting that the ΔExon7/8 isoform may serve as a decoy receptor to block downstream signaling. While the shRNA targets both isoforms of IL-17RC, the ratio of full length versus ΔExon7/8 is decreased in B16-RCKD compared to the pSMP control. In a sharp contrast, the ratio is increased in both 4T1 and MEF cells after the loss of IL-17RC. Given that the loss of IL-17RC exhibited decreased proliferation in B16 cells, but increased cell growth in 4T1 and MEF cells, these data enable us to hypothesize that the intrinsic proliferation control downstream of IL-17RC/A20 may be caused by the preferential expression pattern of full length versus ΔExon7/8 isoforms of IL-1RC in distinct cell types. Besides the identification of functional domain in IL-17R to
maintain A20 level, further studies will be required to reconstitute the two IL-17RC isoforms to examine this hypothesis.

Immunotherapy functions to overcome tumor suppression by (i) boosting the patient’s immune system, (ii) increasing the immunogenicity of the tumor itself, and/or (iii) decreasing cancer-associated immunosuppression. There are a variety of approaches to eliciting an anti-tumor immune response, with advancements in techniques involving therapeutic cancer vaccines, adoptive T cell therapies, anti-tumor antibodies, and immune checkpoint blockade. The concept of utilizing beneficial immunosurveillance effects of acute inflammation in cancer treatment was applied by bone surgeon William Coley in the 1890s (556). “Coley’s toxin” is a Gram-negative bacterial preparation that induces inflammation and was associated with some success in the treatment of sarcoma patients. Subsequently, researchers identified that “therapeutic inflammation” is conducted through the induction of TNF-α triggered by the LPS. More recently, using a wound-induced acute inflammation model in murine tumors, the authors found that the inflammation-induced secretion of IFN-γ interferes with the growth of early tumors. However, in the later stages of tumorigenesis, IFN-γ resistant tumors promote TGF-β against the IFN-γ effect in the restoration of tumor proliferation, invasion, and migration (557). Currently, in line with the “Coley’s toxin” preparation, an attenuated *Mycobacterium bovis* strain (*Mycobacterium bovis* bacillus Calmette-Guerin—BCG)-derived therapeutic vaccine against tuberculosis is used in the treatment of squamous cancer of the bladder (558). The protective immune reaction primarily results from the induction of a variety of pro-inflammatory cytokines, including IL-1, TNF-α, IL-6, IL-8, IL-12, IL-5, IL-15, IL-18, GM-CSF and IFN-γ (558). The hypoxic and necrotic TME in the tumor mass is an attractive environment for anaerobic bacteria such as *Salmonella, Clostridium*, and *Listeria*. As such, the potential use of an engineered version of anaerobic bacteria to induce oncological therapy is promising. Indeed, a recent report by Min et al. (559) engineered *Salmonella typhimurium* to overexpress flagellin B, which stimulates a potent beneficial host immune response to inhibit cancer development and growth. However, there are several potential drawbacks regarding this acute inflammation-driven cancer therapy. Since it is difficult to balance the potency of the inflammation process, the induced anti-cancer responses are normally not cancer-specific. Host may not be able to clear bacteria due to impaired immune system,
and lastly, many pathogens themselves try to avoid immunosurveillance, which may lead to a chronic inflammatory condition that often accompanies cancer relapse with resistance to the same treatment.

Besides inducing acute inflammatory cytokine production to boost the immune system to combat cancer, immunomodulatory antibodies that directly enhance the function of T cells have recently been garnering significant attention. These agents, commonly called “checkpoint inhibitors” because they block negative regulators of T cell immunity, such as α-PD1/PD-L1 and α-CTLA4 have demonstrated meaningful results in terms of efficacy with a good safety profile in selected immunogenic cancers like melanoma and renal cell carcinomas (560, 561). Nevertheless, most patients (50% ~ 80%) do not respond to these therapies, and more concerning, some patients who exhibit encouraging initial responses to the immunotherapy, can acquire resistance over time. In the present study, B16 tumors with attenuated IL-17RA expression induced PD-L1+ cells within the TME, including both CD45*MHCII+ host cells and M2 infiltrates (Figure 25, 26), which are associated with a potent immunosuppression (Figure 23). Therefore, selectively targeting tumors with attenuated IL-17R expression may increase the α-PD-L1 response rate. Furthermore, since IL-17R-silencing may induce JNK1/c-Jun-dependent cell cycle progression and hyper-proliferation of tumor cells, JNK1-specific cell cycle inhibitors may potentially be used as a combination strategy with checkpoint inhibitors, possibly yielding better outcomes for patients.
Figure 37. IL-17RC isoform expression pattern is associated with IL-17R/A20-dependent proliferation control.

(a) Schematic diagram of mouse IL-17RC isoforms. (b) Total RNA was extracted from approximately $3 \times 10^6$ cells of different cells. RNA was reverse-transcribed into cDNA and IL-17RC isoforms were amplified by PCR. The gene expression was normalized to the expression of the housekeeping gene GAPDH. Gel image and quantitative densitometry analysis were shown. (c) The GOR method (http://gor.bb.iastate.edu/) of protein secondary structure prediction of the 24 amino acids deleted in the truncated IL-17RC isoform. (d) The IL-17RC isoform protein tertiary structure and function prediction through iterative threading assembly simulations by I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/).
Exon\(\Delta\) 7,8: 24 amino acid (795-866bp) deletion. (Exon 7: 794-838bp; Exon 8: 839-978bp)

(b) Full Length IL-17RC Protein

(c) GOR method (Garnier-Osguthorpe-Robson):

+ ve residues: Arg (R), Lys (K);
- ve residues: Asp (D), Glu (E).

(d) Isoform1 (FL)

Isoform 2

Trans-membrane domain

SEFIR domain

N-terminus

C-terminus
4.5 Concluding remarks

The role of the IL-17/IL-17R axis in cancer has been widely explored; however, conflicting results were reported without a satisfactory explanation. My findings highlight a previously unrecognized role of baseline IL-17R-A20 signaling in restraining JNK activation and tumor cell proliferation. My revised model emphasizes that both enhanced and severely reduced or blunted IL-17R-dependent signaling may lead to JNK activation. Depending on the endogenous activities of JNK1 and JNK2, IL-17R-dependent signaling may either positively or negatively regulate homeostatic proliferation and invasiveness of tumor cells. Furthermore, my study identifies a prognostic value of this novel tumor-suppression/evasion mechanism, whereby down-regulation of the IL-17R level in CRC tumors was associated with poor overall patient survival. Effective cancer therapies may be devised by manipulating this novel control mechanism. Future work based on the discoveries presented in this study could have significant implications for JNK isoform-specific inhibitors in cancer immunotherapies (253). At last, I would like to quote the wisdom of George Herbert, a Welsh poet, orator and Anglican priest (April 3rd, 1593 to March 1st, 1633): “Sometimes the best gain is to lose” (562). In the context of cancer, when the tumor cells lose the IL-17R/A20 expression, they can actually gain much more!


Katz M, Amit I, Yarden Y. Regulation of MAPks by growth factors and receptor tyrosine kinases. Biochimica et biophysica acta. 2007;1773(8):1161-76.


312. Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clinical and experimental immunology. 2001;125(2):177-83.


373. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. The journal of biological chemistry. 2006;281(47):35603-7.


APPENDIX A IL-17R silencing alters the proliferation of B16 cells independent of ERK or p38 pathways

B16 melanoma cells were treated with DMSO or one of the inhibitors indicated for 48 hrs. Cell proliferation was then measured by MTT assay. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; statistical analysis was compared with the DMSO control. ##p ≤ 0.01; ###p ≤ 0.001; statistical analysis was compared with the pSMP control line. All values are means ± SEM of 4-6 replicates in two independent experiments.

APPENDIX B No change of IL-17RA level in melanoma and breast carcinoma samples compared to normal counterparts

IL-17RA mRNA expression levels in one melanoma and three breast cancer studies are quantified from Oncomine datasets. Statistical analyses were compared with respective normal tissues using nonparametric Mann Whitney test.